Document And Entity Information
Document And Entity Information - USD ($) | 12 Months Ended | ||
Dec. 31, 2021 | Mar. 16, 2022 | Jun. 30, 2021 | |
Document Information [Line Items] | |||
Entity Central Index Key | 0000834365 | ||
Entity Registrant Name | BIOLIFE SOLUTIONS INC | ||
Amendment Flag | false | ||
Current Fiscal Year End Date | --12-31 | ||
Document Fiscal Period Focus | FY | ||
Document Fiscal Year Focus | 2021 | ||
Document Type | 10-K | ||
Document Annual Report | true | ||
Document Period End Date | Dec. 31, 2021 | ||
Document Transition Report | false | ||
Entity File Number | 001-36362 | ||
Entity Incorporation, State or Country Code | DE | ||
Entity Tax Identification Number | 94-3076866 | ||
Entity Address, Address Line One | 3303 MONTE VILLA PARKWAY, SUITE 310 | ||
Entity Address, City or Town | BOTHELL | ||
Entity Address, State or Province | WA | ||
Entity Address, Postal Zip Code | 98021 | ||
City Area Code | 425 | ||
Local Phone Number | 402-1400 | ||
Title of 12(b) Security | Common Stock, par value $0.001 per share | ||
Trading Symbol | BLFS | ||
Security Exchange Name | NASDAQ | ||
Entity Well-known Seasoned Issuer | Yes | ||
Entity Voluntary Filers | No | ||
Entity Current Reporting Status | Yes | ||
Entity Interactive Data Current | Yes | ||
Entity Filer Category | Large Accelerated Filer | ||
Entity Small Business | true | ||
Entity Emerging Growth Company | false | ||
ICFR Auditor Attestation Flag | true | ||
Entity Shell Company | false | ||
Entity Public Float | $ 1,433,451,805 | ||
Entity Common Stock, Shares Outstanding | 42,094,963 | ||
Auditor Name | BDO USA, LLP | ||
Auditor Location | Seattle, Washington | ||
Auditor Firm ID | 243 |
Consolidated Balance Sheets
Consolidated Balance Sheets - USD ($) $ in Thousands | Dec. 31, 2021 | Dec. 31, 2020 |
Current assets: | ||
Cash and cash equivalents | $ 69,860 | $ 90,403 |
Restricted cash | 10 | 53 |
Accounts receivable, trade, net of allowance for doubtful accounts of $275 and $85 as of December 31, 2021 and December 31, 2020, respectively | 23,217 | 8,006 |
Inventories | 28,345 | 11,602 |
Prepaid expenses and other current assets | 4,427 | 4,648 |
Total current assets | 125,859 | 114,712 |
Assets held for rent, net | 9,809 | 4,705 |
Property and equipment, net | 17,657 | 10,120 |
Operating lease right-of-use assets, net | 18,705 | 9,675 |
Financing lease right-of-use assets, net | 440 | 17 |
Long-term deposits and other assets | 325 | 230 |
Investments | 4,372 | 5,872 |
Total intangible assets, net | 152,149 | 31,049 |
Goodwill | 224,741 | 58,449 |
Total assets | 554,057 | 234,829 |
Current liabilities: | ||
Accounts payable | 14,945 | 3,672 |
Accrued expenses and other current liabilities | 7,142 | 4,543 |
Warranty liability | 9,398 | 212 |
Lease liabilities, operating, current portion | 2,758 | 1,107 |
Lease liabilities, financing, current portion | 149 | 8 |
Debt, current portion | 862 | 614 |
Warrant liability | 0 | 2,780 |
Contingent consideration, current portion | 5,127 | 2,637 |
Total current liabilities | 40,381 | 15,573 |
Contingent consideration, long-term | 4,900 | 4,515 |
Lease liabilities, operating, long-term | 16,466 | 8,757 |
Lease liabilities, financing, long-term | 291 | 12 |
Total long-term debt | 6,353 | 655 |
Deferred tax liabilities | 5,487 | 0 |
Other long-term liabilities | 42 | 71 |
Total liabilities | 73,920 | 29,583 |
Commitments and Contingencies (Note 11) | ||
Shareholders’ equity: | ||
Preferred stock, $0.001 par value; 1,000,000 shares authorized, Series A, 4,250 shares designated, and 0 shares issued and outstanding as of December 31, 2021 and December 31, 2020 | 0 | 0 |
Common stock, $0.001 par value; 150,000,000 shares authorized, 41,817,503 and 33,039,146 shares issued and outstanding as of December 31, 2021 and December 31, 2020, respectively | 42 | 33 |
Additional paid-in capital | 585,397 | 302,598 |
Accumulated other comprehensive loss, net of taxes | (282) | 0 |
Accumulated deficit | (105,020) | (97,385) |
Total shareholders’ equity | 480,137 | 205,246 |
Total liabilities and shareholders’ equity | $ 554,057 | $ 234,829 |
Consolidated Balance Sheets (Pa
Consolidated Balance Sheets (Parentheticals) - USD ($) $ in Thousands | Dec. 31, 2021 | Dec. 31, 2020 |
Accounts receivable, allowance for doubtful accounts | $ 275 | $ 85 |
Preferred stock, par value (in dollars per share) | $ 0.001 | $ 0.001 |
Preferred stock, shares authorized (in shares) | 1,000,000 | 1,000,000 |
Common stock, par value (in dollars per share) | $ 0.001 | $ 0.001 |
Common stock, authorized (in shares) | 150,000,000 | 150,000,000 |
Common stock, issued (in shares) | 41,817,503 | 33,039,146 |
Common stock, outstanding (in shares) | 41,817,503 | 33,039,146 |
Series A Preferred Stock [Member] | ||
Preferred stock, shares designated (in shares) | 4,250 | 4,250 |
Preferred stock, issued (in shares) | 0 | 0 |
Preferred stock, outstanding (in shares) | 0 | 0 |
Consolidated Statements of Oper
Consolidated Statements of Operations - USD ($) $ in Thousands | 12 Months Ended | |||||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | ||||
Revenue | $ 119,156 | [1] | $ 48,087 | [2] | $ 27,371 | [3] |
Costs and operating expenses: | ||||||
Research and development | 11,821 | 6,720 | 3,168 | |||
Sales and marketing | 14,006 | 6,413 | 4,701 | |||
General and administrative | 32,448 | 14,607 | 8,893 | |||
Intangible asset amortization | 8,202 | 3,033 | 1,079 | |||
Acquisition costs | 1,636 | 668 | 940 | |||
Change in fair value of contingent consideration | 2,875 | 1,575 | 50 | |||
Total operating expenses | 153,096 | 53,662 | 27,591 | |||
Operating loss | (33,940) | (5,575) | (220) | |||
Other income (expense): | ||||||
Change in fair value of warrant liability | (121) | 3,601 | (12,835) | |||
Change in fair value of investments | 0 | 1,319 | 0 | |||
Interest (expense) income, net | (432) | 58 | 501 | |||
Other income (expense) | 289 | 0 | (13) | |||
Total other income (expense), net | 6,187 | 4,978 | (2,978) | |||
Loss before income tax benefit | (27,753) | (597) | (3,198) | |||
Income tax benefit | 20,118 | 3,264 | 1,541 | |||
Net (loss) income | (7,635) | 2,667 | (1,657) | |||
Net (loss) income attributable to common shareholders: | ||||||
Basic | (7,635) | 2,450 | (1,657) | |||
Diluted | $ (7,635) | $ (954) | $ (1,657) | |||
Basic (in dollars per share) | $ (0.20) | $ 0.09 | $ (0.09) | |||
Diluted (in dollars per share) | $ (0.20) | $ (0.03) | $ (0.09) | |||
Weighted average shares used to compute (loss) earnings per share attributable to common shareholders: | ||||||
Basic and Diluted (in shares) | 38,503,944 | 27,306,258 | 19,460,299 | |||
SAVSU [Member] | ||||||
Other income (expense): | ||||||
Gain on acquisition | $ 0 | $ 0 | $ 10,108 | |||
Sexton Biotechnologies, Inc. [Member] | ||||||
Other income (expense): | ||||||
Gain on acquisition | 6,451 | 0 | 0 | |||
SAVSU [Member] | ||||||
Other income (expense): | ||||||
Loss from equity-method investment in SAVSU | 0 | 0 | (739) | |||
Product [Member] | ||||||
Revenue | 101,913 | 44,540 | 26,844 | |||
Costs and operating expenses: | ||||||
Cost of goods and services | 69,676 | 18,058 | 8,355 | |||
Service Revenue [Member] | ||||||
Revenue | 9,817 | 1,752 | 0 | |||
Costs and operating expenses: | ||||||
Cost of goods and services | 5,381 | 1,367 | 405 | |||
Rental Revenue [Member] | ||||||
Revenue | 7,426 | 1,795 | 527 | |||
Costs and operating expenses: | ||||||
Cost of goods and services | $ 7,051 | $ 1,221 | $ 0 | |||
[1] | 2021 revenue includes product revenue related to Global Cooling from May 3, 2021 through December 31, 2021 and product revenue related to Sexton from September 1, 2021 through December 31, 2021. | |||||
[2] | 2020 revenue includes service revenue related to SciSafe from October 1, 2020 through December 31, 2020. | |||||
[3] | 2019 revenue includes product revenue related to Astero Bio Corporation ("Astero") from April 1, 2019 through December 31, 2019; rental revenue related to SAVSU from August 8, 2019 through December 31, 2019; and product revenue related to CBS from November 12, 2019 through December 31, 2019. |
Consolidated Statements of Comp
Consolidated Statements of Comprehensive (Loss) Income - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Net (loss) income | $ (7,635) | $ 2,667 | $ (1,657) |
Other comprehensive loss - foreign currency translation adjustment, net of tax | (282) | 0 | 0 |
Comprehensive (loss) income | $ (7,917) | $ 2,667 | $ (1,657) |
Consolidated Statements of Shar
Consolidated Statements of Shareholders' Equity - USD ($) $ in Thousands | GCI Acquisition [Member]Common Stock [Member] | GCI Acquisition [Member]Additional Paid-in Capital [Member] | GCI Acquisition [Member] | Sexton Acquisition [Member]Common Stock [Member] | Sexton Acquisition [Member]Additional Paid-in Capital [Member] | Sexton Acquisition [Member] | Preferred Stock [Member]Series A Preferred Stock [Member] | Common Stock [Member] | Additional Paid-in Capital [Member] | AOCI Attributable to Parent [Member] | Retained Earnings [Member] | Total |
Balance (in shares) at Dec. 31, 2018 | 0 | 18,547,406 | ||||||||||
Balance at Dec. 31, 2018 | $ 0 | $ 19 | $ 113,008 | $ (98,395) | $ 14,632 | |||||||
Stock based compensation | 3,043 | 3,043 | ||||||||||
Shares issued in acquisitions (in shares) | 0 | 1,334,219 | ||||||||||
Shares issued in acquisitions | $ 0 | $ 1 | 23,931 | $ 0 | 0 | 23,932 | ||||||
Stock option exercises | $ 0 | $ 1 | 1,180 | 0 | 0 | 1,181 | ||||||
Stock option exercises (in shares) | 697,010 | |||||||||||
Stock issued – on vested RSAs (in shares) | 0 | 125,817 | ||||||||||
Stock issued – on vested RSAs | $ 0 | $ 0 | 0 | 0 | 0 | 0 | ||||||
Warrant exercises (in shares) | 121,000 | |||||||||||
Warrant exercises | 2,323 | 2,323 | ||||||||||
Net (loss) income | 0 | $ 0 | 0 | 0 | (1,657) | (1,657) | ||||||
Balance (in shares) at Dec. 31, 2019 | 20,825,452 | |||||||||||
Balance at Dec. 31, 2019 | $ 21 | 143,485 | 0 | (100,052) | 43,454 | |||||||
Stock based compensation | $ 0 | $ 0 | 5,981 | 0 | 0 | 5,981 | ||||||
Shares issued in acquisitions (in shares) | 0 | 611,683 | ||||||||||
Shares issued in acquisitions | $ 0 | $ 0 | 17,916 | 0 | 0 | 17,916 | ||||||
Stock option exercises | $ 0 | $ 1 | 1,471 | 0 | 0 | 1,472 | ||||||
Stock option exercises (in shares) | 0 | 777,496 | ||||||||||
Stock issued – on vested RSAs (in shares) | 0 | 208,858 | ||||||||||
Stock issued – on vested RSAs | $ 0 | $ 0 | 0 | 0 | 0 | 0 | ||||||
Warrant exercises (in shares) | 0 | 8,500 | ||||||||||
Warrant exercises | $ 0 | $ 0 | 150 | 0 | 0 | 150 | ||||||
Net (loss) income | 2,667 | 2,667 | ||||||||||
Stock issued as 2019 bonus payout | 314 | 314 | ||||||||||
Sale of common stock, net of costs (in shares) | 0 | 7,856,012 | ||||||||||
Sale of common stock, net of costs | $ 0 | $ 8 | 100,113 | 0 | 0 | 100,121 | ||||||
Common stock issued for services (in shares) | 3,175 | |||||||||||
Common stock issued for services | 60 | 60 | ||||||||||
Cashless exercises of warrants | $ 0 | $ 3 | 33,108 | 0 | 0 | 33,111 | ||||||
Cashless exercises of warrants (in shares) | 2,747,970 | |||||||||||
Balance (in shares) at Dec. 31, 2020 | 0 | 33,039,146 | ||||||||||
Balance at Dec. 31, 2020 | $ 0 | $ 33 | 302,598 | 0 | (97,385) | 205,246 | ||||||
Stock based compensation | 0 | 0 | 13,956 | 0 | 0 | 13,956 | ||||||
Shares issued in acquisitions (in shares) | 6,636,470 | 530,502 | ||||||||||
Shares issued in acquisitions | $ 7 | $ 232,734 | $ 232,741 | $ 31,977 | $ 31,977 | |||||||
Stock option exercises | $ 0 | $ 1 | 1,417 | 0 | 0 | 1,418 | ||||||
Stock option exercises (in shares) | 0 | 869,065 | ||||||||||
Stock issued – on vested RSAs (in shares) | 0 | 672,290 | ||||||||||
Stock issued – on vested RSAs | $ 0 | $ 1 | 0 | 0 | 0 | 1 | ||||||
Net (loss) income | $ 0 | 0 | 0 | 0 | (7,635) | (7,635) | ||||||
Cashless exercises of warrants | $ 0 | 2,901 | 2,901 | |||||||||
Cashless exercises of warrants (in shares) | 70,030 | |||||||||||
Fees incurred for registration filings | (186) | (186) | ||||||||||
Foreign currency translation | (282) | (282) | ||||||||||
Balance (in shares) at Dec. 31, 2021 | 0 | 41,817,503 | ||||||||||
Balance at Dec. 31, 2021 | $ 0 | $ 42 | $ 585,397 | $ (282) | $ (105,020) | $ 480,137 |
Consolidated Statements of Sh_2
Consolidated Statements of Shareholders' Equity (Parentheticals) - shares | May 14, 2020 | Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 |
WAVI Holding AG and Taurus4757 GmbH Warrants [Member] | ||||
Cashless warrant exercises (in shares) | 3,871,405 | 79,100 | 3,871,405 | |
Cashless warrant exercises (in shares) | 79,100 | 3,879,905 | 121,000 |
Consolidated Statements of Cash
Consolidated Statements of Cash Flows - USD ($) | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Cash flows from operating activities | |||
Net (loss) income | $ (7,635,000) | $ 2,667,000 | $ (1,657,000) |
Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities | |||
Depreciation | 4,663,000 | 2,035,000 | 718,000 |
Amortization of intangible assets | 8,202,000 | 3,033,000 | 1,079,000 |
Amortization of loan costs | 121,000 | 0 | 0 |
Stock-based compensation | 13,956,000 | 5,981,000 | 3,043,000 |
Non-cash lease expense | 2,053,000 | 737,000 | 512,000 |
Gain on acquisition of SAVSU | (6,451,000) | 0 | 0 |
Deferred income tax benefit | (20,127,000) | (3,297,000) | (1,541,000) |
Change in fair value of contingent consideration | 2,875,000 | 1,575,000 | 50,000 |
Change in fair value of warrant liability | 121,000 | (3,601,000) | 12,835,000 |
Change in fair value of investments | 0 | (1,319,000) | 0 |
Stock issued for services | 0 | 60,000 | 0 |
Loss on disposal of assets held for rent, net | 609,000 | 365,000 | 0 |
Loss on disposal of property and equipment, net | 482,000 | 0 | 0 |
Forgiveness of loans payable | (284,000) | 0 | 0 |
Other | 353,000 | 190,000 | 15,000 |
Change in operating assets and liabilities, net of effects of acquisitions | |||
Accounts receivable, trade, net | (10,132,000) | (1,786,000) | (290,000) |
Inventories | 114,000 | (629,000) | (3,777,000) |
Prepaid expenses and other current assets | 2,802,000 | 25,000 | (704,000) |
Accounts payable | 2,018,000 | (171,000) | 768,000 |
Accrued expenses and other current liabilities | (3,936,000) | 780,000 | (327,000) |
Warranty liability | 5,833,000 | 0 | 0 |
Other | (230,000) | 0 | (142,000) |
Net cash (used in) provided by operating activities | (4,593,000) | 6,645,000 | 1,213,000 |
Cash flows from investing activities | |||
Purchases of property and equipment | (8,385,000) | (1,961,000) | (675,000) |
Deposits on property and equipment | 0 | (2,672,000) | 0 |
Purchases of assets held for rent | (6,371,000) | (2,813,000) | (1,655,000) |
Deposits on assets held for rent | 0 | (362,000) | 0 |
Proceeds from sale of equipment | 5,000 | 35,000 | 0 |
Net cash used in investing activities | (13,192,000) | (24,715,000) | (27,018,000) |
Cash flows from financing activities | |||
Payments of contingent consideration | 0 | (483,000) | 0 |
Proceeds from sale of common stock, net of $6.2 million of costs in 2020 | 0 | 100,121,000 | 0 |
Fees paid related to issuance of common stock | (145,000) | (6,200,000) | |
Proceeds from line of credit | 27,306,000 | 0 | 0 |
Payments on line of credit | (31,536,000) | 0 | 0 |
Proceeds from exercise of common stock options | 1,418,000 | 1,472,000 | 1,181,000 |
Proceeds from exercise of warrants | 0 | 40,000 | 574,000 |
Other | (124,000) | (56,000) | (159,000) |
Net cash (used in) provided by financing activities | (2,778,000) | 102,078,000 | 1,596,000 |
Net (decrease) increase in cash, cash equivalents, and restricted cash | (20,563,000) | 84,008,000 | (24,209,000) |
Cash, cash equivalents, and restricted cash – beginning of period | 90,456,000 | 6,448,000 | 30,657,000 |
Effects of currency translation on cash, cash equivalents, and restricted cash | (23,000) | 0 | 0 |
Cash, cash equivalents, and restricted cash – end of period | 69,870,000 | 90,456,000 | 6,448,000 |
Non-cash investing and financing activities | |||
Cashless exercise of warrants reclassified from warrant liability to common stock | 2,901,000 | 33,111,000 | 0 |
Stock issued as consideration to acquire Global Cooling, Inc. and Sexton Biotechnologies, Inc. | 264,718,000 | 0 | 0 |
Equipment acquired under operating leases | 6,875,000 | 8,096,000 | 0 |
Equipment acquired under finance leases | 440,000 | 0 | 0 |
Purchase of property and equipment not yet paid | 197,000 | 0 | 29,000 |
Reclassification of warrant liabilities to equity upon exercise | 0 | 110,000 | 1,749,000 |
Cash interest paid | 452,000 | 0 | 0 |
Bonus Consideration [Member] | |||
Non-cash investing and financing activities | |||
Stock issued as bonus consideration | 0 | 314,000 | 0 |
Paycheck Protection Program CARES Act [Member] | |||
Cash flows from financing activities | |||
Proceeds from Loan | 0 | 2,175,000 | 0 |
Payoff of PPP Loan | 0 | (2,175,000) | 0 |
Equipment Loans [Member] | |||
Cash flows from financing activities | |||
Proceeds from Loan | 1,550,000 | 984,000 | 0 |
Payoff of PPP Loan | (214,000) | 0 | 0 |
Financed Insurance Premium [Member] | |||
Cash flows from financing activities | |||
Payments on financed insurance premium | (1,033,000) | 0 | 0 |
SAVSU [Member] | |||
Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities | |||
Gain on acquisition of SAVSU | 0 | 0 | (10,108,000) |
Cash flows from investing activities | |||
Cash acquired in acquisition | 0 | 0 | 1,251,000 |
Non-cash investing and financing activities | |||
Stock issued as consideration to acquire Global Cooling, Inc. and Sexton Biotechnologies, Inc. | 0 | 0 | 19,932,000 |
Astero [Member] | |||
Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities | |||
Change in fair value of contingent consideration | (81,000) | ||
Cash flows from investing activities | |||
Payments to Acquire Businesses, Net of Cash Acquired, Total | 0 | 0 | (12,439,000) |
CBS Acquisition [Member] | |||
Cash flows from investing activities | |||
Payments to Acquire Businesses, Net of Cash Acquired, Total | 0 | 0 | (11,000,000) |
Cash flows from financing activities | |||
Payments of contingent consideration | 0 | 0 | |
Non-cash investing and financing activities | |||
Stock issued as consideration to acquire Global Cooling, Inc. and Sexton Biotechnologies, Inc. | 0 | 0 | 4,000,000 |
SciSafe [Member] | |||
Cash flows from investing activities | |||
Payments to Acquire Businesses, Net of Cash Acquired, Total | (14,947,000) | 0 | |
Non-cash investing and financing activities | |||
Stock issued as consideration to acquire Global Cooling, Inc. and Sexton Biotechnologies, Inc. | 0 | 17,916,000 | 0 |
Sexton Acquisition [Member] | |||
Cash flows from investing activities | |||
Cash acquired in acquisition | 1,559,000 | ||
SAVSU Investment [Member] | |||
Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities | |||
Loss from equity method investment in SAVSU | 0 | 0 | 739,000 |
Sexton Biotechnologies, Inc. [Member] | |||
Cash flows from investing activities | |||
Investment | 0 | 0 | (1,500,000) |
IVexSol Convertible Debt Investment [Member] | |||
Cash flows from investing activities | |||
Investment in iVexSol convertible debt | 0 | 0 | (1,000,000) |
IVexSol Preferred Stock Investment [Member] | |||
Cash flows from investing activities | |||
Investment | 0 | (1,000,000) | 0 |
PanTHERA Cryosolutions Investment [Member] | |||
Cash flows from investing activities | |||
Investment | $ 0 | $ (995,000) | $ 0 |
Consolidated Statements of Ca_2
Consolidated Statements of Cash Flows (Parentheticals) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Stock issuance costs | $ 145 | $ 6,200 |
Note 1 - Organization and Signi
Note 1 - Organization and Significant Accounting Policies | 12 Months Ended |
Dec. 31, 2021 | |
Notes to Financial Statements | |
Basis of Presentation and Significant Accounting Policies [Text Block] | 1. Organization and significant accounting policies Business BioLife Solutions, Inc. (“BioLife”, “us”, “we”, “our”, or the “Company”) is a developer, manufacturer, and supplier of a portfolio of bioproduction tools and services including proprietary biopreservation media, automated thawing devices, cloud-connected shipping containers, ultra-low temperature mechanical freezers, cryogenic and controlled rate freezers and biological and pharmaceutical materials storage. Our CryoStor® freeze media and HypoThermosol® hypothermic storage media are optimized to preserve cells in the regenerative medicine market. These novel biopreservation media products are serum-free and protein-free, fully defined, and are formulated to reduce preservation-induced cell damage and death. Our Sexton cell processing product line includes human platelet lysates (“hPL”) for cell expansion reducing risk and improving downstream performance over fetal bovine serum, human serum, and other chemically defined media, CellSeal® cryogenic vials that are purpose-built rigid containers used in cell and gene therapy (“CGT”) that can be filled manually or with high throughput systems, and automated cell processing machines that bring multiple processes traditionally performed by manual techniques under a higher level of control to protect therapies from loss or contamination. Our ThawSTAR® product line is comprised of a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. These products help administer temperature-sensitive biologic therapies to patients by standardizing the thawing process and reducing the risks of contamination and overheating, which are inherent with the use of traditional water baths. Our cryogenic freezer technology provides for controlled rate freezing and cryogenic storage of biologic materials. Our ultra-low temperature mechanical freezers allow biological materials and vaccines to be stored at temperatures which range from negative 20℃ 86℃. Use of estimates The preparation of financial statements in conformity with generally accepted accounting principles in the United States (“U.S. GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities as of the date of the financial statements and reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates and assumptions by management affect the Company’s allowance for doubtful accounts, the net realizable value of inventory, fair value of warrant liability, valuation of market based awards, valuations and purchase price allocations related to investments and business combinations, expected future cash flows including growth rates, discount rates, terminal values and other assumptions and estimates used to evaluate the recoverability of long-lived assets, estimated fair values of intangible assets and goodwill, amortization methods and periods, warranty reserves, certain accrued expenses, share-based compensation, contingent consideration from business combinations, and the recoverability of the Company’s deferred tax assets and the related valuation allowance. The Company regularly assesses these estimates; however, actual results could differ materially from these estimates. Changes in estimates are recorded in the period in which they become known. The Company bases its estimates on historical experience and various other assumptions that it believes to be reasonable under the circumstances. Basis of presentation The Consolidated Financial Statements include the accounts of the Company and its wholly-owned subsidiaries, SAVSU Technologies, Inc. (“SAVSU” acquired on August 8, 2019), November 12, 2019), October 1, 2020), May 3, 2021), September 1, 2021). All long-lived assets are maintained in the United States of America and the Netherlands. Financial statement reclassification Certain classifications on the Consolidated Balance Sheets related to accrued expenses and other current liabilities, debt, current portion, and debt, long-term as of December 31, 2020 no Foreign currency translation The Company translates balance sheet and income statement items into U.S. dollars. For the Company’s subsidiaries that operate in a local currency functional environment, all assets and liabilities are translated into U.S. dollars using current exchange rates at the balance sheet date; revenue and expenses are translated using quarterly exchange rates which approximate to average exchange rates in effect during each period. Resulting translation adjustments are reported as a separate component of accumulated other comprehensive (loss) income in shareholders' equity. Segment reporting The Company views its operations and makes decisions regarding how to allocate resources and manages its business as one one Revenue recognition To determine revenue recognition for contractual arrangements that we determine are within the scope of Financial Accounting Standards Board (“FASB”) Topic 606, Revenue from Contracts with Customers five five may not 30 90 December 31, 2021, The Company primarily recognizes product revenues, service revenues, and rental revenues. Product revenues are generated from the sale of biopreservation media, ThawSTAR, and freezer products. We recognize product revenue, including shipping and handling charges billed to customers, at a point in time when we transfer control of our products to our customers, which is upon shipment for substantially all transactions. Shipping and handling costs are classified as part of cost of product revenue in the Consolidated Statement of Operations. Service revenues are generated from the storage of biological and pharmaceutical materials. We recognize service revenues over time as services are performed or ratably over the contract term. To the extent the transaction price includes variable consideration, the Company estimates the amount of variable consideration that should be included in the transaction price utilizing the expected value method or the most likely amount method, depending on the facts and circumstances relative to the contract. When determining the transaction price of a contract, an adjustment is made if payment from a customer occurs either significantly before or significantly after performance, resulting in a significant financing component. Applying the practical expedient in paragraph 606 10 32 18, not one None December 31, 2021. The Company also generates revenue from the leasing of our property, plant, and equipment, operating right-of-use assets, and evo cold chain systems to customers pursuant to service contracts or rental arrangements entered into with the customer. Revenue from these arrangements is not 606 842, Lease The Company enters into various customer service agreements (collectively, “Service Contracts”) with customers to provide biological and pharmaceutical storage services. In certain of these Service Contracts, the property, plant, and equipment or operating right-of-use assets used to store the customer product are used only for the benefit of one may not The Company has assessed its Service Contracts and concluded that certain of the contracts for the storage of customer products met the criteria to be considered a leasing arrangement (“Embedded Leases”), with the Company as the lessor. The specific Service Contracts that met the criteria were those that provided a single customer with the ability to substantially direct the use of the Company’s property, plant, and equipment or operating right-of-use assets. Under ASC 842, None None Embedded Leases may Total bioproduction tools and services revenue for the years ended December 31, 2021, 2020, 2019 Year Ended December 31, (In thousands, except percentages) 2021 2020 2019 Product revenue Freezer and thaw $ 56,620 $ 13,548 $ 3,312 Cell processing 44,965 30,946 23,367 Storage and cold chain services 328 46 165 Service revenue Storage and cold chain services 9,817 1,752 - Rental revenue Storage and cold chain services 7,426 1,795 527 Total revenue $ 119,156 $ 48,087 $ 27,371 ( 1 2021 May 3, 2021 December 31, 2021 September 1, 2021 December 31, 2021. ( 2 2020 October 1, 2020 December 31, 2020. ( 3 2019 April 1, 2019 December 31, 2019; August 8, 2019 December 31, 2019; November 12, 2019 December 31, 2019. The following table includes estimated rental revenue expected to be recognized in the future related to embedded leases as well as estimated service revenue expected to be recognized in the future related to performance obligations that are unsatisfied or partially unsatisfied as of the end of the reporting periods. The Company is electing not one 2014 09, Revenue from Contracts with Customers not one December 31, 2021. The balances in the table below are partially based on judgments involved in estimating future orders from customers subject to the exercise of material rights pursuant to respective contracts: Year Ending December 31, (In thousands) 2022 2023 2024 Total Rental revenue $ 10,151 $ 3,748 $ 900 $ 14,799 Service revenue $ 67 $ 31 $ 10 $ 108 Risks and uncertainties COVID- 19 Our domestic and international operations have been and continue to be affected by the ongoing global pandemic of a novel strain of coronavirus (“COVID- 19” December 31, 2021, In the year ended December 31, 2021, 19 not 19 19. The Company reviews capital and amortizing intangible assets (long-lived assets) for impairment on an annual basis or whenever events or changes in circumstances indicate that the carrying amount may not 19 June 30, 2020 19. As a result of the Company’s outlook for revenue from the ThawSTAR and freezer product lines, estimated undiscounted cash flow projections were developed to determine if any impairment of the related intangible assets was warranted. After conducting such review, the Company determined that there was no June 30, 2020. 19 The Company revised the revenue projections for the ThawSTAR and freezer product lines in the second June 30, 2020 December 31, 2020 two no December 31, 2020. June 30, 2020, December 31, 2020 December 31, 2020. The Company may 19 third Any disruption and volatility in the global capital markets as a result of the pandemic may 19 not The ultimate extent to which the COVID- 19 19 On March 27, 2020, On March 11, 2021, 2021” We determined that we met the original eligibility requirements per the guidelines original established by the U.S. federal government as part of the CARES Act for the Pursuant to the Paycheck Protection Program (the “PPP”). As such, on April 20, 2020, April 29, 2020. March 30, 2020, December 31, 2021, December 31, 2021, December 31, 2022. In the SciSafe acquisition, the Company acquired a $295,300 loan from the PPP. The loan incurred interest at 1% and was unsecured. Of the principal borrowed, $284,000 was forgiven in December 2021. not December 2021. Earnings per share The Company considers its unexercised warrants and unvested restricted shares, which contain non-forfeitable rights to dividends, participating securities, and includes such participating securities in its computation of earnings per share pursuant to the two two two The following table presents computations of basic and diluted earnings per share under the two Year Ended December 31, (In thousands, except share and earnings per share data) 2021 2020 2019 Basic earnings (loss) per common share Numerator: Net (loss) income $ (7,635 ) $ 2,667 $ (1,657 ) Amount attributable to unvested restricted shares - (135 ) - Amount attributable to warrants outstanding - (82 ) - Net (loss) income allocated to common shareholders (7,635 ) 2,450 (1,657 ) Denominator: Weighted-average common shares issued and outstanding 38,503,944 27,306,258 19,460,299 Basic (loss) earnings per common share $ (0.20 ) $ 0.09 $ (0.09 ) Diluted earnings (loss) per common share Numerator: Net (loss) income $ (7,635 ) $ 2,667 $ (1,657 ) Amount attributable to warrants - (20 ) - Less: gain related to change in fair value of warrants - (3,601 ) - Diluted (loss) earnings per common share (7,635 ) (954 ) (1,657 ) Denominator: Weighted-average common shares issued and outstanding 38,503,944 27,306,258 19,460,299 Diluted (loss) earnings per common share $ (0.20 ) $ (0.03 ) $ (0.09 ) The following table sets forth the number of shares excluded from the computation of diluted loss per share, as their inclusion would have been anti-dilutive: Year Ended December 31, 2021 2020 2019 Stock options and restricted stock awards 1,637,745 2,131,794 2,564,456 Warrants 18,204 1,499,953 2,956,039 Total 1,655,949 3,631,747 5,520,495 Cash, cash equivalents, and restricted cash Cash equivalents consist primarily of interest-bearing money market accounts. We consider all highly liquid debt instruments purchased with an initial maturity of three may not Restricted cash consists entirely of amounts that will be recovered from escrow in relation to the acquisition of SciSafe. The restricted cash is short term in nature, as the Company anticipates to receive the funds within one The following is a summary of the Company’s cash, cash equivalents, and restricted cash total as presented in the Company’s consolidated statements of cash flows for the years ended December 31, 2021, 2020, 2019. Year Ended December 31, (In thousands) 2021 2020 2019 Cash and cash equivalents $ 69,860 $ 90,403 $ 6,448 Restricted cash 10 53 - Total cash, cash equivalents, and restricted cash $ 69,870 $ 90,456 $ 6,448 Inventories Inventories relate to the Company’s cell and gene therapy products. The Company values biopreservation media inventory at cost or, if lower, net realizable value, using the specific identification method. All other inventory is valued at cost or, if lower, net realizable value, using the first first no Accounts receivable Accounts receivable consist of short-term amounts due from our customers (generally 30 90 Accounts receivable are stated at principal amount, do not Investments We periodically invest in securities of private companies to promote business and strategic objectives. These investments are measured and recorded as follows: Non-marketable equity securities are equity securities without a readily determinable fair value. As of December 31, 2021, 1 2 December 31, 2020, 1 2 As of December 31, 2021, September 1, 2021. December 31, 2020, not September 2019, December 31, 2021, 2020, 2019, November 2020, 1 2 In November 2020, June 2021, first As of December 31, 2021, no Property and equipment Property and equipment are stated at cost and are depreciated using the straight-line method over estimated useful lives of three ten Property and equipment are reviewed for impairment whenever events or changes in circumstances indicate that their net book value may not may December 31, 2021, 2020, 2019. Assets held for rent Assets held for rent are carried at cost less accumulated depreciation. These assets consist of dedicated storage space, evo shippers and related components in production shippers complete and ready to be deployed and placed in service upon a customer order, shippers in the process of being assembled, and components available to build shippers. Assets utilized to provide dedicated storage space are depreciated over their applicable useful lives once placed in service. Shippers are depreciated over a useful life of three Our customers rent assets per a rental agreement. Each agreement provides for fixed monthly rent. Rental revenue and fees are recognized over the rental term on a straight-line basis. We retain the ownership of the assets rented. At the end of the rental agreement, the customer returns the asset to the Company. Assets held for rent are reviewed for impairment whenever events or changes in circumstances indicate that their net book value may not may no December 31, 2021, 2020, 2019. Lease accounting We determine if an arrangement is a lease at inception. Where an arrangement is a lease, we determine if it is an operating lease or a finance lease. At lease commencement, we record a lease liability and corresponding right-of-use (“ROU”) asset. Lease liabilities represent the present value of our future lease payments over the expected lease term which includes options to extend or terminate the lease when it is reasonably certain those options will be exercised. The present value of our lease liability is determined using our incremental collateralized borrowing rate at lease inception. ROU assets represent our right to control the use of the leased asset during the lease and are recognized in an amount equal to the lease liability for leases with an initial term greater than 12 We elected to apply the practical expedient for short-term leases and accordingly do not twelve Warranty Our standard warranty terms typically extend between one seven Income taxes We account for income taxes using an asset and liability method which generally requires recognition of deferred tax assets and liabilities for the expected future tax effects of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are recognized for the future tax effects of differences between tax bases of assets and liabilities, and financial reporting amounts, based upon enacted tax laws and statutory rates applicable to the periods in which the differences are expected to affect taxable income. We evaluate the likelihood of realization of deferred tax assets and provide an allowance where, in management’s opinion, it is more likely than not not We determine any uncertain tax positions based on a determination of whether and how much of a tax benefit taken in the Company’s tax filings or positions is more likely than not Judgment is applied in the determination of the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. As of December 31, 2021, Advertising Advertising costs are expensed as incurred and totaled $552,000, $167,000, and $43,000 for the years ended December 31, 2021, 2020, 2019, Concentrations of risk In the years ended December 31, 2021, 2020, 2019, one No 10% In the year ended December 31, 2019, No 10% December 31, 2021, 2020, 2019. The following table represents the Company’s total revenue by geographic area (based on the location of the customer): Year Ended December 31, Revenue by customers geographic locations 2021 2020 2019 United States 78 % 73 % 69 % Canada 7 % 13 % 16 % Germany 4 % 4 % 3 % Europe, Middle East, Africa (excluding Germany) 10 % 8 % 11 % Other 1 % 2 % 1 % Total revenue 100 % 100 % 100 % The following table represents the Company’s long-lived assets by geographic area as of December 31: (In thousands) 2021 2020 United States $ 40,708 $ 30,389 Netherlands 5,903 - Total $ 46,611 $ 30,389 As of December 31, 2021 2020, two one No 10% As of December 31, 2021 2020, one one No 10% Research and development Research and development costs are expensed as incurred. Stock-based compensation We measure and record compensation expense using the applicable accounting guidance for share-based payments related to stock options, time-based restricted stock, market-based restricted stock awards and performance-based restricted stock awards granted to our directors and employees. The fair value of stock options, including performance awards, without a market-based condition is determined by using the Black-Scholes option-pricing model. The fair value of restricted stock awards with a market condition is estimated at the date of grant using the Monte Carlo Simulation model. The Black-Scholes and Monte Carlo Simulation valuation models incorporate assumptions as to stock price volatility, the expected life of options or awards, a risk-free interest rate and dividend yield. The fair value of restricted stock, including performance awards, without a market condition is estimated using the current market price of our common stock on the date of grant. We expense stock-based compensation for stock options, restricted stock awards, and performance awards over the requisite service period. For awards with only a service condition, we expense stock-based compensation using the straight-line method over the requisite service period for the entire award. For awards with a market condition, we expense the grant date fair value over the vesting period regardless of the value that the award recipients ultimately receive. We have, from time to time, modified the terms of restricted stock awards awarded to employees. We account for the incremental increase in the fair value over the original award on the date of the modification as an expense for vested awards or over the remaining service (vesting) period for unvested awards. The incremental compensation cost is the excess of the fair value of the modified award on the date of modification over the fair value of the original award immediately before the modification. Business combinations, goodwill and intangible assets Business combinations The Company accounts for business acquisitions using the acquisition method as required by FASB ASC Topic 805, Business Combinations The Company’s identifiable assets acquired and liabilities, including identified intangible assets, assumed in a business combination are recorded at their acquisition date fair values. The valuation requires management to make significant estimates and assumptions, especially with respect to long-lived and intangible assets. Critical estimates in valuing intangible assets include, but are not ● future expected cash flows, including revenue and expense projections; ● discount rates to determine the present value of recognized assets and liabilities and; ● revenue volatility to determine contingent consideration using option pricing models Goodwill is calculated as the excess of the acquisition price over the fair value of net assets acquired, including the amount assigned to identifiable intangible assets. Acquisition-related costs, including advisory, legal, accounting, valuation, and other costs, are expensed in the periods in which these costs are incurred. The results of operations of an acquired business are included in the consolidated financial statements beginning at the acquisition date. The Company estimates the acquisition date fair value of the acquisition-related contingent consideration using various valuation approaches, including option pricing models, as well as significant unobservable inputs, reflecting the Company’s assessment of the assumptions market participants would use to value these liabilities. The fair value of the contingent consideration is remeasured each reporting period. During the measurement period, which may one Goodwill Goodwill represents the excess of the purchase price over the net amount of identifiable assets acquired and liabilities assumed in a business combination measured at fair value. Goodwill is not fourth may first not 350, Intangibles Goodwill and Other not 50 not not not not one fourth 2021. no Intangible assets Intangible assets with a definite life are amortized over their estimated useful lives using the straight-line method and the amortization expense is recorded within intangible asset amortization in the Consolidated Statements of Operations. If the estimate of a definite-lived intangible asset’s remaining useful life is changed, the remaining carrying amount of the intangible asset is amortized prospectively over the revised remaining useful life. Definite-lived intangible assets and their related estimated useful lives are reviewed at least annually to determine if any adverse conditions exist that would indicate the carrying value of these assets may not no may not Indefinite-lived intangibles are carried at the initially recorded fair value less any recognized impairment. In-process research and development (“IPR&D”) is initially capitalized at fair value as an intangible asset with an indefinite life. When the IPR&D project is complete, it is reclassified as a definite-lived intangible asset and is amortized over its estimated useful life. If an IPR&D project is abandoned, a charge would be recorded for the value of the related intangible asset to our Consolidated Statement of Operations in the period it is abandoned. Indefinite-lived intangibles are tested annually for impairment. Impairment assessments are conducted more frequently if certain conditions exist, including a change in the competitive landscape, any internal decisions to pursue new or different technology strategies, a loss of a significant customer, or a significant change in the marketplace, including changes in the prices paid for the Company’s products or changes in the size of the market for the Company’s products. If impairment indicators are present, the Company determines whether the underlying intangible asset is recoverable through estimated future undiscounted cash flows. If the asset is not one 2021 fourth 2021 no 2021 no Certain warrants which have features that may Warrants that include cash settlement features are recorded as liabilities at their estimated fair value at the date of issuance and are remeasured at fair value each reporting period with the increase or decrease in fair value recorded in the Consolidated Statements of Operations. The warrants are measured at estimated fair value using the Black Scholes valuation model, which is based, in part, upon inputs for which there is little or no zero December 31, 2021, no December 31: 2020 2019 Risk free interest rate 0.1 % 1.9 % Expected dividend yield 0.0 % 0.0 % Contractual remaining lives 0.2 1.7 Expected volatility 56.8 % 70.3 % Recent accounting pronouncements In November 2021, No. 2021 10, Government Assistance (Topic 832 December 15, 2023, In October 2021, No. 2021 08, Business Combinations (Topic 805 Accounting for Contract Assets and Contract Liabilities from Contracts with Customers Revenue from Contracts with Customers (Topic 606 606 2021 08 December 15, 2022, In July 2021, No. 2021 05, Leases (Topic 842 2021 05 840. not 1 842 10 25 2 25 3; 2 one 2021 05 December 15, 2021, not In May 2021, No. 2021 04, Issuer s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options 2021 04 2021 04 December 15, 2021, 2021 04 not In August 2020, No. 2020 06, Debt - Debt with Conversion and Other Options (Subtopic 470 20 s Own Equity (Subtopic 815 40 2020 06 2020 06 2020 06 December 15, 2021, no December 15, 2020. not In March 2020, No. 2020 04, Reference Rate Reform (Topic 848 2020 04 January 2021, 2021 01, no December 1, 2022, not In June 2016, No. 2016 13, Financial Instruments Credit Losses (Topic 326 2016 13 November 19, 2019, 2016 13 December 15, 2023, |
Note 2 - Fair Value Measurement
Note 2 - Fair Value Measurement | 12 Months Ended |
Dec. 31, 2021 | |
Notes to Financial Statements | |
Fair Value Disclosures [Text Block] | 2. Fair value measurement In accordance with FASB ASC Topic 820, Fair Value Measurements and Disclosures 820” 2 820 820 three Level 1 Level 2 1 not Level 3 For the investment in iVexSol convertible debt that was converted to Series A- 1 November 2020, 3 September 2019 The fair value of the Astero contingent consideration liability was initially valued based on unobservable inputs using a Black-Scholes valuation model. These inputs included the estimated amount and timing of projected future revenue, a discount rate of 17.5%, risk-free rates between 2.29% and 2.41% and revenue volatility of 56%. Significant increases (decreases) in any of those inputs in isolation would result in a significantly higher (lower) fair value measurement. Generally, changes used in the assumptions for projected future revenue and revenue volatility would be accompanied by a directionally similar change in the fair value measurement. Conversely, changes in the discount rate would be accompanied by a directionally opposite change in the related fair value measurement. However, due to the contingent consideration having a maximum payout amount, changes in these assumptions would not December 31, 2021, December 31, 2021. December 31, 2020 $81,000. The fair value of the CBS contingent consideration liability was initially valued based on unobservable inputs using a Monte Carlo simulation. These inputs included the estimated amount and timing of projected future revenue, a discount rate of 26.0%, a risk-free rate of approximately 1.74% and revenue volatility of 70%. Significant increases (decreases) in any of those inputs in isolation would result in a significantly higher (lower) fair value measurement. Generally, changes used in the assumptions for projected future revenue and revenue volatility would be accompanied by a directionally similar change in the fair value measurement. Conversely, changes in the discount rate would be accompanied by a directionally opposite change in the related fair value measurement. However, due to the contingent consideration having a maximum payout amount, changes in these assumptions would not December 31, 2021, December 31, 2021 2020 The fair value of the SciSafe contingent consideration liability was initially valued based on unobservable inputs using a Monte Carlo simulation. These inputs included the estimated amount and timing of projected future revenue, a discount rate of 4.5%, a risk-free rate of approximately 0.20%, asset volatility of 60%, and revenue volatility of 15%. Significant increases (decreases) in any of those inputs in isolation would result in a significantly higher (lower) fair value measurement. Generally, changes used in the assumptions for projected future revenue and revenue volatility would be accompanied by a directionally similar change in the fair value measurement. Conversely, changes in the discount rate would be accompanied by a directionally opposite change in the related fair value measurement. However, due to the contingent consideration having a maximum payout amount, changes in these assumptions would not December 31, 2021, December 31, 2021 2020 December 31, 2021 2020, For the warrant liability, the significant Level 3 March 25, 2021. December 31, 2020, not March 25, 2021, There were no December 31, 2021 not The following tables set forth the Company’s financial assets and liabilities measured at fair value on a recurring basis as of December 31, 2021 2020, three (In thousands) As of December 31, 2021 Level 1 Level 2 Level 3 Total Assets: Money market accounts $ 63,873 $ - $ - $ 63,873 Total 63,873 - - 63,873 Liabilities: Contingent consideration - business combinations - - 10,027 10,027 Total $ - $ - $ 10,027 $ 10,027 As of December 31, 2020 Level 1 Level 2 Level 3 Total Assets: Money market accounts $ 90,403 $ - $ - $ 90,403 Total 90,403 - - 90,403 Liabilities: Contingent consideration - business combinations - - 7,152 7,152 Warrant liability - - 2,780 2,780 Total $ - $ - $ 9,932 $ 9,932 The fair values of money market funds classified as Level 1 3 1 Organization and Significant Accounting Policies. no The following table presents the changes in fair value of contingent consideration liabilities which are measured using Level 3 December 31, 2021, 2020, 2019: Year Ended December 31, (In thousands) 2021 2020 2019 Beginning balance $ 7,152 $ 1,914 - Additions - 3,663 2,347 Change in fair value recognized in net (loss) income 2,875 1,575 50 Payments earned, reclassified to accrued liabilities - - (483 ) Ending balance $ 10,027 $ 7,152 $ 1,914 The following table presents the changes in fair value of warrant liabilities which are measured using Level 3 December 31, 2021, 2020, 2019: Year Ended December 31, (In thousands) 2021 2020 2019 Beginning balance $ 2,780 $ 39,602 28,516 Exercised warrants (2,901 ) (33,221 ) (1,749 ) Change in fair value recognized in net (loss) income 121 (3,601 ) 12,835 Ending balance $ - $ 2,780 $ 39,602 |
Note 3 - Inventories
Note 3 - Inventories | 12 Months Ended |
Dec. 31, 2021 | |
Notes to Financial Statements | |
Inventory Disclosure [Text Block] | 3. Inventories Inventories consist of the following as of December 31, 2021 2020: (In thousands) 2021 2020 Raw materials $ 17,252 $ 2,855 Work in progress 5,015 2,006 Finished goods 6,078 6,741 Total $ 28,345 $ 11,602 |
Note 4 - Assets Held for Rent
Note 4 - Assets Held for Rent | 12 Months Ended |
Dec. 31, 2021 | |
Notes to Financial Statements | |
Assets Held For Rent [Text Block] | 4. Assets held for rent Assets held for rent consist of the following as of December 31, 2021 2020: (In thousands) 2021 2020 Shippers placed in service $ 5,645 $ 3,171 Fixed assets held for rent 4,040 - Accumulated depreciation (2,272 ) (411 ) Net 7,413 2,760 Shippers and related components in production 2,396 1,945 Total $ 9,809 $ 4,705 Shippers and related components in production include shippers complete and ready to be deployed and placed in service upon a customer order, shippers in the process of being assembled, and components available to build shippers. We recognized $1.9 million, $671,000, and $174,000 in depreciation expense related to assets held for rent during the years ended December 31, 2021, 2020, 2019, |
Note 5 - Leases
Note 5 - Leases | 12 Months Ended |
Dec. 31, 2021 | |
Notes to Financial Statements | |
Lessee, Leases [Text Block] | 5. Leases We have various operating lease agreements for office space, warehouses, manufacturing, and production locations as well as vehicles and other equipment. Our real estate leases have remaining lease terms of one ten not one five one five Our financing leases relate to research equipment, machinery, and other equipment. The table below presents certain information related to the weighted average discount rate and weighted average remaining lease term for the Company’s leases as of December 31, 2021 2020: 2021 2020 Weighted average discount rate - operating leases 3.8 % 3.3 % Weighted average discount rate - finance leases 6.1 % 5.7 % Weighted average remaining lease term in years - operating leases 7.8 9.4 Weighted average remaining lease term in years - finance leases 3.0 2.6 The components of lease expense for the years ended December 31, 2021, 2020, 2019 Year Ended December 31, (In thousands) 2021 2020 2019 Operating lease costs $ 2,817 $ 839 $ 612 Short-term lease costs 1,727 277 51 Total operating lease costs 4,544 1,116 663 Variable lease costs 749 357 299 Total lease expense $ 5,293 $ 1,473 $ 962 Maturities of our lease liabilities as of December 31, 2021 (In thousands) Operating Leases Financing Leases 2022 $ 3,443 $ 171 2023 3,151 171 2024 2,883 101 2025 2,497 37 2026 2,006 2 Thereafter 8,364 - Total lease payments 22,344 482 Less: interest (3,120 ) (42 ) Total present value of lease liabilities $ 19,224 $ 440 |
Note 6 - Goodwill and Intangibl
Note 6 - Goodwill and Intangible Assets | 12 Months Ended |
Dec. 31, 2021 | |
Notes to Financial Statements | |
Goodwill and Intangible Assets Disclosure [Text Block] | 6. Goodwill and intangible assets Goodwill The following table represents the changes in the carrying value of goodwill for the years ended December 31, 2021 2020: (In thousands) Goodwill Balance as of December 31, 2019 $ 33,637 Correction of an error related to CBS goodwill (131 ) Goodwill related to SciSafe acquisition 24,943 Balance as of December 31, 2020 58,449 Goodwill related to Global Cooling acquisition 137,822 Goodwill related to Sexton acquisition 28,470 Balance as of December 31, 2021 $ 224,741 We adjusted goodwill from the CBS Acquisition related to an immaterial error of $131,000 in payables that were paid during closing and incorrectly recorded as liabilities in our purchase price accounting as of December 31, 2019. December 31, 2020. Intangible assets Intangible assets, net consisted of the following as of December 31, 2021 2020: (In thousands, except weighted average useful life) December 31, 2021 Intangible assets: Gross Carrying Value Accumulated Amortization Net Carrying Value Weighted Average Useful Life (in years) Customer Relationships $ 17,516 $ (1,776 ) $ 15,740 10.3 Tradenames 35,574 (2,306 ) 33,268 13.8 Technology - acquired 41,942 (7,789 ) 34,153 5.9 Non-compete agreements 1,990 (442 ) 1,548 3.0 In-process research and development⁽¹⁾ 67,440 - 67,440 N/A Total intangible assets $ 164,462 $ (12,313 ) $ 152,149 9.8 December 31, 2020 Intangible assets: Gross Carrying Value Accumulated Amortization Net Carrying Value Weighted Average Useful Life (in years) Customer Relationships $ 8,220 $ (330 ) $ 7,890 12.8 Tradenames 6,610 (508 ) 6,102 14.0 Technology - acquired 19,670 (3,232 ) 16,438 7.1 Non-compete agreements 660 (41 ) 619 3.8 Total intangible assets $ 35,160 $ (4,111 ) $ 31,049 9.7 ( 1 In-process R&D represents the fair value of incomplete research and development that has not Amortization expense for finite-lived intangible assets was $8.2 million, $3.0 million, and $1.1 million for the years ended December 31, 2021, 2020, 2019, December 31, 2021, (In thousands) For the Years Ending December 31, Estimated Amortization Expense 2022 $ 11,421 2023 10,951 2024 10,126 2025 9,748 2026 9,346 Thereafter 33,117 Total $ 84,709 |
Note 7 - Line of Credit and Lon
Note 7 - Line of Credit and Long-term Debt | 12 Months Ended |
Dec. 31, 2021 | |
Notes to Financial Statements | |
Long-term Debt [Text Block] | 7. Line of credit and long-term debt Line of credit In May 2021, 3 October 2021, Long-term debt In May 2021, three 3 In October 2021, three one two one three one Long-term debt consisted of the following as of December 31, 2021 2020: December 31, (In thousands) Maturity Date Interest Rate 2021 2020 2022 term loan 1 Sep-24 4.0 % $ 1,750 $ - 2022 term loan 2 Various 4.0 % 2,813 - Insurance premium financing Apr-22 4.0 % 373 - Paycheck Protection Program loan May-22 1.0 % - 295 Freezer equipment loan Dec-25 5.7 % 612 365 Manufacturing equipment loans Oct-25 5.7 % 355 439 Freezer installation loan Various 6.3 % 1,334 156 Other loans Various Various 9 14 Total debt, excluding unamortized debt issuance costs 7,246 1,269 Less: unamortized debt issuance costs (31 ) - Total debt 7,215 1,269 Less: current portion of debt (862 ) (614 ) Total long-term debt $ 6,353 $ 655 The 2022 As of December 31, 2021, five (In thousands) Amount 2022 $ 862 2023 813 2024 2,294 2025 543 2026 221 Thereafter 2,513 Total debt, excluding unamortized debt issuance costs 7,246 Less: unamortized debt issuance costs (31 ) Total debt $ 7,215 |
Note 8 - Income Taxes
Note 8 - Income Taxes | 12 Months Ended |
Dec. 31, 2021 | |
Notes to Financial Statements | |
Income Tax Disclosure [Text Block] | 8. Income taxes The following are the domestic and foreign components of the Company's loss before income taxes: Year Ended December 31, (In thousands) 2021 2020 2019 Domestic $ (27,317 ) $ (597 ) $ (3,198 ) Foreign (436 ) - - Total $ (27,753 ) $ (597 ) $ (3,198 ) Income tax benefit consists of the following: Year Ended December 31, (In thousands) 2021 2020 2019 Current: Federal $ - $ - $ - State - 33 - Foreign 9 - - Total current tax provision 9 33 - Deferred: Federal (17,703 ) (3,297 ) (1,541 ) State (2,424 ) - - Foreign - - - Total deferred tax benefit (20,127 ) (3,297 ) (1,541 ) Income tax benefit $ (20,118 ) $ (3,264 ) $ (1,541 ) In the years ended December 31, 2021, 2020, 2019, In connection with the 2021 2021 In connection with the 2020 $3.3 In connection with the 2019 $1.5 A reconciliation of income taxes computed using the U.S. federal statutory rate to that reflected in operations follows: Year Ended December 31, 2021 2020 2019 Federal statutory tax 21 % 21 % 21 % State tax, net of federal benefit 7 % 39 % - Stock compensation 38 % 538 % 74 % Sec. 162(m) limitation on executive compensation (12 %) (35 %) (17 %) Fair value change in contingent consideration (2 %) (81 %) - Fair value change in warrant liability - 127 % (82 %) Transaction costs (1 %) (6 %) (4 %) Gain on stock acquisition 5 % - 64 % Tax credits - 12 % 5 % Change in valuation allowance 21 % 35 % (5 %) Book loss on equity method investment - - (5 %) Expired net operating losses (5 %) (100 %) (5 %) Other - (3 %) 1 % Total 72 % 547 % 47 % The principal components of the Company’s net deferred tax assets are as follows as of December 31, 2021 2020: (In thousands) 2021 2020 Deferred tax assets related to: Net operating loss carryforwards $ 27,500 $ 12,314 Stock-based compensation 2,066 1,678 Accruals and reserves 2,902 427 Inventory 236 142 Lease liabilities 4,198 2,247 Tax credit carryforward 594 225 Other 318 48 Total deferred tax assets 37,814 17,081 Deferred tax liabilities related to: Intangibles (35,241 ) (5,025 ) Right-of-use assets (4,070 ) (2,261 ) Fair value change in investments (294 ) (287 ) Fixed assets (1,203 ) (959 ) Other - (51 ) Total deferred tax liabilities (40,808 ) (8,583 ) Net deferred tax (liabilities) assets before valuation allowance (2,994 ) 8,498 Less: valuation allowance (2,493 ) (8,498 ) Net deferred tax liabilities $ (5,487 ) $ - Realization of deferred tax assets is dependent upon the generation of future taxable income, if any, the timing and amount of which are uncertain. The assessment regarding whether a valuation allowance is required on deferred tax assets considers the evaluation of both positive and negative evidence when concluding whether it is more likely than not December 31, 2021 2020 The changes in the valuation allowance for deferred tax assets were as follows: (In thousands) 2021 2020 2019 Balance at January 1 $ 8,498 $ 8,706 $ 8,345 Deferred tax liabilities assumed through acquisitions (8,498 ) (3,297 ) (1,541 ) Charged to income tax expense 2,493 3,089 1,902 Balance at December 31 $ 2,493 $ 8,498 $ 8,706 As of December 31, 2021, 2023 2037, may The Company determines its uncertain tax positions based on a determination of whether and how much of a tax benefit taken by the Company in its tax filings or positions is more likely than not A reconciliation of the beginning and ending balances of uncertain tax positions in the years ended December 31, 2021 2020 (In thousands) 2021 2020 Balance as of January 1 $ 96 $ - Increase related to prior year tax positions - 36 Increase related to current year tax positions 159 60 Balance as of December 31 $ 255 $ 96 The Company did not December 31, 2019. 2003 2021. |
Note 9 - Warrants
Note 9 - Warrants | 12 Months Ended |
Dec. 31, 2021 | |
Notes to Financial Statements | |
Warrants [Text Block] | 9. Warrants In March 2014, March 2021. In May 2016, May 2021. In May 2020, Taurus4757 In March 2021, The following table summarizes warrant activity for the years ended December 31, 2021, 2020, 2019: 2021 2020 2019 Shares Wtd. Avg. Exercise Price Shares Wtd. Avg. Exercise Price Shares Wtd. Avg. Exercise Price Outstanding at beginning of year 79,100 $ 4.75 3,959,005 $ 4.33 4,080,005 $ 4.35 Exercised (79,100 ) 4.75 (3,879,905 ) 4.33 (121,000 ) 4.75 Outstanding and exercisable at end of year - $ - 79,100 $ 4.75 3,959,005 $ 4.33 |
Note 10 - Stock-based Compensat
Note 10 - Stock-based Compensation | 12 Months Ended |
Dec. 31, 2021 | |
Notes to Financial Statements | |
Share-based Payment Arrangement [Text Block] | 10. Stock-based compensation Stock compensation plans Our stock-based compensation programs are long-term retention programs that are intended to attract, retain and provide incentives for talented employees, officers and directors, and to align stockholder and employee interests. We have the following stock-based compensation plans and programs: During 2013, 2013 “2013 2013 May 2017, July 2020, June 2021, December 31, 2021, 2013 The Company also issued, outside any approved compensation plans, non-incentive stock options. As of December 31, 2021, 2019. Issuance of shares When options and warrants are exercised, it is the Company’s policy to issue new shares. Stock option activity Service vesting-based stock options The following is a summary of service vesting-based stock option activity for the year ended December 31, 2021 2020, December 31, 2021 2020: 2021 2020 Shares Wtd. Avg. Exercise Price Shares Wtd. Avg. Exercise Price Outstanding as of beginning of year 844,455 $ 2.00 1,570,455 $ 1.96 Exercised (183,064 ) 1.61 - - Forfeited (1,146 ) 5.69 (726,000 ) 1.91 Expired (35,714 ) 1.73 - - Outstanding as of end of year 624,531 $ 2.13 844,455 $ 2.00 Stock options exercisable at year end 624,531 $ 2.13 832,478 $ 1.98 We recognized stock compensation expense related to service-based options of $25,000, $119,000, and $370,000 during the years ended December 31, 2021, 2020, 2019. December 31, 2021, December 31, 2021. December 31, 2021, 2020, 2019 December 31, 2021, 2020, 2019. December 31, 2021 December 31, 2021. The following table summarizes information about service vesting-based stock options outstanding as of December 31, 2021: Range of Exercise Prices Number Outstanding as of December 31, 2021 Weighted Average Remaining Contractual Life Weighted Average Exercise Price $1.00 - 1.50 26,428 1.05 $ 1.38 $1.51 - 2.00 290,760 3.27 1.87 $2.01 - 2.50 265,775 3.35 2.06 $2.51 - 8.60 41,568 3.75 4.86 624,531 3.24 $ 2.13 Performance-based stock options The Company’s Board of Directors implemented a Management Performance Bonus Plan for 2017. December 31, 2017, 2017 not no February 27, 2018, 2017 2018. The following is a summary of performance-based stock option activity under our stock option plans for the years ended December 31, 2021 2020, December 31, 2021 2020: 2021 2020 Shares Wtd. Avg. Exercise Price Shares Wtd. Avg. Exercise Price Outstanding as of beginning of year 686,001 $ 1.64 737,497 $ 1.64 Exercised (686,001 ) 1.64 (51,496 ) 1.64 Outstanding as of end of year - $ - 686,001 $ 1.64 Stock options exercisable as of year end - $ - 686,001 $ 1.64 No stock compensation expense was recognized during the years ended December 31, 2021, 2020, 2019 December 31, 2021, 2020, 2019 December 31, 2021, 2020, 2019. Restricted stock Service vesting-based restricted stock The following is a summary of service vesting-based restricted stock activity for the years ended December 31, 2021 2020, December 31, 2021 2020: 2021 2020 Shares Wtd. Avg. Grant Date Fair Value Shares Wtd. Avg. Grant Date Fair Value Outstanding as of beginning of year 930,854 $ 19.31 429,399 $ 13.25 Granted 801,484 47.20 717,267 20.88 Granted in lieu of cash - - 34,154 9.18 Vested (378,502 ) 19.31 (208,858 ) 11.32 Forfeited (141,053 ) 36.95 (41,108 ) 15.47 Non-vested as of year end 1,212,783 $ 37.48 930,854 $ 19.31 On November 4, 2021, one 2023. four December 31, 2022. December 31, 2021 The aggregate fair value of the service vesting-based awards granted during the years ended December 31, 2021, 2020, 2019 December 31, 2021, 2020, 2019 On March 25, 2020, 2019 September 25, 2020 December 31, 2019. We recognized stock compensation expense of $12.7 million, $3.0 million, and $1.2 million related to service vesting-based awards during the years ended December 31, 2021, 2020, 2019, December 31, 2021, Performance-based restricted stock On March 25, 2020, 2020 December 31, 2020. The following is a summary of performance-based restricted stock activity for the years ended December 31, 2021 2020: 2021 2020 Shares Wtd. Avg. Grant Date Fair Value Shares Wtd. Avg. Grant Date Fair Value Outstanding as of beginning of year - $ - - $ - Granted - - 82,805 9.18 Vested - - (82,805 ) 9.18 Non-vested as of year end - $ - - $ - We recognized stock compensation expense of zero, $760,000, and zero related to performance-based restricted stock awards for the years ended December 31, 2021, 2020, 2019, December 31, 2021, no The aggregate fair value of the performance-based awards granted during the years ended December 31, 2021, 2020, 2019 December 31, 2021, 2020, 2019 zero zero Market-based restricted stock The following is a summary of market-based restricted stock activity under our stock option plan for the years ended December 31, 2021 2020 December 31, 2021 2020: 2021 2020 Shares Wtd. Avg. Grant Date Fair Value Shares Wtd. Avg. Grant Date Fair Value Outstanding as of beginning of year 224,774 $ 19.20 123,851 $ 26.99 Granted 152,665 32.50 109,140 10.95 Vested (231,268 ) 26.98 - - Forfeited (6,415 ) 40.65 (8,217 ) 27.02 Non-vested as of year end 139,756 $ 19.86 224,774 $ 19.20 On February 25, 2019 April 1, 2019 February 8, 2021, January 1, 2019 December 31, 2020 20 2 0% December 31, 2020. On March 25, 2020, January 1, 2020 December 31, 2021 20 0% 2 December 31, 2021. On February 8, 2021, January 1, 2021 December 31, 2022 20 0% December 31, 2022. On May 3, 2021, one January 1, 2021 December 31, 2022 20 0% November 2021, December 31, 2021 We recognized stock compensation expense of $1.4 million, $2.1 million, and $1.5 million related to market-based restricted stock awards for the years ended December 31, 2021, 2020, 2019. December 31, 2021, The aggregate fair value of the market-based awards granted during the years ended December 31, 2021, 2020, 2019 December 31, 2021, 2020, 2019 Total stock compensation expense We recorded total stock compensation expense for the years ended December 31, 2021, 2020, 2019, 2021 2020 2019 Research and development costs $ 1,906 $ 1,012 $ 571 Sales and marketing costs 1,788 852 711 General and administrative costs 8,061 3,518 1,584 Cost of revenue 2,201 599 177 Total $ 13,956 $ 5,981 $ 3,043 |
Note 11 - Commitments and Conti
Note 11 - Commitments and Contingencies | 12 Months Ended |
Dec. 31, 2021 | |
Notes to Financial Statements | |
Commitments and Contingencies Disclosure [Text Block] | 11. Commitments and contingencies Employment agreements We have employment agreements with certain key employees. None may Litigation From time to time, the Company is subject to various legal proceedings that arise in the ordinary course of business, none may not Indemnification As permitted under Delaware law and in accordance with the Company’s bylaws, the Company is required to indemnify its officers and directors for certain errors and occurrences while the officer or director is or was serving in such capacity. The Company is also party to indemnification agreements with its directors. The Company believes the fair value of the indemnification rights and agreements is minimal. Accordingly, the Company has not December 31, 2021. |
Note 12 - Acquisitions
Note 12 - Acquisitions | 12 Months Ended |
Dec. 31, 2021 | |
Notes to Financial Statements | |
Business Combination Disclosure [Text Block] | 12. Acquisitions Sexton acquisition General terms and effects On August 9, 2021, On September 1, 2021, December 31, 2021. Total consideration transferred (in thousands, except number of shares and stock price): Merger consideration shares 530,502 BioLife stock price (as of September 1, 2021) $ 60.50 Value of issued shares $ 32,095 plus: Fair value of BioLife’s existing investment in Sexton $ 7,951 less: Net working capital adjustment $ (118 ) Merger Consideration $ 39,928 Transaction costs related to the acquisition are expensed as incurred and are not Fair value of net assets acquired Under the acquisition method of accounting, the assets acquired and liabilities assumed from Sexton were calculated as of the merger date, at their respective fair values, and consolidated with those of BioLife. The gross contractual accounts receivable acquired in the acquisition was $509,000. Of the acquired accounts receivable, $17,000 is estimated to be uncollectable. The fair value calculations required critical estimates, including, but not The table below represents the fair value of the net assets acquired and liabilities assumed, which were recorded as of the merger date (amounts in thousands). Cash $ 1,516 Accounts receivable, net 492 Inventory 1,310 Prepaid expenses and other current assets 670 Property, plant and equipment, net 737 Operating lease right-of-use assets, net 470 Developed technology 4,132 Customer relationships 2,276 Tradenames 2,324 Non-compete agreements 90 Goodwill 28,470 Accounts payable (291 ) Lease liabilities, operating (470 ) Deferred tax liability (1,482 ) Other liabilities (316 ) Fair value of net assets acquired $ 39,928 We recorded a measurement period adjustment in the fourth December 31, 2021 The fair value of Sexton’s identifiable intangible assets and useful lives are as follows (amounts in thousands, except years): Fair Value Useful Life (Years) Developed technology $ 4,132 5 - 9 Customer relationships 2,276 2 Tradenames 2,324 11 Non-compete agreements 90 1 Total identifiable intangible assets $ 8,822 Fair value measurement methodologies used to calculate the value of any asset can be broadly classified into one three three not Some of the more significant assumptions inherent in the development of intangible asset fair values, from the perspective of a market participant, include, but are not Acquired goodwill The goodwill of $28.5 million represents future economic benefits expected to arise from synergies from combining operations and commercial organizations to increase market presence and the extension of existing customer relationships. The goodwill recorded is not Global Cooling acquisition General terms and effects On March 19, 2021, On May 3, 2021, Merger consideration The aggregate merger consideration paid pursuant to the GCI Merger Agreement to the GCI Stockholders was 6,646,870 newly issued shares of common stock, provided, however, that the GCI Merger Consideration otherwise payable to GCI Stockholders is subject to the withholding of the GCI Escrow Shares (as defined below) and is subject to reduction for indemnification obligations. The GCI Merger Consideration allocable to one 805, not Total consideration transferred (in thousands, except number of shares, stock price, and consideration percentage): BioLife shares outstanding (as of March 19, 2021) 33,401,359 Merger consideration percentage 19.9 % Merger consideration shares 6,646,870 less: Merger consideration shares withheld to satisfy outstanding GCI stockholder obligations to GCI 10,400 Subtotal 6,636,470 BioLife stock price (as of May 3, 2021) $ 35.07 Value of issued shares $ 232,741 plus: Settlement of BioLife prepaid deposits $ 2,152 plus: Net settlement of BioLife accounts receivable $ 16 Merger Consideration $ 234,909 Transaction costs related to the acquisition are expensed as incurred and are not Escrow shares At the GCI Closing, approximately nine The GCI Escrow Property will be held for a period of up to twenty-four Fair value of net assets acquired Under the acquisition method of accounting, the assets acquired and liabilities assumed from Global Cooling were calculated as of the merger date, at their respective fair values, and consolidated with those of BioLife. The gross contractual accounts receivable acquired in the acquisition was $7.1 million. Of the acquired accounts receivable, $53,000 was estimated to be uncollectable. The fair value calculations required critical estimates, including, but not The table below represents the fair value of the net assets acquired and liabilities assumed, which were recorded as of the merger date (amounts in thousands). Cash $ 43 Accounts receivable, net 7,076 Inventory 15,547 Prepaid expenses and other current assets 639 Property, plant and equipment, net 3,512 Operating lease right-of-use assets, net 1,741 Financing lease right-of-use assets, net 114 Long-term deposits and other assets 4 Developed technology 18,140 Customer relationships 7,020 Tradenames 26,640 Non-compete agreements 1,240 In-process research and development 67,440 Goodwill 137,822 Accounts payable (9,837 ) Line of credit (4,231 ) Lease liabilities, operating (1,880 ) Lease liabilities, financing (114 ) Long-term debt (4,410 ) Deferred tax liability (24,133 ) Other liabilities (7,464 ) Fair value of net assets acquired $ 234,909 We recorded a measurement period adjustment in the fourth December 31, 2021 The fair value of Global Cooling’s identifiable intangible assets and useful lives are as follows (amounts in thousands, except years): Fair Value Useful Life (Years) Developed technology $ 18,140 6 Customer relationships 7,020 12 Tradenames 26,640 15 Non-compete agreements 1,240 4 In-process research and development 67,440 N/A Total identifiable intangible assets $ 120,480 Fair value measurement methodologies used to calculate the value of any asset can be broadly classified into one three three not Some of the more significant assumptions inherent in the development of intangible asset fair values, from the perspective of a market participant, include, but are not Acquired goodwill The goodwill of $137.8 million represents future economic benefits expected to arise from synergies from combining operations and commercial organizations to increase market presence and the extension of existing customer relationships. The goodwill recorded is not SciSafe acquisition On September 18, 2020, one hundred October 1, 2020. Consideration transferred The SciSafe Acquisition was accounted for as a purchase of a business under FASB ASC Topic 805, Business Combinations 2021 2024. not Total consideration transferred (in thousands): Cash consideration $ 15,000 Stock consideration 17,916 Contingent consideration 3,663 Working capital adjustment (53 ) Total consideration transferred $ 36,526 Fair value of net assets acquired The table below represents the purchase price allocation to the net assets acquired based on their fair values (amounts in thousands). Cash $ 500 Accounts receivable, net 945 Prepaid expenses and other current assets 31 Property, plant and equipment, net 3,400 Customer relationships 7,420 Tradenames 4,020 Non-compete agreements 660 Goodwill 24,943 Other assets 1,547 Accounts payable (885 ) Deferred tax liability (3,297 ) Other liabilities (2,758 ) Fair value of net assets acquired $ 36,526 On September 30, 2020, The fair value of SciSafe’s identifiable intangible assets and useful lives are as follows (amounts in thousands except years): Fair Value Useful Life (Years) Customer relationships $ 7,420 14 Tradenames 4,020 19 Non-compete agreements 660 4 Total identifiable intangible assets $ 12,100 Fair value measurement methodologies used to calculate the value of any asset can be broadly classified into one three three not Some of the more significant assumptions inherent in the development of intangible asset fair values, from the perspective of a market participant, include, but are not Indemnification asset In 2020, 805. Acquired goodwill The goodwill of $24.9 million represents future economic benefits expected to arise from synergies from combining operations and commercial organizations to increase market presence and the extension of existing customer relationships. The goodwill recorded is not Custom Biogenic Systems Acquisition On November 10, 2019, November 12, 2019. In connection with the CBS Acquisition, we paid to CBS (i) a base payment in the amount of $15.0 million, consisting of a cash payment of $11.0 million paid at the closing of the CBS Acquisition, less a cash holdback escrow of $550,000 to satisfy certain indemnification claims, and an aggregate number of shares of our common stock, with an aggregate fair value equal to $4.0 million, less a holdback escrow of shares of Common Stock with an aggregate value equal to $3.0 million to satisfy potential payments related to any product liability claims outstanding as of March 13, 2019, 2020, 2021, 2022, 2023 2024 not 2020 2021 not The CBS Acquisition was accounted for as a purchase of a business under FASB ASC Topic 805, Business Combinations not Total consideration transferred (in thousands): Cash consideration $ 11,000 Stock consideration 4,000 Contingent consideration 856 Total consideration transferred $ 15,856 Fair Value of Net Assets Acquired The table below represents the purchase price allocation to the net assets acquired based on their fair values (amounts in thousands). Accounts receivable, net $ 1,044 Inventory 3,232 Prepaid expenses and other current assets 29 Property, plant and equipment, net 3,615 Customer relationships 560 Tradenames 800 Developed technology 5,430 Goodwill 2,954 Accounts Payable (1,197 ) Other liabilities (611 ) Fair value of net assets acquired $ 15,856 The fair value of CBS’s identifiable intangible assets and weighted average useful lives are as follows (amounts in thousands except years): Fair Value Useful Life (Years) Customer relationships $ 560 6 Tradenames 800 6 Developed technology 5,430 9 Total identifiable intangible assets $ 6,790 Fair value measurement methodologies used to calculate the value of any asset can be broadly classified into one three three Some of the more significant assumptions inherent in the development of intangible asset fair values, from the perspective of a market participant, include, but are not not Acquired Goodwill The goodwill of $3.0 million represents future economic benefits expected to arise from synergies from combining operations and commercial organizations to increase market presence and the extension of existing customer relationships. All of the goodwill recorded is deductible for income tax purposes. SAVSU Acquisition On August 8, 2019, not August 8, 2019, Consideration transferred The SAVSU acquisition was accounted for as a purchase of a business under FASB ASC Topic 805, Business Combinations not Under the acquisition method of accounting, the assets acquired and liabilities assumed from SAVSU were recorded as of the acquisition date, at their respective fair values, and consolidated with those of BioLife. The fair value estimates required critical estimates, including, but not Total consideration paid for the acquisition of SAVSU is as follows (amounts in thousands): Stock consideration for 55.6% $ 19,932 This stock consideration plus the fair value of our existing equity investment in SAVSU of $15.9 million results in the total purchase price for accounting purposes of $35.8 million. Fair Value of Net Assets Acquired The table below represents the purchase price allocation to the net assets acquired based on their fair values (amounts in thousands). Cash and cash equivalents $ 1,251 Accounts receivable, net 753 Prepaid expenses and other current assets 19 Property, plant and equipment, net 546 Operating right-of-use asset 233 Assets held for lease 2,441 Customer relationships 80 Tradenames 1,320 Developed technology 10,750 Goodwill 21,037 Accounts Payable and accrued expenses (807 ) Deferred tax liabilities (1,541 ) Other liabilities (232 ) Fair value of net assets acquired $ 35,850 The fair value of SAVSU’s identifiable intangible assets and useful lives are as follows (amounts in thousands except years): Fair Value Useful Life (Years) Customer relationships $ 80 6 Tradenames 1,320 9 Developed technology 10,750 7 - 8 Total identifiable intangible assets $ 12,150 Astero Acquisition On April 1, 2019, In connection with the acquisition, the Company paid (i) a base payment in the amount of $12.5 million consisting of an initial cash payment of $8.0 million at the closing of the transactions, subject to adjustment for working capital, net debt and transaction expenses, and a deferred cash payment that was paid into escrow and subsequently paid to Astero of $4.5 million which was payable upon the earlier of Astero meeting certain product development milestones or one 2019, 2020 2021 2021, three 2019 2021. second 2020 2019 2020, 2021, 2019 2021 not no Consideration transferred The Astero acquisition was accounted for as a purchase of a business under FASB ASC Topic 805, Business Combinations not Total consideration recorded for the acquisition of Astero is as follows (amounts in thousands): Cash consideration $ 12,521 Contingent consideration 1,491 Working capital adjustment (71 ) Total consideration transferred $ 13,941 Fair Value of Net Assets Acquired The table below represents the purchase price allocation to the net assets acquired based on their fair values (amounts in thousands). Cash and cash equivalents $ 11 Accounts receivable, net 154 Inventory 456 Customer relationships 160 Tradenames 470 Developed technology 2,840 In-process research and development 650 Goodwill 9,515 Other assets 99 Accounts Payable (250 ) Other liabilities (164 ) Fair value of net assets acquired $ 13,941 The fair value of Astero’s identifiable intangible assets and useful lives are as follows (amounts in thousands except years): Fair Value Useful Life (Years) Customer relationships $ 160 4 Tradenames 470 9 Developed technology 2,840 5 - 9 In-process research and development 650 N/A Total identifiable intangible assets $ 4,120 Fair value measurement methodologies used to calculate the value of any asset can be broadly classified into one three three third Some of the more significant assumptions inherent in the development of intangible asset fair values, from the perspective of a market participant, include, but are not not Acquired Goodwill The goodwill of $9.5 million represents future economic benefits expected to arise from synergies from combining operations and commercial organizations to increase market presence and the extension of existing customer relationships. All but $1.1 million of the goodwill recorded is not Revenue, net income and pro forma presentation The Company recorded revenue from Sexton of $1.8 million and a net loss of $1.0 million from September 1, 2021, December 31, 2021. May 3, 2021, December 31, 2021. October 1, 2020, December 31, 2020. November 12, 2019, December 31, 2019. August 8, 2019, December 31, 2019. April 1, 2019, December 31, 2019. The following unaudited pro forma financial information presents the combined results of operations of Sexton as if the acquisition had occurred on January 1, 2020 2021 2020 (In thousands) (unaudited) (unaudited) Total revenue $ 122,494 $ 50,856 Net (loss) income $ (9,860 ) $ (1,028 ) The following unaudited pro forma financial information presents the combined results of operations of Global Cooling as if the acquisition had occurred on January 1, 2020 2021 2020 (In thousands) (unaudited) (unaudited) Total revenue $ 143,732 $ 87,370 Net income (loss) $ (16,375 ) $ 501 The following unaudited pro forma financial information presents the combined results of operations of SciSafe as if the acquisition had occurred on January 1, 2019 2020 2019 (In thousands) (unaudited) (unaudited) Total revenue $ 52,613 $ 43,221 Net income (loss) $ 1,798 $ (4,528 ) The following unaudited pro forma financial information presents the combined results of operations of CBS as if the acquisition had occurred on January 1, 2018 2019 (In thousands) (unaudited) Total revenue $ 37,001 Net income (loss) $ (493 ) The following unaudited pro forma financial information presents the combined results of operations of SAVSU as if the acquisition had occurred on January 1, 2018 2019 (In thousands) (unaudited) Total revenue $ 28,824 Net income (loss) $ (1,518 ) The following unaudited pro forma financial information presents the combined results of operations of Astero as if the acquisition had occurred on January 1, 2018 2019 (In thousands) (unaudited) Total revenue $ 28,745 Net income (loss) $ (183 ) |
Note 13 - Consolidated Balance
Note 13 - Consolidated Balance Sheet Detail | 12 Months Ended |
Dec. 31, 2021 | |
Notes to Financial Statements | |
Supplemental Balance Sheet Disclosures [Text Block] | 13. Consolidated balance sheet detail Property and equipment Property and equipment consist of the following as of December 31, 2021 2020: (In thousands) 2021 2020 Property and equipment Leasehold improvements $ 3,840 $ 2,393 Furniture and computer equipment 1,861 902 Manufacturing and other equipment 16,675 10,076 Construction in-progress 2,022 591 Subtotal 24,398 13,962 Less: Accumulated depreciation (6,741 ) (3,842 ) Net property and equipment $ 17,657 $ 10,120 Depreciation expense for property and equipment was $2.9 million, $1.4 million, and $544,000 for the years ended December 31, 2021, 2020, 2019, Accrued expenses and other current liabilities Accrued expenses and other current liabilities consist of the following as of December 31, 2021 2020: (In thousands) 2021 2020 Accrued expenses $ 1,656 $ 472 Accrued taxes 27 112 Accrued compensation 4,351 2,898 Deferred revenue, current 814 931 Other 294 130 Total accrued expenses and other current liabilities $ 7,142 $ 4,543 Warranty reserve liability We reserve estimated exposures on known claims, as well as on a portion of anticipated claims, for product warranty and rework cost, based on historical product liability claims. Claim costs are deducted from the accrual when paid. Factors that could have an impact on the warranty accrual in any given period include the following: changes in manufacturing quality, changes in product costs, changes in product mix and any significant changes in sales volume. A rollforward of our warranty liability is as follows: (In thousands) 2021 2020 Beginning balance $ 212 $ 191 Warranty reserve acquired in the acquisition of Global Cooling 3,353 - Provision for warranties 9,845 137 Settlements of warranty claims (4,012 ) (116 ) Ending Balance $ 9,398 $ 212 |
Note 14 - Employee Benefit Plan
Note 14 - Employee Benefit Plan | 12 Months Ended |
Dec. 31, 2021 | |
Notes to Financial Statements | |
Defined Contribution Plan [Text Block] | 14. Employee benefit plan The Company sponsors 401 may December 31, 2021, 2020, 2019. |
Note 15 - Subsequent Events
Note 15 - Subsequent Events | 12 Months Ended |
Dec. 31, 2021 | |
Notes to Financial Statements | |
Subsequent Events [Text Block] | 15. Subsequent events The Company has evaluated events subsequent to December 31, 2021 no |
Significant Accounting Policies
Significant Accounting Policies (Policies) | 12 Months Ended |
Dec. 31, 2021 | |
Accounting Policies [Abstract] | |
Use of Estimates, Policy [Policy Text Block] | Use of estimates The preparation of financial statements in conformity with generally accepted accounting principles in the United States (“U.S. GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities as of the date of the financial statements and reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates and assumptions by management affect the Company’s allowance for doubtful accounts, the net realizable value of inventory, fair value of warrant liability, valuation of market based awards, valuations and purchase price allocations related to investments and business combinations, expected future cash flows including growth rates, discount rates, terminal values and other assumptions and estimates used to evaluate the recoverability of long-lived assets, estimated fair values of intangible assets and goodwill, amortization methods and periods, warranty reserves, certain accrued expenses, share-based compensation, contingent consideration from business combinations, and the recoverability of the Company’s deferred tax assets and the related valuation allowance. The Company regularly assesses these estimates; however, actual results could differ materially from these estimates. Changes in estimates are recorded in the period in which they become known. The Company bases its estimates on historical experience and various other assumptions that it believes to be reasonable under the circumstances. |
Basis of Accounting, Policy [Policy Text Block] | Basis of presentation The Consolidated Financial Statements include the accounts of the Company and its wholly-owned subsidiaries, SAVSU Technologies, Inc. (“SAVSU” acquired on August 8, 2019), November 12, 2019), October 1, 2020), May 3, 2021), September 1, 2021). All long-lived assets are maintained in the United States of America and the Netherlands. Financial statement reclassification Certain classifications on the Consolidated Balance Sheets related to accrued expenses and other current liabilities, debt, current portion, and debt, long-term as of December 31, 2020 no |
Foreign Currency Transactions and Translations Policy [Policy Text Block] | Foreign currency translation The Company translates balance sheet and income statement items into U.S. dollars. For the Company’s subsidiaries that operate in a local currency functional environment, all assets and liabilities are translated into U.S. dollars using current exchange rates at the balance sheet date; revenue and expenses are translated using quarterly exchange rates which approximate to average exchange rates in effect during each period. Resulting translation adjustments are reported as a separate component of accumulated other comprehensive (loss) income in shareholders' equity. |
Segment Reporting, Policy [Policy Text Block] | Segment reporting The Company views its operations and makes decisions regarding how to allocate resources and manages its business as one one |
Revenue [Policy Text Block] | Revenue recognition To determine revenue recognition for contractual arrangements that we determine are within the scope of Financial Accounting Standards Board (“FASB”) Topic 606, Revenue from Contracts with Customers five five may not 30 90 December 31, 2021, The Company primarily recognizes product revenues, service revenues, and rental revenues. Product revenues are generated from the sale of biopreservation media, ThawSTAR, and freezer products. We recognize product revenue, including shipping and handling charges billed to customers, at a point in time when we transfer control of our products to our customers, which is upon shipment for substantially all transactions. Shipping and handling costs are classified as part of cost of product revenue in the Consolidated Statement of Operations. Service revenues are generated from the storage of biological and pharmaceutical materials. We recognize service revenues over time as services are performed or ratably over the contract term. To the extent the transaction price includes variable consideration, the Company estimates the amount of variable consideration that should be included in the transaction price utilizing the expected value method or the most likely amount method, depending on the facts and circumstances relative to the contract. When determining the transaction price of a contract, an adjustment is made if payment from a customer occurs either significantly before or significantly after performance, resulting in a significant financing component. Applying the practical expedient in paragraph 606 10 32 18, not one None December 31, 2021. The Company also generates revenue from the leasing of our property, plant, and equipment, operating right-of-use assets, and evo cold chain systems to customers pursuant to service contracts or rental arrangements entered into with the customer. Revenue from these arrangements is not 606 842, Lease The Company enters into various customer service agreements (collectively, “Service Contracts”) with customers to provide biological and pharmaceutical storage services. In certain of these Service Contracts, the property, plant, and equipment or operating right-of-use assets used to store the customer product are used only for the benefit of one may not The Company has assessed its Service Contracts and concluded that certain of the contracts for the storage of customer products met the criteria to be considered a leasing arrangement (“Embedded Leases”), with the Company as the lessor. The specific Service Contracts that met the criteria were those that provided a single customer with the ability to substantially direct the use of the Company’s property, plant, and equipment or operating right-of-use assets. Under ASC 842, None None Embedded Leases may Total bioproduction tools and services revenue for the years ended December 31, 2021, 2020, 2019 Year Ended December 31, (In thousands, except percentages) 2021 2020 2019 Product revenue Freezer and thaw $ 56,620 $ 13,548 $ 3,312 Cell processing 44,965 30,946 23,367 Storage and cold chain services 328 46 165 Service revenue Storage and cold chain services 9,817 1,752 - Rental revenue Storage and cold chain services 7,426 1,795 527 Total revenue $ 119,156 $ 48,087 $ 27,371 ( 1 2021 May 3, 2021 December 31, 2021 September 1, 2021 December 31, 2021. ( 2 2020 October 1, 2020 December 31, 2020. ( 3 2019 April 1, 2019 December 31, 2019; August 8, 2019 December 31, 2019; November 12, 2019 December 31, 2019. The following table includes estimated rental revenue expected to be recognized in the future related to embedded leases as well as estimated service revenue expected to be recognized in the future related to performance obligations that are unsatisfied or partially unsatisfied as of the end of the reporting periods. The Company is electing not one 2014 09, Revenue from Contracts with Customers not one December 31, 2021. The balances in the table below are partially based on judgments involved in estimating future orders from customers subject to the exercise of material rights pursuant to respective contracts: Year Ending December 31, (In thousands) 2022 2023 2024 Total Rental revenue $ 10,151 $ 3,748 $ 900 $ 14,799 Service revenue $ 67 $ 31 $ 10 $ 108 |
Risk and Uncertainties, Policy [Policy Text Block] | Risks and uncertainties COVID- 19 Our domestic and international operations have been and continue to be affected by the ongoing global pandemic of a novel strain of coronavirus (“COVID- 19” December 31, 2021, In the year ended December 31, 2021, 19 not 19 19. The Company reviews capital and amortizing intangible assets (long-lived assets) for impairment on an annual basis or whenever events or changes in circumstances indicate that the carrying amount may not 19 June 30, 2020 19. As a result of the Company’s outlook for revenue from the ThawSTAR and freezer product lines, estimated undiscounted cash flow projections were developed to determine if any impairment of the related intangible assets was warranted. After conducting such review, the Company determined that there was no June 30, 2020. 19 The Company revised the revenue projections for the ThawSTAR and freezer product lines in the second June 30, 2020 December 31, 2020 two no December 31, 2020. June 30, 2020, December 31, 2020 December 31, 2020. The Company may 19 third Any disruption and volatility in the global capital markets as a result of the pandemic may 19 not The ultimate extent to which the COVID- 19 19 On March 27, 2020, On March 11, 2021, 2021” We determined that we met the original eligibility requirements per the guidelines original established by the U.S. federal government as part of the CARES Act for the Pursuant to the Paycheck Protection Program (the “PPP”). As such, on April 20, 2020, April 29, 2020. March 30, 2020, December 31, 2021, December 31, 2021, December 31, 2022. In the SciSafe acquisition, the Company acquired a $295,300 loan from the PPP. The loan incurred interest at 1% and was unsecured. Of the principal borrowed, $284,000 was forgiven in December 2021. not December 2021. |
Earnings Per Share, Policy [Policy Text Block] | Earnings per share The Company considers its unexercised warrants and unvested restricted shares, which contain non-forfeitable rights to dividends, participating securities, and includes such participating securities in its computation of earnings per share pursuant to the two two two The following table presents computations of basic and diluted earnings per share under the two Year Ended December 31, (In thousands, except share and earnings per share data) 2021 2020 2019 Basic earnings (loss) per common share Numerator: Net (loss) income $ (7,635 ) $ 2,667 $ (1,657 ) Amount attributable to unvested restricted shares - (135 ) - Amount attributable to warrants outstanding - (82 ) - Net (loss) income allocated to common shareholders (7,635 ) 2,450 (1,657 ) Denominator: Weighted-average common shares issued and outstanding 38,503,944 27,306,258 19,460,299 Basic (loss) earnings per common share $ (0.20 ) $ 0.09 $ (0.09 ) Diluted earnings (loss) per common share Numerator: Net (loss) income $ (7,635 ) $ 2,667 $ (1,657 ) Amount attributable to warrants - (20 ) - Less: gain related to change in fair value of warrants - (3,601 ) - Diluted (loss) earnings per common share (7,635 ) (954 ) (1,657 ) Denominator: Weighted-average common shares issued and outstanding 38,503,944 27,306,258 19,460,299 Diluted (loss) earnings per common share $ (0.20 ) $ (0.03 ) $ (0.09 ) The following table sets forth the number of shares excluded from the computation of diluted loss per share, as their inclusion would have been anti-dilutive: Year Ended December 31, 2021 2020 2019 Stock options and restricted stock awards 1,637,745 2,131,794 2,564,456 Warrants 18,204 1,499,953 2,956,039 Total 1,655,949 3,631,747 5,520,495 |
Cash and Cash Equivalents, Policy [Policy Text Block] | Cash, cash equivalents, and restricted cash Cash equivalents consist primarily of interest-bearing money market accounts. We consider all highly liquid debt instruments purchased with an initial maturity of three may not Restricted cash consists entirely of amounts that will be recovered from escrow in relation to the acquisition of SciSafe. The restricted cash is short term in nature, as the Company anticipates to receive the funds within one The following is a summary of the Company’s cash, cash equivalents, and restricted cash total as presented in the Company’s consolidated statements of cash flows for the years ended December 31, 2021, 2020, 2019. Year Ended December 31, (In thousands) 2021 2020 2019 Cash and cash equivalents $ 69,860 $ 90,403 $ 6,448 Restricted cash 10 53 - Total cash, cash equivalents, and restricted cash $ 69,870 $ 90,456 $ 6,448 |
Inventory, Policy [Policy Text Block] | Inventories Inventories relate to the Company’s cell and gene therapy products. The Company values biopreservation media inventory at cost or, if lower, net realizable value, using the specific identification method. All other inventory is valued at cost or, if lower, net realizable value, using the first first no |
Accounts Receivable [Policy Text Block] | Accounts receivable Accounts receivable consist of short-term amounts due from our customers (generally 30 90 Accounts receivable are stated at principal amount, do not |
Investment, Policy [Policy Text Block] | Investments We periodically invest in securities of private companies to promote business and strategic objectives. These investments are measured and recorded as follows: Non-marketable equity securities are equity securities without a readily determinable fair value. As of December 31, 2021, 1 2 December 31, 2020, 1 2 As of December 31, 2021, September 1, 2021. December 31, 2020, not September 2019, December 31, 2021, 2020, 2019, November 2020, 1 2 In November 2020, June 2021, first As of December 31, 2021, no |
Property, Plant and Equipment, Policy [Policy Text Block] | Property and equipment Property and equipment are stated at cost and are depreciated using the straight-line method over estimated useful lives of three ten Property and equipment are reviewed for impairment whenever events or changes in circumstances indicate that their net book value may not may December 31, 2021, 2020, 2019. |
Assets Held for Rent, Policy [Policy Text Block] | Assets held for rent Assets held for rent are carried at cost less accumulated depreciation. These assets consist of dedicated storage space, evo shippers and related components in production shippers complete and ready to be deployed and placed in service upon a customer order, shippers in the process of being assembled, and components available to build shippers. Assets utilized to provide dedicated storage space are depreciated over their applicable useful lives once placed in service. Shippers are depreciated over a useful life of three Our customers rent assets per a rental agreement. Each agreement provides for fixed monthly rent. Rental revenue and fees are recognized over the rental term on a straight-line basis. We retain the ownership of the assets rented. At the end of the rental agreement, the customer returns the asset to the Company. Assets held for rent are reviewed for impairment whenever events or changes in circumstances indicate that their net book value may not may no December 31, 2021, 2020, 2019. |
Lessee, Leases [Policy Text Block] | Lease accounting We determine if an arrangement is a lease at inception. Where an arrangement is a lease, we determine if it is an operating lease or a finance lease. At lease commencement, we record a lease liability and corresponding right-of-use (“ROU”) asset. Lease liabilities represent the present value of our future lease payments over the expected lease term which includes options to extend or terminate the lease when it is reasonably certain those options will be exercised. The present value of our lease liability is determined using our incremental collateralized borrowing rate at lease inception. ROU assets represent our right to control the use of the leased asset during the lease and are recognized in an amount equal to the lease liability for leases with an initial term greater than 12 We elected to apply the practical expedient for short-term leases and accordingly do not twelve |
Standard Product Warranty, Policy [Policy Text Block] | Warranty Our standard warranty terms typically extend between one seven |
Income Tax, Policy [Policy Text Block] | Income taxes We account for income taxes using an asset and liability method which generally requires recognition of deferred tax assets and liabilities for the expected future tax effects of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are recognized for the future tax effects of differences between tax bases of assets and liabilities, and financial reporting amounts, based upon enacted tax laws and statutory rates applicable to the periods in which the differences are expected to affect taxable income. We evaluate the likelihood of realization of deferred tax assets and provide an allowance where, in management’s opinion, it is more likely than not not We determine any uncertain tax positions based on a determination of whether and how much of a tax benefit taken in the Company’s tax filings or positions is more likely than not Judgment is applied in the determination of the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. As of December 31, 2021, |
Advertising Cost [Policy Text Block] | Advertising Advertising costs are expensed as incurred and totaled $552,000, $167,000, and $43,000 for the years ended December 31, 2021, 2020, 2019, |
Concentration Risk, Credit Risk, Policy [Policy Text Block] | Concentrations of risk In the years ended December 31, 2021, 2020, 2019, one No 10% In the year ended December 31, 2019, No 10% December 31, 2021, 2020, 2019. The following table represents the Company’s total revenue by geographic area (based on the location of the customer): Year Ended December 31, Revenue by customers geographic locations 2021 2020 2019 United States 78 % 73 % 69 % Canada 7 % 13 % 16 % Germany 4 % 4 % 3 % Europe, Middle East, Africa (excluding Germany) 10 % 8 % 11 % Other 1 % 2 % 1 % Total revenue 100 % 100 % 100 % The following table represents the Company’s long-lived assets by geographic area as of December 31: (In thousands) 2021 2020 United States $ 40,708 $ 30,389 Netherlands 5,903 - Total $ 46,611 $ 30,389 As of December 31, 2021 2020, two one No 10% As of December 31, 2021 2020, one one No 10% |
Research and Development Expense, Policy [Policy Text Block] | Research and development Research and development costs are expensed as incurred. |
Share-based Payment Arrangement [Policy Text Block] | Stock-based compensation We measure and record compensation expense using the applicable accounting guidance for share-based payments related to stock options, time-based restricted stock, market-based restricted stock awards and performance-based restricted stock awards granted to our directors and employees. The fair value of stock options, including performance awards, without a market-based condition is determined by using the Black-Scholes option-pricing model. The fair value of restricted stock awards with a market condition is estimated at the date of grant using the Monte Carlo Simulation model. The Black-Scholes and Monte Carlo Simulation valuation models incorporate assumptions as to stock price volatility, the expected life of options or awards, a risk-free interest rate and dividend yield. The fair value of restricted stock, including performance awards, without a market condition is estimated using the current market price of our common stock on the date of grant. We expense stock-based compensation for stock options, restricted stock awards, and performance awards over the requisite service period. For awards with only a service condition, we expense stock-based compensation using the straight-line method over the requisite service period for the entire award. For awards with a market condition, we expense the grant date fair value over the vesting period regardless of the value that the award recipients ultimately receive. We have, from time to time, modified the terms of restricted stock awards awarded to employees. We account for the incremental increase in the fair value over the original award on the date of the modification as an expense for vested awards or over the remaining service (vesting) period for unvested awards. The incremental compensation cost is the excess of the fair value of the modified award on the date of modification over the fair value of the original award immediately before the modification. |
Business Combinations Policy [Policy Text Block] | Business combinations The Company accounts for business acquisitions using the acquisition method as required by FASB ASC Topic 805, Business Combinations The Company’s identifiable assets acquired and liabilities, including identified intangible assets, assumed in a business combination are recorded at their acquisition date fair values. The valuation requires management to make significant estimates and assumptions, especially with respect to long-lived and intangible assets. Critical estimates in valuing intangible assets include, but are not ● future expected cash flows, including revenue and expense projections; ● discount rates to determine the present value of recognized assets and liabilities and; ● revenue volatility to determine contingent consideration using option pricing models Goodwill is calculated as the excess of the acquisition price over the fair value of net assets acquired, including the amount assigned to identifiable intangible assets. Acquisition-related costs, including advisory, legal, accounting, valuation, and other costs, are expensed in the periods in which these costs are incurred. The results of operations of an acquired business are included in the consolidated financial statements beginning at the acquisition date. The Company estimates the acquisition date fair value of the acquisition-related contingent consideration using various valuation approaches, including option pricing models, as well as significant unobservable inputs, reflecting the Company’s assessment of the assumptions market participants would use to value these liabilities. The fair value of the contingent consideration is remeasured each reporting period. During the measurement period, which may one |
Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block] | Goodwill Goodwill represents the excess of the purchase price over the net amount of identifiable assets acquired and liabilities assumed in a business combination measured at fair value. Goodwill is not fourth may first not 350, Intangibles Goodwill and Other not 50 not not not not one fourth 2021. no |
Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block] | Intangible assets Intangible assets with a definite life are amortized over their estimated useful lives using the straight-line method and the amortization expense is recorded within intangible asset amortization in the Consolidated Statements of Operations. If the estimate of a definite-lived intangible asset’s remaining useful life is changed, the remaining carrying amount of the intangible asset is amortized prospectively over the revised remaining useful life. Definite-lived intangible assets and their related estimated useful lives are reviewed at least annually to determine if any adverse conditions exist that would indicate the carrying value of these assets may not no may not Indefinite-lived intangibles are carried at the initially recorded fair value less any recognized impairment. In-process research and development (“IPR&D”) is initially capitalized at fair value as an intangible asset with an indefinite life. When the IPR&D project is complete, it is reclassified as a definite-lived intangible asset and is amortized over its estimated useful life. If an IPR&D project is abandoned, a charge would be recorded for the value of the related intangible asset to our Consolidated Statement of Operations in the period it is abandoned. Indefinite-lived intangibles are tested annually for impairment. Impairment assessments are conducted more frequently if certain conditions exist, including a change in the competitive landscape, any internal decisions to pursue new or different technology strategies, a loss of a significant customer, or a significant change in the marketplace, including changes in the prices paid for the Company’s products or changes in the size of the market for the Company’s products. If impairment indicators are present, the Company determines whether the underlying intangible asset is recoverable through estimated future undiscounted cash flows. If the asset is not one 2021 fourth 2021 no 2021 no |
Warrants, Policy [Policy Text Block] | Certain warrants which have features that may Warrants that include cash settlement features are recorded as liabilities at their estimated fair value at the date of issuance and are remeasured at fair value each reporting period with the increase or decrease in fair value recorded in the Consolidated Statements of Operations. The warrants are measured at estimated fair value using the Black Scholes valuation model, which is based, in part, upon inputs for which there is little or no zero December 31, 2021, no December 31: 2020 2019 Risk free interest rate 0.1 % 1.9 % Expected dividend yield 0.0 % 0.0 % Contractual remaining lives 0.2 1.7 Expected volatility 56.8 % 70.3 % |
New Accounting Pronouncements, Policy [Policy Text Block] | Recent accounting pronouncements In November 2021, No. 2021 10, Government Assistance (Topic 832 December 15, 2023, In October 2021, No. 2021 08, Business Combinations (Topic 805 Accounting for Contract Assets and Contract Liabilities from Contracts with Customers Revenue from Contracts with Customers (Topic 606 606 2021 08 December 15, 2022, In July 2021, No. 2021 05, Leases (Topic 842 2021 05 840. not 1 842 10 25 2 25 3; 2 one 2021 05 December 15, 2021, not In May 2021, No. 2021 04, Issuer s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options 2021 04 2021 04 December 15, 2021, 2021 04 not In August 2020, No. 2020 06, Debt - Debt with Conversion and Other Options (Subtopic 470 20 s Own Equity (Subtopic 815 40 2020 06 2020 06 2020 06 December 15, 2021, no December 15, 2020. not In March 2020, No. 2020 04, Reference Rate Reform (Topic 848 2020 04 January 2021, 2021 01, no December 1, 2022, not In June 2016, No. 2016 13, Financial Instruments Credit Losses (Topic 326 2016 13 November 19, 2019, 2016 13 December 15, 2023, |
Note 1 - Organization and Sig_2
Note 1 - Organization and Significant Accounting Policies (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Notes Tables | |
Revenues By Product Line [Table Text Block] | Year Ended December 31, (In thousands, except percentages) 2021 2020 2019 Product revenue Freezer and thaw $ 56,620 $ 13,548 $ 3,312 Cell processing 44,965 30,946 23,367 Storage and cold chain services 328 46 165 Service revenue Storage and cold chain services 9,817 1,752 - Rental revenue Storage and cold chain services 7,426 1,795 527 Total revenue $ 119,156 $ 48,087 $ 27,371 |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table Text Block] | Year Ending December 31, (In thousands) 2022 2023 2024 Total Rental revenue $ 10,151 $ 3,748 $ 900 $ 14,799 Service revenue $ 67 $ 31 $ 10 $ 108 |
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] | Year Ended December 31, (In thousands, except share and earnings per share data) 2021 2020 2019 Basic earnings (loss) per common share Numerator: Net (loss) income $ (7,635 ) $ 2,667 $ (1,657 ) Amount attributable to unvested restricted shares - (135 ) - Amount attributable to warrants outstanding - (82 ) - Net (loss) income allocated to common shareholders (7,635 ) 2,450 (1,657 ) Denominator: Weighted-average common shares issued and outstanding 38,503,944 27,306,258 19,460,299 Basic (loss) earnings per common share $ (0.20 ) $ 0.09 $ (0.09 ) Diluted earnings (loss) per common share Numerator: Net (loss) income $ (7,635 ) $ 2,667 $ (1,657 ) Amount attributable to warrants - (20 ) - Less: gain related to change in fair value of warrants - (3,601 ) - Diluted (loss) earnings per common share (7,635 ) (954 ) (1,657 ) Denominator: Weighted-average common shares issued and outstanding 38,503,944 27,306,258 19,460,299 Diluted (loss) earnings per common share $ (0.20 ) $ (0.03 ) $ (0.09 ) |
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] | Year Ended December 31, 2021 2020 2019 Stock options and restricted stock awards 1,637,745 2,131,794 2,564,456 Warrants 18,204 1,499,953 2,956,039 Total 1,655,949 3,631,747 5,520,495 |
Schedule of Cash and Cash Equivalents [Table Text Block] | Year Ended December 31, (In thousands) 2021 2020 2019 Cash and cash equivalents $ 69,860 $ 90,403 $ 6,448 Restricted cash 10 53 - Total cash, cash equivalents, and restricted cash $ 69,870 $ 90,456 $ 6,448 |
Revenue from External Customers by Products and Services [Table Text Block] | Year Ended December 31, Revenue by customers geographic locations 2021 2020 2019 United States 78 % 73 % 69 % Canada 7 % 13 % 16 % Germany 4 % 4 % 3 % Europe, Middle East, Africa (excluding Germany) 10 % 8 % 11 % Other 1 % 2 % 1 % Total revenue 100 % 100 % 100 % (In thousands) 2021 2020 United States $ 40,708 $ 30,389 Netherlands 5,903 - Total $ 46,611 $ 30,389 |
Fair Value Measurement Inputs and Valuation Techniques [Table Text Block] | 2020 2019 Risk free interest rate 0.1 % 1.9 % Expected dividend yield 0.0 % 0.0 % Contractual remaining lives 0.2 1.7 Expected volatility 56.8 % 70.3 % |
Note 2 - Fair Value Measureme_2
Note 2 - Fair Value Measurement (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Notes Tables | |
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] | As of December 31, 2021 Level 1 Level 2 Level 3 Total Assets: Money market accounts $ 63,873 $ - $ - $ 63,873 Total 63,873 - - 63,873 Liabilities: Contingent consideration - business combinations - - 10,027 10,027 Total $ - $ - $ 10,027 $ 10,027 As of December 31, 2020 Level 1 Level 2 Level 3 Total Assets: Money market accounts $ 90,403 $ - $ - $ 90,403 Total 90,403 - - 90,403 Liabilities: Contingent consideration - business combinations - - 7,152 7,152 Warrant liability - - 2,780 2,780 Total $ - $ - $ 9,932 $ 9,932 |
Warrant Liabilities [Member] | |
Notes Tables | |
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] | Year Ended December 31, (In thousands) 2021 2020 2019 Beginning balance $ 2,780 $ 39,602 28,516 Exercised warrants (2,901 ) (33,221 ) (1,749 ) Change in fair value recognized in net (loss) income 121 (3,601 ) 12,835 Ending balance $ - $ 2,780 $ 39,602 |
Contingent Consideration Liabilities [Member] | |
Notes Tables | |
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] | Year Ended December 31, (In thousands) 2021 2020 2019 Beginning balance $ 7,152 $ 1,914 - Additions - 3,663 2,347 Change in fair value recognized in net (loss) income 2,875 1,575 50 Payments earned, reclassified to accrued liabilities - - (483 ) Ending balance $ 10,027 $ 7,152 $ 1,914 |
Note 3 - Inventories (Tables)
Note 3 - Inventories (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Notes Tables | |
Schedule of Inventory, Current [Table Text Block] | (In thousands) 2021 2020 Raw materials $ 17,252 $ 2,855 Work in progress 5,015 2,006 Finished goods 6,078 6,741 Total $ 28,345 $ 11,602 |
Note 4 - Assets Held for Rent (
Note 4 - Assets Held for Rent (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Notes Tables | |
Scheduleof Assets Held for Rent [Table Text Block] | (In thousands) 2021 2020 Shippers placed in service $ 5,645 $ 3,171 Fixed assets held for rent 4,040 - Accumulated depreciation (2,272 ) (411 ) Net 7,413 2,760 Shippers and related components in production 2,396 1,945 Total $ 9,809 $ 4,705 |
Note 5 - Leases (Tables)
Note 5 - Leases (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Notes Tables | |
Lessee, Operating and Finance Lease Term And Discount Rate [Table Text Block] | 2021 2020 Weighted average discount rate - operating leases 3.8 % 3.3 % Weighted average discount rate - finance leases 6.1 % 5.7 % Weighted average remaining lease term in years - operating leases 7.8 9.4 Weighted average remaining lease term in years - finance leases 3.0 2.6 |
Lease, Cost [Table Text Block] | Year Ended December 31, (In thousands) 2021 2020 2019 Operating lease costs $ 2,817 $ 839 $ 612 Short-term lease costs 1,727 277 51 Total operating lease costs 4,544 1,116 663 Variable lease costs 749 357 299 Total lease expense $ 5,293 $ 1,473 $ 962 |
Lessee, Operating Lease, Liability, Maturity [Table Text Block] | (In thousands) Operating Leases Financing Leases 2022 $ 3,443 $ 171 2023 3,151 171 2024 2,883 101 2025 2,497 37 2026 2,006 2 Thereafter 8,364 - Total lease payments 22,344 482 Less: interest (3,120 ) (42 ) Total present value of lease liabilities $ 19,224 $ 440 |
Note 6 - Goodwill and Intangi_2
Note 6 - Goodwill and Intangible Assets (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Notes Tables | |
Schedule of Goodwill [Table Text Block] | (In thousands) Goodwill Balance as of December 31, 2019 $ 33,637 Correction of an error related to CBS goodwill (131 ) Goodwill related to SciSafe acquisition 24,943 Balance as of December 31, 2020 58,449 Goodwill related to Global Cooling acquisition 137,822 Goodwill related to Sexton acquisition 28,470 Balance as of December 31, 2021 $ 224,741 |
Schedule of Finite-Lived Intangible Assets [Table Text Block] | (In thousands, except weighted average useful life) December 31, 2021 Intangible assets: Gross Carrying Value Accumulated Amortization Net Carrying Value Weighted Average Useful Life (in years) Customer Relationships $ 17,516 $ (1,776 ) $ 15,740 10.3 Tradenames 35,574 (2,306 ) 33,268 13.8 Technology - acquired 41,942 (7,789 ) 34,153 5.9 Non-compete agreements 1,990 (442 ) 1,548 3.0 In-process research and development⁽¹⁾ 67,440 - 67,440 N/A Total intangible assets $ 164,462 $ (12,313 ) $ 152,149 9.8 December 31, 2020 Intangible assets: Gross Carrying Value Accumulated Amortization Net Carrying Value Weighted Average Useful Life (in years) Customer Relationships $ 8,220 $ (330 ) $ 7,890 12.8 Tradenames 6,610 (508 ) 6,102 14.0 Technology - acquired 19,670 (3,232 ) 16,438 7.1 Non-compete agreements 660 (41 ) 619 3.8 Total intangible assets $ 35,160 $ (4,111 ) $ 31,049 9.7 |
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] | (In thousands) For the Years Ending December 31, Estimated Amortization Expense 2022 $ 11,421 2023 10,951 2024 10,126 2025 9,748 2026 9,346 Thereafter 33,117 Total $ 84,709 |
Note 7 - Line of Credit and L_2
Note 7 - Line of Credit and Long-term Debt (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Notes Tables | |
Schedule of Debt [Table Text Block] | December 31, (In thousands) Maturity Date Interest Rate 2021 2020 2022 term loan 1 Sep-24 4.0 % $ 1,750 $ - 2022 term loan 2 Various 4.0 % 2,813 - Insurance premium financing Apr-22 4.0 % 373 - Paycheck Protection Program loan May-22 1.0 % - 295 Freezer equipment loan Dec-25 5.7 % 612 365 Manufacturing equipment loans Oct-25 5.7 % 355 439 Freezer installation loan Various 6.3 % 1,334 156 Other loans Various Various 9 14 Total debt, excluding unamortized debt issuance costs 7,246 1,269 Less: unamortized debt issuance costs (31 ) - Total debt 7,215 1,269 Less: current portion of debt (862 ) (614 ) Total long-term debt $ 6,353 $ 655 |
Schedule of Maturities of Long-term Debt [Table Text Block] | (In thousands) Amount 2022 $ 862 2023 813 2024 2,294 2025 543 2026 221 Thereafter 2,513 Total debt, excluding unamortized debt issuance costs 7,246 Less: unamortized debt issuance costs (31 ) Total debt $ 7,215 |
Note 8 - Income Taxes (Tables)
Note 8 - Income Taxes (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Notes Tables | |
Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block] | Year Ended December 31, (In thousands) 2021 2020 2019 Domestic $ (27,317 ) $ (597 ) $ (3,198 ) Foreign (436 ) - - Total $ (27,753 ) $ (597 ) $ (3,198 ) |
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] | Year Ended December 31, (In thousands) 2021 2020 2019 Current: Federal $ - $ - $ - State - 33 - Foreign 9 - - Total current tax provision 9 33 - Deferred: Federal (17,703 ) (3,297 ) (1,541 ) State (2,424 ) - - Foreign - - - Total deferred tax benefit (20,127 ) (3,297 ) (1,541 ) Income tax benefit $ (20,118 ) $ (3,264 ) $ (1,541 ) |
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] | Year Ended December 31, 2021 2020 2019 Federal statutory tax 21 % 21 % 21 % State tax, net of federal benefit 7 % 39 % - Stock compensation 38 % 538 % 74 % Sec. 162(m) limitation on executive compensation (12 %) (35 %) (17 %) Fair value change in contingent consideration (2 %) (81 %) - Fair value change in warrant liability - 127 % (82 %) Transaction costs (1 %) (6 %) (4 %) Gain on stock acquisition 5 % - 64 % Tax credits - 12 % 5 % Change in valuation allowance 21 % 35 % (5 %) Book loss on equity method investment - - (5 %) Expired net operating losses (5 %) (100 %) (5 %) Other - (3 %) 1 % Total 72 % 547 % 47 % |
Schedule of Deferred Tax Assets and Liabilities [Table Text Block] | (In thousands) 2021 2020 Deferred tax assets related to: Net operating loss carryforwards $ 27,500 $ 12,314 Stock-based compensation 2,066 1,678 Accruals and reserves 2,902 427 Inventory 236 142 Lease liabilities 4,198 2,247 Tax credit carryforward 594 225 Other 318 48 Total deferred tax assets 37,814 17,081 Deferred tax liabilities related to: Intangibles (35,241 ) (5,025 ) Right-of-use assets (4,070 ) (2,261 ) Fair value change in investments (294 ) (287 ) Fixed assets (1,203 ) (959 ) Other - (51 ) Total deferred tax liabilities (40,808 ) (8,583 ) Net deferred tax (liabilities) assets before valuation allowance (2,994 ) 8,498 Less: valuation allowance (2,493 ) (8,498 ) Net deferred tax liabilities $ (5,487 ) $ - |
Summary of Valuation Allowance [Table Text Block] | (In thousands) 2021 2020 2019 Balance at January 1 $ 8,498 $ 8,706 $ 8,345 Deferred tax liabilities assumed through acquisitions (8,498 ) (3,297 ) (1,541 ) Charged to income tax expense 2,493 3,089 1,902 Balance at December 31 $ 2,493 $ 8,498 $ 8,706 |
Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block] | (In thousands) 2021 2020 Balance as of January 1 $ 96 $ - Increase related to prior year tax positions - 36 Increase related to current year tax positions 159 60 Balance as of December 31 $ 255 $ 96 |
Note 9 - Warrants (Tables)
Note 9 - Warrants (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Notes Tables | |
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] | 2021 2020 2019 Shares Wtd. Avg. Exercise Price Shares Wtd. Avg. Exercise Price Shares Wtd. Avg. Exercise Price Outstanding at beginning of year 79,100 $ 4.75 3,959,005 $ 4.33 4,080,005 $ 4.35 Exercised (79,100 ) 4.75 (3,879,905 ) 4.33 (121,000 ) 4.75 Outstanding and exercisable at end of year - $ - 79,100 $ 4.75 3,959,005 $ 4.33 |
Note 10 - Stock-based Compens_2
Note 10 - Stock-based Compensation (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Notes Tables | |
Share-based Payment Arrangement, Option, Activity [Table Text Block] | 2021 2020 Shares Wtd. Avg. Exercise Price Shares Wtd. Avg. Exercise Price Outstanding as of beginning of year 844,455 $ 2.00 1,570,455 $ 1.96 Exercised (183,064 ) 1.61 - - Forfeited (1,146 ) 5.69 (726,000 ) 1.91 Expired (35,714 ) 1.73 - - Outstanding as of end of year 624,531 $ 2.13 844,455 $ 2.00 Stock options exercisable at year end 624,531 $ 2.13 832,478 $ 1.98 2021 2020 Shares Wtd. Avg. Exercise Price Shares Wtd. Avg. Exercise Price Outstanding as of beginning of year 686,001 $ 1.64 737,497 $ 1.64 Exercised (686,001 ) 1.64 (51,496 ) 1.64 Outstanding as of end of year - $ - 686,001 $ 1.64 Stock options exercisable as of year end - $ - 686,001 $ 1.64 |
Share-based Payment Arrangement, Option, Exercise Price Range [Table Text Block] | Range of Exercise Prices Number Outstanding as of December 31, 2021 Weighted Average Remaining Contractual Life Weighted Average Exercise Price $1.00 - 1.50 26,428 1.05 $ 1.38 $1.51 - 2.00 290,760 3.27 1.87 $2.01 - 2.50 265,775 3.35 2.06 $2.51 - 8.60 41,568 3.75 4.86 624,531 3.24 $ 2.13 |
Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block] | 2021 2020 Shares Wtd. Avg. Grant Date Fair Value Shares Wtd. Avg. Grant Date Fair Value Outstanding as of beginning of year 930,854 $ 19.31 429,399 $ 13.25 Granted 801,484 47.20 717,267 20.88 Granted in lieu of cash - - 34,154 9.18 Vested (378,502 ) 19.31 (208,858 ) 11.32 Forfeited (141,053 ) 36.95 (41,108 ) 15.47 Non-vested as of year end 1,212,783 $ 37.48 930,854 $ 19.31 2021 2020 Shares Wtd. Avg. Grant Date Fair Value Shares Wtd. Avg. Grant Date Fair Value Outstanding as of beginning of year - $ - - $ - Granted - - 82,805 9.18 Vested - - (82,805 ) 9.18 Non-vested as of year end - $ - - $ - 2021 2020 Shares Wtd. Avg. Grant Date Fair Value Shares Wtd. Avg. Grant Date Fair Value Outstanding as of beginning of year 224,774 $ 19.20 123,851 $ 26.99 Granted 152,665 32.50 109,140 10.95 Vested (231,268 ) 26.98 - - Forfeited (6,415 ) 40.65 (8,217 ) 27.02 Non-vested as of year end 139,756 $ 19.86 224,774 $ 19.20 |
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] | 2021 2020 2019 Research and development costs $ 1,906 $ 1,012 $ 571 Sales and marketing costs 1,788 852 711 General and administrative costs 8,061 3,518 1,584 Cost of revenue 2,201 599 177 Total $ 13,956 $ 5,981 $ 3,043 |
Note 12 - Acquisitions (Tables)
Note 12 - Acquisitions (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Notes Tables | |
Schedule of Business Acquisitions, by Acquisition [Table Text Block] | Merger consideration shares 530,502 BioLife stock price (as of September 1, 2021) $ 60.50 Value of issued shares $ 32,095 plus: Fair value of BioLife’s existing investment in Sexton $ 7,951 less: Net working capital adjustment $ (118 ) Merger Consideration $ 39,928 BioLife shares outstanding (as of March 19, 2021) 33,401,359 Merger consideration percentage 19.9 % Merger consideration shares 6,646,870 less: Merger consideration shares withheld to satisfy outstanding GCI stockholder obligations to GCI 10,400 Subtotal 6,636,470 BioLife stock price (as of May 3, 2021) $ 35.07 Value of issued shares $ 232,741 plus: Settlement of BioLife prepaid deposits $ 2,152 plus: Net settlement of BioLife accounts receivable $ 16 Merger Consideration $ 234,909 Cash consideration $ 15,000 Stock consideration 17,916 Contingent consideration 3,663 Working capital adjustment (53 ) Total consideration transferred $ 36,526 Cash consideration $ 11,000 Stock consideration 4,000 Contingent consideration 856 Total consideration transferred $ 15,856 Stock consideration for 55.6% $ 19,932 Cash consideration $ 12,521 Contingent consideration 1,491 Working capital adjustment (71 ) Total consideration transferred $ 13,941 |
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] | Cash $ 1,516 Accounts receivable, net 492 Inventory 1,310 Prepaid expenses and other current assets 670 Property, plant and equipment, net 737 Operating lease right-of-use assets, net 470 Developed technology 4,132 Customer relationships 2,276 Tradenames 2,324 Non-compete agreements 90 Goodwill 28,470 Accounts payable (291 ) Lease liabilities, operating (470 ) Deferred tax liability (1,482 ) Other liabilities (316 ) Fair value of net assets acquired $ 39,928 Cash $ 43 Accounts receivable, net 7,076 Inventory 15,547 Prepaid expenses and other current assets 639 Property, plant and equipment, net 3,512 Operating lease right-of-use assets, net 1,741 Financing lease right-of-use assets, net 114 Long-term deposits and other assets 4 Developed technology 18,140 Customer relationships 7,020 Tradenames 26,640 Non-compete agreements 1,240 In-process research and development 67,440 Goodwill 137,822 Accounts payable (9,837 ) Line of credit (4,231 ) Lease liabilities, operating (1,880 ) Lease liabilities, financing (114 ) Long-term debt (4,410 ) Deferred tax liability (24,133 ) Other liabilities (7,464 ) Fair value of net assets acquired $ 234,909 Cash $ 500 Accounts receivable, net 945 Prepaid expenses and other current assets 31 Property, plant and equipment, net 3,400 Customer relationships 7,420 Tradenames 4,020 Non-compete agreements 660 Goodwill 24,943 Other assets 1,547 Accounts payable (885 ) Deferred tax liability (3,297 ) Other liabilities (2,758 ) Fair value of net assets acquired $ 36,526 Accounts receivable, net $ 1,044 Inventory 3,232 Prepaid expenses and other current assets 29 Property, plant and equipment, net 3,615 Customer relationships 560 Tradenames 800 Developed technology 5,430 Goodwill 2,954 Accounts Payable (1,197 ) Other liabilities (611 ) Fair value of net assets acquired $ 15,856 Cash and cash equivalents $ 1,251 Accounts receivable, net 753 Prepaid expenses and other current assets 19 Property, plant and equipment, net 546 Operating right-of-use asset 233 Assets held for lease 2,441 Customer relationships 80 Tradenames 1,320 Developed technology 10,750 Goodwill 21,037 Accounts Payable and accrued expenses (807 ) Deferred tax liabilities (1,541 ) Other liabilities (232 ) Fair value of net assets acquired $ 35,850 Cash and cash equivalents $ 11 Accounts receivable, net 154 Inventory 456 Customer relationships 160 Tradenames 470 Developed technology 2,840 In-process research and development 650 Goodwill 9,515 Other assets 99 Accounts Payable (250 ) Other liabilities (164 ) Fair value of net assets acquired $ 13,941 |
Schedule of Acquired Finite-Lived Intangible Assets by Major Class [Table Text Block] | Fair Value Useful Life (Years) Developed technology $ 4,132 5 - 9 Customer relationships 2,276 2 Tradenames 2,324 11 Non-compete agreements 90 1 Total identifiable intangible assets $ 8,822 Fair Value Useful Life (Years) Developed technology $ 18,140 6 Customer relationships 7,020 12 Tradenames 26,640 15 Non-compete agreements 1,240 4 In-process research and development 67,440 N/A Total identifiable intangible assets $ 120,480 Fair Value Useful Life (Years) Customer relationships $ 7,420 14 Tradenames 4,020 19 Non-compete agreements 660 4 Total identifiable intangible assets $ 12,100 Fair Value Useful Life (Years) Customer relationships $ 560 6 Tradenames 800 6 Developed technology 5,430 9 Total identifiable intangible assets $ 6,790 Fair Value Useful Life (Years) Customer relationships $ 80 6 Tradenames 1,320 9 Developed technology 10,750 7 - 8 Total identifiable intangible assets $ 12,150 Fair Value Useful Life (Years) Customer relationships $ 160 4 Tradenames 470 9 Developed technology 2,840 5 - 9 In-process research and development 650 N/A Total identifiable intangible assets $ 4,120 |
Business Acquisition, Pro Forma Information [Table Text Block] | 2021 2020 (In thousands) (unaudited) (unaudited) Total revenue $ 122,494 $ 50,856 Net (loss) income $ (9,860 ) $ (1,028 ) 2021 2020 (In thousands) (unaudited) (unaudited) Total revenue $ 143,732 $ 87,370 Net income (loss) $ (16,375 ) $ 501 2020 2019 (In thousands) (unaudited) (unaudited) Total revenue $ 52,613 $ 43,221 Net income (loss) $ 1,798 $ (4,528 ) 2019 (In thousands) (unaudited) Total revenue $ 37,001 Net income (loss) $ (493 ) 2019 (In thousands) (unaudited) Total revenue $ 28,824 Net income (loss) $ (1,518 ) 2019 (In thousands) (unaudited) Total revenue $ 28,745 Net income (loss) $ (183 ) |
Note 13 - Consolidated Balanc_2
Note 13 - Consolidated Balance Sheet Detail (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Notes Tables | |
Property, Plant and Equipment [Table Text Block] | (In thousands) 2021 2020 Property and equipment Leasehold improvements $ 3,840 $ 2,393 Furniture and computer equipment 1,861 902 Manufacturing and other equipment 16,675 10,076 Construction in-progress 2,022 591 Subtotal 24,398 13,962 Less: Accumulated depreciation (6,741 ) (3,842 ) Net property and equipment $ 17,657 $ 10,120 |
Schedule of Accrued Liabilities [Table Text Block] | (In thousands) 2021 2020 Accrued expenses $ 1,656 $ 472 Accrued taxes 27 112 Accrued compensation 4,351 2,898 Deferred revenue, current 814 931 Other 294 130 Total accrued expenses and other current liabilities $ 7,142 $ 4,543 |
Schedule of Product Warranty Liability [Table Text Block] | (In thousands) 2021 2020 Beginning balance $ 212 $ 191 Warranty reserve acquired in the acquisition of Global Cooling 3,353 - Provision for warranties 9,845 137 Settlements of warranty claims (4,012 ) (116 ) Ending Balance $ 9,398 $ 212 |
Note 1 - Organization and Sig_3
Note 1 - Organization and Significant Accounting Policies (Details Textual) | 1 Months Ended | 4 Months Ended | 9 Months Ended | 12 Months Ended | ||||||
Dec. 31, 2021USD ($) | Jun. 30, 2020USD ($) | Apr. 20, 2020USD ($) | Sep. 30, 2021USD ($) | Dec. 31, 2021USD ($) | Dec. 31, 2020USD ($) | Dec. 31, 2019USD ($) | Nov. 30, 2020USD ($) | Oct. 01, 2020USD ($) | Sep. 30, 2019USD ($) | |
Number of Reportable Segments | 1 | |||||||||
Number of Reporting Units | 1 | |||||||||
Contract with Customer, Liability, Revenue Recognized | $ 671,000 | |||||||||
Impairment of Intangible Assets (Excluding Goodwill), Total | $ 0 | |||||||||
Business Combination, Contingent Consideration, Liability, Total | $ 388,000 | $ 221,000 | ||||||||
Deferred Tax Payments, Social Security | $ 297,000 | 297,000 | ||||||||
Payments of Deferred Payments | 135,000 | |||||||||
Debt Instrument, Decrease, Forgiveness | 284,000 | |||||||||
Impairment Loss Recognized During Period | 0 | 0 | $ 0 | |||||||
Unrecognized Tax Benefits, Ending Balance | 255,000 | 255,000 | 96,000 | 0 | ||||||
Advertising Expense | 552,000 | $ 167,000 | $ 43,000 | |||||||
Goodwill, Impairment Loss | $ 0 | |||||||||
Customer Concentration Risk [Member] | Revenue Benchmark [Member] | ||||||||||
Number of Major Customers | 1 | 1 | 1 | |||||||
Customer Concentration Risk [Member] | Revenue Benchmark [Member] | One Customer [Member] | ||||||||||
Concentration Risk, Percentage | 17.00% | 13.00% | 15.00% | |||||||
Customer Concentration Risk [Member] | Accounts Receivable [Member] | ||||||||||
Number of Major Customers | 2 | 1 | ||||||||
Customer Concentration Risk [Member] | Accounts Receivable [Member] | One Customer [Member] | ||||||||||
Concentration Risk, Percentage | 17.00% | |||||||||
Customer Concentration Risk [Member] | Accounts Receivable [Member] | Two Customers [Member] | ||||||||||
Concentration Risk, Percentage | 32.00% | |||||||||
Supplier Concentration Risk [Member] | Revenue Benchmark [Member] | ||||||||||
Number of Suppliers | 1 | |||||||||
Supplier Concentration Risk [Member] | Revenue Benchmark [Member] | One Supplier [Member] | ||||||||||
Concentration Risk, Percentage | 12.00% | |||||||||
Supplier Concentration Risk [Member] | Accounts Payable [Member] | ||||||||||
Number of Suppliers | 1 | 1 | ||||||||
Supplier Concentration Risk [Member] | Accounts Payable [Member] | One Supplier [Member] | ||||||||||
Concentration Risk, Percentage | 10.00% | 21.00% | ||||||||
Assets Held for Rent [Member] | ||||||||||
Property, Plant and Equipment, Useful Life (Year) | 3 years | |||||||||
Minimum [Member] | ||||||||||
Property, Plant and Equipment, Useful Life (Year) | 3 years | |||||||||
Maximum [Member] | ||||||||||
Property, Plant and Equipment, Useful Life (Year) | 10 years | |||||||||
Contingent Convertible Preferred Stock [Member] | ||||||||||
Debt Securities, Gain (Loss), Total | $ 0 | |||||||||
Contingent Convertible Preferred Stock [Member] | Series A-1 and A-2, Preferred Stock [Member] | ||||||||||
Equity Securities without Readily Determinable Fair Value, Amount | 3,400,000 | $ 3,400,000 | 3,400,000 | |||||||
Contingent Convertible Preferred Stock [Member] | Series E Preferred Stock [Member] | ||||||||||
Equity Securities without Readily Determinable Fair Value, Amount | 995,000 | 995,000 | ||||||||
Contingent Convertible Preferred Stock [Member] | Series A-2 Preferred Stock [Member] | ||||||||||
Equity Securities without Readily Determinable Fair Value, Amount | $ 1,000,000 | |||||||||
Contingent Convertible Preferred Stock [Member] | Preferred Stock, Class E [Member] | ||||||||||
Contingent Milestone Payment | 2,000,000 | |||||||||
Contingent Millstone Payment, #1 | 200,000 | |||||||||
Convertible Debt Securities [Member] | ||||||||||
Debt Securities, Available-for-sale, Amortized Cost, Total | $ 1,000,000 | |||||||||
Debt Securities, Gain (Loss), Total | 1,300,000 | |||||||||
SciSafe Holdings, Inc [Member] | ||||||||||
Business Combination, Contingent Consideration, Liability, Total | $ 9,900,000 | 9,900,000 | 6,900,000 | $ 3,700,000 | ||||||
Sexton Biotechnologies [Member] | Contingent Convertible Preferred Stock [Member] | ||||||||||
Equity Securities without Readily Determinable Fair Value, Amount | 1,500,000 | |||||||||
PanTHERA Cryosolutions Investment [Member] | Contingent Convertible Preferred Stock [Member] | Series E Preferred Stock [Member] | ||||||||||
Equity Securities without Readily Determinable Fair Value, Amount | 995,000 | |||||||||
PanTHERA Cryosolutions Investment [Member] | Contingent Convertible Preferred Stock [Member] | Preferred Stock, Class E [Member] | ||||||||||
Equity Securities without Readily Determinable Fair Value, Amount | $ 995,000 | |||||||||
Paycheck Protection Program CARES Act [Member] | ||||||||||
Repayments of Debt | $ 2,175,320 | $ 0 | $ 2,175,000 | $ 0 | ||||||
Debt Instrument, Interest Rate, Stated Percentage | 1.00% | 1.00% | ||||||||
Paycheck Protection Program CARES Act [Member] | SciSafe Holdings, Inc [Member] | ||||||||||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt | $ 295,300 | |||||||||
Debt Instrument, Interest Rate, Stated Percentage | 1.00% |
Note 1 - Organization and Sig_4
Note 1 - Organization and Significant Accounting Policies - Revenues By Product Line (Details) - USD ($) $ in Thousands | 12 Months Ended | |||||
Dec. 31, 2021 | [1] | Dec. 31, 2020 | [2] | Dec. 31, 2019 | [3] | |
Total revenue | $ 119,156 | $ 48,087 | $ 27,371 | |||
Product, Freezer and Thaw [Member] | ||||||
Total revenue | 56,620 | 13,548 | 3,312 | |||
Product, Cell Processing [Member] | ||||||
Total revenue | 44,965 | 30,946 | 23,367 | |||
Product, Storage and Cold Chain Services [Member] | ||||||
Total revenue | 328 | 46 | 165 | |||
Service, Storage and Cold Chain Services [Member] | ||||||
Total revenue | 9,817 | 1,752 | 0 | |||
Rental, Storage and Cold Chain Services [Member] | ||||||
Total revenue | $ 7,426 | $ 1,795 | $ 527 | |||
[1] | 2021 revenue includes product revenue related to Global Cooling from May 3, 2021 through December 31, 2021 and product revenue related to Sexton from September 1, 2021 through December 31, 2021. | |||||
[2] | 2020 revenue includes service revenue related to SciSafe from October 1, 2020 through December 31, 2020. | |||||
[3] | 2019 revenue includes product revenue related to Astero Bio Corporation ("Astero") from April 1, 2019 through December 31, 2019; rental revenue related to SAVSU from August 8, 2019 through December 31, 2019; and product revenue related to CBS from November 12, 2019 through December 31, 2019. |
Note 1 - Organization and Sig_5
Note 1 - Organization and Significant Accounting Policies - Summary of Remaining Performance Obligations (Details) $ in Thousands | Dec. 31, 2021USD ($) |
Rental Revenue [Member] | |
Revenue, expected to be recognized in the future | $ 14,799 |
Service Revenue [Member] | |
Revenue, expected to be recognized in the future | $ 108 |
Note 1 - Organization and Sig_6
Note 1 - Organization and Significant Accounting Policies - Summary of Remaining Performance Obligations 2 (Details) $ in Thousands | Dec. 31, 2021USD ($) |
Rental Revenue [Member] | |
Revenue, expected to be recognized in the future | $ 14,799 |
Service Revenue [Member] | |
Revenue, expected to be recognized in the future | 108 |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-01-01 | Rental Revenue [Member] | |
Revenue, expected to be recognized in the future | $ 10,151 |
Revenue, expected to be recognized in the future, period (Year) | 1 year |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-01-01 | Service Revenue [Member] | |
Revenue, expected to be recognized in the future | $ 67 |
Revenue, expected to be recognized in the future, period (Year) | 1 year |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01 | Rental Revenue [Member] | |
Revenue, expected to be recognized in the future | $ 3,748 |
Revenue, expected to be recognized in the future, period (Year) | 1 year |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01 | Service Revenue [Member] | |
Revenue, expected to be recognized in the future | $ 31 |
Revenue, expected to be recognized in the future, period (Year) | 1 year |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01 | Rental Revenue [Member] | |
Revenue, expected to be recognized in the future | $ 900 |
Revenue, expected to be recognized in the future, period (Year) | 1 year |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01 | Service Revenue [Member] | |
Revenue, expected to be recognized in the future | $ 10 |
Revenue, expected to be recognized in the future, period (Year) | 1 year |
Note 1 - Organization and Sig_7
Note 1 - Organization and Significant Accounting Policies - Calculation of Diluted Shares (Details) - USD ($) $ / shares in Units, $ in Thousands | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Net (loss) income | $ (7,635) | $ 2,667 | $ (1,657) |
Amount attributable to unvested restricted shares | 0 | (135) | 0 |
Amount attributable to warrants outstanding | 0 | (82) | 0 |
Net (loss) income allocated to common shareholders | $ (7,635) | $ 2,450 | $ (1,657) |
Weighted-average common shares issued and outstanding (in shares) | 38,503,944 | 27,306,258 | 19,460,299 |
Basic (loss) earnings per common share (in dollars per share) | $ (0.20) | $ 0.09 | $ (0.09) |
Amount attributable to warrants | $ 0 | $ (20) | $ 0 |
Less: gain related to change in fair value of warrants | 0 | (3,601) | 0 |
Diluted (loss) earnings per common share | $ (7,635) | $ (954) | $ (1,657) |
Diluted (loss) earnings per common share (in dollars per share) | $ (0.20) | $ (0.03) | $ (0.09) |
Note 1 - Organization and Sig_8
Note 1 - Organization and Significant Accounting Policies - Anti-dilutive (Details) - shares | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Anti-dilutive securities (in shares) | 1,655,949 | 3,631,747 | 5,520,495 |
Share-based Payment Arrangement, Option and Restricted Stock Awards [Member] | |||
Anti-dilutive securities (in shares) | 1,637,745 | 2,131,794 | 2,564,456 |
Warrant [Member] | |||
Anti-dilutive securities (in shares) | 18,204 | 1,499,953 | 2,956,039 |
Note 1 - Organization and Sig_9
Note 1 - Organization and Significant Accounting Policies - Summary of Cash, Cash Equivalents, and Restricted Cash (Details) - USD ($) $ in Thousands | Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 |
Cash and cash equivalents | $ 69,860 | $ 90,403 | $ 6,448 |
Restricted cash | 10 | 53 | 0 |
Total cash, cash equivalents, and restricted cash | $ 69,870 | $ 90,456 | $ 6,448 |
Note 1 - Organization and Si_10
Note 1 - Organization and Significant Accounting Policies - Concentrations Risk by Geographic Locations (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Long-Lived Assets | $ 46,611 | $ 30,389 | |
Revenue Benchmark [Member] | Geographic Concentration Risk [Member] | |||
Canada | 100.00% | 100.00% | 100.00% |
UNITED STATES | |||
Long-Lived Assets | $ 40,708 | $ 30,389 | |
UNITED STATES | Revenue Benchmark [Member] | Geographic Concentration Risk [Member] | |||
Canada | 7.00% | 13.00% | 16.00% |
NETHERLANDS | |||
Long-Lived Assets | $ 5,903 | $ 0 | |
CANADA | Revenue Benchmark [Member] | Geographic Concentration Risk [Member] | |||
Canada | 4.00% | 4.00% | 3.00% |
EMEA [Member] | Revenue Benchmark [Member] | Geographic Concentration Risk [Member] | |||
Canada | 10.00% | 8.00% | 11.00% |
Geographic, Other [Member] | Revenue Benchmark [Member] | Geographic Concentration Risk [Member] | |||
Canada | 1.00% | 2.00% | 1.00% |
Note 1 - Organization and Si_11
Note 1 - Organization and Significant Accounting Policies - Weighted Average Assumptions (Details) | Dec. 31, 2020 | Dec. 31, 2019 |
Measurement Input, Risk Free Interest Rate [Member] | ||
Warrants and right, measurement input | 0.001 | 0.019 |
Measurement Input, Expected Dividend Rate [Member] | ||
Warrants and right, measurement input | 0 | 0 |
Measurement Input, Expected Term [Member] | ||
Warrants and right, measurement input | 0.2 | 1.7 |
Measurement Input, Price Volatility [Member] | ||
Warrants and right, measurement input | 0.568 | 0.703 |
Note 2 - Fair Value Measureme_3
Note 2 - Fair Value Measurement (Details Textual) | 12 Months Ended | ||||||
Dec. 31, 2021USD ($) | Dec. 31, 2020USD ($) | Dec. 31, 2019USD ($) | Oct. 01, 2020USD ($) | Jun. 30, 2020USD ($) | Nov. 10, 2019 | Apr. 01, 2019 | |
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability | $ 2,875,000 | $ 1,575,000 | $ 50,000 | ||||
Business Combination, Contingent Consideration, Liability, Total | 221,000 | $ 388,000 | |||||
Astero [Member] | |||||||
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability | (81,000) | ||||||
Business Combination, Contingent Consideration, Liability, Total | 81,000 | ||||||
CBS Acquisition [Member] | |||||||
Business Combination, Contingent Consideration, Liability, Total | 140,000 | ||||||
SciSafe Holdings, Inc [Member] | |||||||
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability | 3,000,000 | 3,300,000 | |||||
Business Combination, Contingent Consideration, Liability, Total | $ 9,900,000 | $ 6,900,000 | $ 3,700,000 | ||||
Measurement Input, Discount Rate [Member] | Astero [Member] | |||||||
Business Combination, Contingent Consideration, Liability, Measurement Input | 0.175 | ||||||
Measurement Input, Discount Rate [Member] | CBS Acquisition [Member] | |||||||
Business Combination, Contingent Consideration, Liability, Measurement Input | 0.210 | 0.260 | |||||
Measurement Input, Discount Rate [Member] | SciSafe Holdings, Inc [Member] | |||||||
Business Combination, Contingent Consideration, Liability, Measurement Input | 0.071 | 0.045 | |||||
Measurement Input, Risk Free Interest Rate [Member] | |||||||
Warrants and Rights Outstanding, Measurement Input | 0.001 | 0.019 | |||||
Measurement Input, Risk Free Interest Rate [Member] | CBS Acquisition [Member] | |||||||
Business Combination, Contingent Consideration, Liability, Measurement Input | 0.0023 | 0.0174 | |||||
Measurement Input, Risk Free Interest Rate [Member] | SciSafe Holdings, Inc [Member] | |||||||
Business Combination, Contingent Consideration, Liability, Measurement Input | 0.0085 | 0.0020 | |||||
Measurement Input, Risk Free Interest Rate [Member] | Minimum [Member] | Astero [Member] | |||||||
Business Combination, Contingent Consideration, Liability, Measurement Input | 0.0229 | ||||||
Measurement Input, Risk Free Interest Rate [Member] | Maximum [Member] | Astero [Member] | |||||||
Business Combination, Contingent Consideration, Liability, Measurement Input | 0.0241 | ||||||
Measurement Input, Price Volatility [Member] | |||||||
Warrants and Rights Outstanding, Measurement Input | 0.568 | 0.703 | |||||
Measurement Input, Price Volatility [Member] | Astero [Member] | |||||||
Business Combination, Contingent Consideration, Liability, Measurement Input | 0.56 | ||||||
Measurement Input, Price Volatility [Member] | CBS Acquisition [Member] | |||||||
Business Combination, Contingent Consideration, Liability, Measurement Input | 0.63 | 0.70 | |||||
Measurement Input, Price Volatility [Member] | Minimum [Member] | |||||||
Warrants and Rights Outstanding, Measurement Input | 0.568 | ||||||
Measurement Input, Price Volatility [Member] | Maximum [Member] | |||||||
Warrants and Rights Outstanding, Measurement Input | 0.846 | ||||||
Measurement Input, Asset Price Volatility [Member] | SciSafe Holdings, Inc [Member] | |||||||
Business Combination, Contingent Consideration, Liability, Measurement Input | 0.72 | 0.60 | |||||
Measurement Input, Revenue Volatility [Member] | SciSafe Holdings, Inc [Member] | |||||||
Business Combination, Contingent Consideration, Liability, Measurement Input | 0.27 | 0.15 | |||||
Convertible Debt Securities [Member] | Minimum [Member] | |||||||
Debt Securities, Term (Year) | 1 year | ||||||
Convertible Debt Securities [Member] | Maximum [Member] | |||||||
Debt Securities, Term (Year) | 2 years | ||||||
Convertible Debt Securities [Member] | Measurement Input, Prepayment Rate [Member] | |||||||
Debt Securities, Trading, Measurement Input | 0.080 | ||||||
Convertible Debt Securities [Member] | Measurement Input, Prepayment Rate [Member] | Minimum [Member] | |||||||
Debt Securities, Trading, Measurement Input | 0.05 | ||||||
Convertible Debt Securities [Member] | Measurement Input, Prepayment Rate [Member] | Maximum [Member] | |||||||
Debt Securities, Trading, Measurement Input | 0.50 |
Note 2 - Fair Value Measureme_4
Note 2 - Fair Value Measurement - Financial Assets and Liabilities on Recurring Basis (Details) - Fair Value, Recurring [Member] - USD ($) $ in Thousands | Dec. 31, 2021 | Dec. 31, 2020 |
Assets | $ 63,873 | $ 90,403 |
Liabilities | 10,027 | 9,932 |
Contingent Consideration Liabilities [Member] | ||
Liabilities | 10,027 | |
Warrant Liabilities [Member] | ||
Liabilities | 2,780 | |
Money Market Funds [Member] | ||
Assets | 63,873 | 90,403 |
Contingent Consideration Liabilities [Member] | ||
Liabilities | 7,152 | |
Fair Value, Inputs, Level 1 [Member] | ||
Assets | 63,873 | 90,403 |
Liabilities | 0 | 0 |
Fair Value, Inputs, Level 1 [Member] | Contingent Consideration Liabilities [Member] | ||
Liabilities | 0 | |
Fair Value, Inputs, Level 1 [Member] | Warrant Liabilities [Member] | ||
Liabilities | 0 | |
Fair Value, Inputs, Level 1 [Member] | Money Market Funds [Member] | ||
Assets | 63,873 | 90,403 |
Fair Value, Inputs, Level 1 [Member] | Contingent Consideration Liabilities [Member] | ||
Liabilities | 0 | |
Fair Value, Inputs, Level 2 [Member] | ||
Assets | 0 | 0 |
Liabilities | 0 | 0 |
Fair Value, Inputs, Level 2 [Member] | Contingent Consideration Liabilities [Member] | ||
Liabilities | 0 | |
Fair Value, Inputs, Level 2 [Member] | Warrant Liabilities [Member] | ||
Liabilities | 0 | |
Fair Value, Inputs, Level 2 [Member] | Money Market Funds [Member] | ||
Assets | 0 | 0 |
Fair Value, Inputs, Level 2 [Member] | Contingent Consideration Liabilities [Member] | ||
Liabilities | 0 | |
Fair Value, Inputs, Level 3 [Member] | ||
Assets | 0 | 0 |
Liabilities | 10,027 | 9,932 |
Fair Value, Inputs, Level 3 [Member] | Contingent Consideration Liabilities [Member] | ||
Liabilities | 10,027 | |
Fair Value, Inputs, Level 3 [Member] | Warrant Liabilities [Member] | ||
Liabilities | 2,780 | |
Fair Value, Inputs, Level 3 [Member] | Money Market Funds [Member] | ||
Assets | $ 0 | 0 |
Fair Value, Inputs, Level 3 [Member] | Contingent Consideration Liabilities [Member] | ||
Liabilities | $ 7,152 |
Note 2 - Fair Value Measureme_5
Note 2 - Fair Value Measurement - Fair Value of Contingent Consideration Using Level 3 Inputs (Details) - Contingent Consideration Liabilities [Member] - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Beginning balance | $ 7,152 | $ 1,914 | $ 0 |
Additions | 0 | 3,663 | 2,347 |
Change in fair value recognized in net (loss) income | (2,875) | (1,575) | (50) |
Payments earned, reclassified to accrued liabilities | 0 | 0 | (483) |
Ending balance | $ 10,027 | $ 7,152 | $ 1,914 |
Note 2 - Fair Value Measureme_6
Note 2 - Fair Value Measurement - Fair Value of Warrant Liabilities Using Level 3 Inputs (Details) - Warrant Liabilities [Member] - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Beginning balance | $ 2,780 | $ 39,602 | $ 28,516 |
Exercised warrants | (2,901) | (33,221) | (1,749) |
Change in fair value recognized in net (loss) income | (121) | 3,601 | (12,835) |
Ending balance | $ 0 | $ 2,780 | $ 39,602 |
Note 3 - Inventories - Summary
Note 3 - Inventories - Summary of Inventories (Details) - USD ($) $ in Thousands | Dec. 31, 2021 | Dec. 31, 2020 |
Raw materials | $ 17,252 | $ 2,855 |
Work in progress | 5,015 | 2,006 |
Finished goods | 6,078 | 6,741 |
Total | $ 28,345 | $ 11,602 |
Note 4 - Assets Held for Rent_2
Note 4 - Assets Held for Rent (Details Textual) - USD ($) | 11 Months Ended | 12 Months Ended | |
Dec. 13, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Assets Held for Rent, Depreciation | $ 1,900,000 | $ 671,000 | $ 174,000 |
Note 4 - Assets Held for Rent -
Note 4 - Assets Held for Rent - Assets Held for Rent (Details) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Shippers placed in service | $ 5,645 | $ 3,171 |
Fixed assets held for rent | 4,040 | 0 |
Accumulated depreciation | (2,272) | (411) |
Net | 7,413 | 2,760 |
Shippers and related components in production | 2,396 | 1,945 |
Total | $ 9,809 | $ 4,705 |
Note 5 - Leases (Details Textua
Note 5 - Leases (Details Textual) | Dec. 31, 2021 |
Minimum [Member] | Real Estate Lease[Member] | |
Lessee, Operating Lease, Remaining Lease Term (Year) | 1 year |
Minimum [Member] | Lease Extensions [Member] | |
Lessee, Operating Lease, Term of Contract (Year) | 1 year |
Maximum [Member] | Real Estate Lease[Member] | |
Lessee, Operating Lease, Remaining Lease Term (Year) | 10 years |
Maximum [Member] | Lease Extensions [Member] | |
Lessee, Operating Lease, Term of Contract (Year) | 5 years |
Note 5 - Leases - Lease Term an
Note 5 - Leases - Lease Term and Discount Rate (Details) | Dec. 31, 2021 | Dec. 31, 2020 |
Weighted average discount rate - operating leases | 3.80% | 3.30% |
Weighted average discount rate - finance leases | 6.10% | 5.70% |
Weighted average remaining lease term in years - operating leases (Year) | 7 years 9 months 18 days | 9 years 4 months 24 days |
Weighted average remaining lease term in years - finance leases (Year) | 3 years | 2 years 7 months 6 days |
Note 5 - Leases - Components of
Note 5 - Leases - Components of Lease Expense (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Operating lease costs | $ 2,817 | $ 839 | $ 612 |
Short-term lease costs | 1,727 | 277 | 51 |
Total operating lease costs | 4,544 | 1,116 | 663 |
Variable lease costs | 749 | 357 | 299 |
Total lease expense | $ 5,293 | $ 1,473 | $ 962 |
Note 5 - Leases - Maturities of
Note 5 - Leases - Maturities of Lease Liabilities (Details) $ in Thousands | Dec. 31, 2021USD ($) |
2022, operating leases | $ 3,443 |
2022, finance leases | 171 |
2023, operating leases | 3,151 |
2023. finance leases | 171 |
2024, operating leases | 2,883 |
2024, finance leases | 101 |
2025, operating leases | 2,497 |
2025, finance leases | 37 |
2026, operating leases | 2,006 |
2026, finance leases | 2 |
Thereafter, operating leases | 8,364 |
Thereafter, finance leases | 0 |
Total operating lease payments | 22,344 |
Total financing lease payments, finance leases | 482 |
Less: operating lease interest | (3,120) |
Less: financing lease interest | (42) |
Total present value of operating lease liabilities | 19,224 |
Total present value of financing lease liabilities | $ 440 |
Note 6 - Goodwill and Intangi_3
Note 6 - Goodwill and Intangible Assets (Details Textual) - USD ($) | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Goodwill, Purchase Accounting Adjustments | $ (131,000) | ||
Increase (Decrease) in Accounts Payable, Total | $ 2,018,000 | (171,000) | $ 768,000 |
Amortization of Intangible Assets, Total | $ 8,202,000 | 3,033,000 | 1,079,000 |
CBS Acquisition [Member] | Immaterial Error [Member] | |||
Goodwill, Purchase Accounting Adjustments | $ (131,000) | ||
Increase (Decrease) in Accounts Payable, Total | $ (131,000) |
Note 6 - Goodwill and Intangi_4
Note 6 - Goodwill and Intangible Assets - Goodwill (Details) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Balance | $ 58,449 | $ 33,637 |
Correction of an error related to CBS goodwill | (131) | |
Balance | 224,741 | 58,449 |
SciSafe Holdings, Inc [Member] | ||
Goodwill related to acquisition | $ 24,943 | |
Global Cooling[Member] | ||
Goodwill related to acquisition | 137,822 | |
Sexton Biotechnologies, Inc. [Member] | ||
Goodwill related to acquisition | $ 28,470 |
Note 6 - Goodwill and Intangi_5
Note 6 - Goodwill and Intangible Assets - Intangible Assets (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | ||
Gross Carrying Value | $ 35,160 | ||
Accumulated Amortization | $ (12,313) | (4,111) | |
Net Carrying Value | 84,709 | 31,049 | |
Total intangible assets, gross | 164,462 | ||
Total intangible assets, net | 152,149 | $ 31,049 | |
In Process Research and Development [Member] | |||
In-process research and development | [1] | $ 67,440 | |
Weighted Average [Member] | |||
Weighted Average Useful Life (Year) | 9 years 9 months 18 days | 9 years 8 months 12 days | |
Customer Relationships [Member] | |||
Gross Carrying Value | $ 17,516 | $ 8,220 | |
Accumulated Amortization | (1,776) | (330) | |
Net Carrying Value | $ 15,740 | $ 7,890 | |
Customer Relationships [Member] | Weighted Average [Member] | |||
Weighted Average Useful Life (Year) | 10 years 3 months 18 days | 12 years 9 months 18 days | |
Trade Names [Member] | |||
Gross Carrying Value | $ 35,574 | $ 6,610 | |
Accumulated Amortization | (2,306) | (508) | |
Net Carrying Value | $ 33,268 | $ 6,102 | |
Trade Names [Member] | Weighted Average [Member] | |||
Weighted Average Useful Life (Year) | 13 years 9 months 18 days | 14 years | |
Technology-Based Intangible Assets [Member] | |||
Gross Carrying Value | $ 41,942 | $ 19,670 | |
Accumulated Amortization | (7,789) | (3,232) | |
Net Carrying Value | $ 34,153 | $ 16,438 | |
Technology-Based Intangible Assets [Member] | Weighted Average [Member] | |||
Weighted Average Useful Life (Year) | 5 years 10 months 24 days | 7 years 1 month 6 days | |
Noncompete Agreements [Member] | |||
Gross Carrying Value | $ 1,990 | $ 660 | |
Accumulated Amortization | (442) | (41) | |
Net Carrying Value | $ 1,548 | $ 619 | |
Noncompete Agreements [Member] | Weighted Average [Member] | |||
Weighted Average Useful Life (Year) | 3 years | 3 years 9 months 18 days | |
[1] | In-process R&D represents the fair value of incomplete research and development that has not yet reached technological feasibility. We will amortize the asset upon technological feasibility. |
Note 6 - Goodwill and Intangi_6
Note 6 - Goodwill and Intangible Assets - Future Amortization Expense (Details) - USD ($) $ in Thousands | Dec. 31, 2021 | Dec. 31, 2020 |
2022 | $ 11,421 | |
2023 | 10,951 | |
2024 | 10,126 | |
2025 | 9,748 | |
2026 | 9,346 | |
Thereafter | 33,117 | |
Total | $ 84,709 | $ 31,049 |
Note 7 - Line of Credit and L_3
Note 7 - Line of Credit and Long-term Debt (Details Textual) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2021 | Oct. 01, 2021 | Dec. 31, 2020 | |
Long-term Debt, Gross | $ 7,246 | $ 1,269 | |
Line of Credit [Member] | |||
Line of Credit Facility, Maximum Borrowing Capacity | $ 5,000 | ||
Line of Credit [Member] | London Interbank Offered Rate (LIBOR) [Member] | |||
Debt Instrument, Basis Spread on Variable Rate | 5.50% | ||
Notes Payable [Member] | |||
Long-term Debt, Gross | $ 4,400 | ||
Notes Payable [Member] | Advantage Term Note 1 [Member] | |||
Debt Instrument, Face Amount | $ 1,400 | ||
Debt Instrument, Interest Rate, Stated Percentage | 4.00% | ||
Notes Payable [Member] | Advantage Term Note 2 [Member] | |||
Debt Instrument, Face Amount | $ 1,400 | ||
Debt Instrument, Interest Rate, Stated Percentage | 4.00% | ||
Notes Payable [Member] | Enhanced Term Note [Member] | |||
Debt Instrument, Face Amount | $ 1,800 | ||
Debt Instrument, Interest Rate, Stated Percentage | 4.00% | ||
Notes Payable [Member] | London Interbank Offered Rate (LIBOR) [Member] | |||
Debt Instrument, Basis Spread on Variable Rate | 6.50% |
Note 7 - Line of Credit and L_4
Note 7 - Line of Credit and Long-term Debt - Long-term Debt (Details) - USD ($) $ in Thousands | Dec. 31, 2021 | Dec. 31, 2020 |
Debt, carrying amount | $ 7,246 | $ 1,269 |
Less: unamortized debt issuance costs | (31) | 0 |
Total debt | 7,215 | 1,269 |
Less: current portion of debt | (862) | (614) |
Total long-term debt | $ 6,353 | 655 |
The 2019 Term Loan [Member] | ||
Interest rate | 4.00% | |
Debt, carrying amount | $ 1,750 | 0 |
The 2018 Term Loan [Member] | ||
Interest rate | 4.00% | |
Debt, carrying amount | $ 2,813 | 0 |
Financed Insurance Premium [Member] | ||
Interest rate | 4.00% | |
Debt, carrying amount | $ 373 | 0 |
Paycheck Protection Program CARES Act [Member] | ||
Interest rate | 1.00% | |
Debt, carrying amount | $ 0 | 295 |
Freezer Equipment Loan [Member] | ||
Interest rate | 5.70% | |
Debt, carrying amount | $ 612 | 365 |
Manufacturing Equipment Loans [Member] | ||
Interest rate | 5.70% | |
Debt, carrying amount | $ 355 | 439 |
Freezer Installation Loan [Member] | ||
Interest rate | 6.30% | |
Debt, carrying amount | $ 1,334 | 156 |
Other Loans [Member] | ||
Debt, carrying amount | $ 9 | $ 14 |
Note 7 - Line of Credit and L_5
Note 7 - Line of Credit and Long-term Debt - Maturities of Loans Payable (Details) - USD ($) $ in Thousands | Dec. 31, 2021 | Dec. 31, 2020 |
2022 | $ 862 | |
2023 | 813 | |
2024 | 2,294 | |
2025 | 543 | |
2026 | 221 | |
Thereafter | 2,513 | |
Total debt, excluding unamortized debt issuance costs | 7,246 | $ 1,269 |
Less: unamortized debt issuance costs | (31) | 0 |
Total debt | $ 7,215 | $ 1,269 |
Note 8 - Income Taxes (Details
Note 8 - Income Taxes (Details Textual) - USD ($) $ in Thousands | 12 Months Ended | ||||||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | Sep. 01, 2021 | May 03, 2021 | Oct. 01, 2020 | Aug. 07, 2019 | |
Stock-based Compensation, Tax Benefits | $ 10,500 | $ 3,200 | $ 2,300 | ||||
Operating Loss Carryforwards, Total | 120,600 | ||||||
Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration | 39,500 | ||||||
Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration | 81,100 | ||||||
GCI Acquisition [Member] | |||||||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities | 24,100 | $ 24,133 | |||||
Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount | 8,000 | ||||||
Sexton Acquisition [Member] | |||||||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities | 1,500 | $ 1,482 | |||||
SciSafe Holdings, Inc [Member] | |||||||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities | $ 3,297 | ||||||
Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount | 3,300 | ||||||
SAVSU [Member] | |||||||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities | $ 1,541 | ||||||
Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount | $ 1,500 |
Note 8 - Income Taxes - Schedul
Note 8 - Income Taxes - Schedule of Income before Income Tax, Domestic and Foreign (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Domestic | $ (27,317) | $ (597) | $ (3,198) |
Foreign | (436) | 0 | 0 |
Total | $ (27,753) | $ (597) | $ (3,198) |
Note 8 - Income Taxes - Provisi
Note 8 - Income Taxes - Provision (Benefit) for Income Taxes (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Federal | $ 0 | $ 0 | $ 0 |
State | 0 | 33 | 0 |
Foreign | 9 | 0 | 0 |
Total current tax provision | 9 | 33 | 0 |
Federal | (17,703) | (3,297) | (1,541) |
State | (2,424) | 0 | 0 |
Foreign | 0 | 0 | 0 |
Total deferred tax benefit | (20,127) | (3,297) | (1,541) |
Income tax benefit | $ (20,118) | $ (3,264) | $ (1,541) |
Note 8 - Income Taxes - Effecti
Note 8 - Income Taxes - Effective Income Tax Rate Reconciliation (Details) | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Federal statutory tax | 21.00% | 21.00% | 21.00% |
State tax, net of federal benefit | 7.00% | 39.00% | 0.00% |
Stock compensation | 38.00% | 538.00% | 74.00% |
Sec. 162(m) limitation on executive compensation | (12.00%) | (35.00%) | (17.00%) |
Fair value change in contingent consideration | (2.00%) | (81.00%) | 0.00% |
Fair value change in warrant liability | 0.00% | 127.00% | (82.00%) |
Transaction costs | (1.00%) | (6.00%) | (4.00%) |
Gain on stock acquisition | 5.00% | 0.00% | 64.00% |
Tax credits | 0.00% | 12.00% | 5.00% |
Change in valuation allowance | 21.00% | 35.00% | (5.00%) |
Book loss on equity method investment | 0.00% | 0.00% | (5.00%) |
Expired net operating losses | (5.00%) | (100.00%) | (5.00%) |
Other | 0.00% | (3.00%) | 1.00% |
Total | 72.00% | 547.00% | 47.00% |
Note 8 - Income Taxes - Deferre
Note 8 - Income Taxes - Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Thousands | Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 |
Net operating loss carryforwards | $ 27,500 | $ 12,314 | ||
Stock-based compensation | 2,066 | 1,678 | ||
Accruals and reserves | 2,902 | 427 | ||
Inventory | 236 | 142 | ||
Lease liabilities | 4,198 | 2,247 | ||
Tax credit carryforward | 594 | 225 | ||
Other | 318 | 48 | ||
Total deferred tax assets | 37,814 | 17,081 | ||
Intangibles | (35,241) | (5,025) | ||
Right-of-use assets | (4,070) | (2,261) | ||
Fair value change in investments | (294) | (287) | ||
Fixed assets | (1,203) | (959) | ||
Other | 0 | (51) | ||
Total deferred tax liabilities | (40,808) | (8,583) | ||
Net deferred tax (liabilities) assets before valuation allowance | (2,994) | 8,498 | ||
Less: valuation allowance | (2,493) | (8,498) | $ (8,706) | $ (8,345) |
Net deferred tax liabilities | $ (5,487) | $ 0 |
Note 8 - Income Taxes - Change
Note 8 - Income Taxes - Change in Valuation Allowance for Deferred Tax Assets (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Balance at January 1 | $ 8,498 | $ 8,706 | $ 8,345 |
Deferred tax liabilities assumed through acquisitions | (8,498) | (3,297) | (1,541) |
Charged to income tax expense | 2,493 | 3,089 | 1,902 |
Balance at December 31 | $ 2,493 | $ 8,498 | $ 8,706 |
Note 8 - Income Taxes - Summary
Note 8 - Income Taxes - Summary of Income Tax Contingencies (Details) - USD ($) | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Balance | $ 96,000 | $ 0 |
Increase related to prior year tax positions | 0 | 36,000 |
Increase related to current year tax positions | 159,000 | 60,000 |
Balance | $ 255,000 | $ 96,000 |
Note 9 - Warrants (Details Text
Note 9 - Warrants (Details Textual) - $ / shares | Mar. 25, 2021 | May 14, 2020 | Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 | May 31, 2016 | Mar. 31, 2014 |
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 0 | $ 4.75 | $ 4.33 | $ 4.35 | ||||
Class of Warrant or Right, Exercised During Period (in shares) | 79,100 | 3,879,905 | 121,000 | |||||
Warrants to Purchase Common Stock [Member] | ||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 6,910,283 | |||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 4.75 | |||||||
Warrants in Connection with WAVI Credit Facility [Member] | ||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 550,000 | |||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 1.75 | |||||||
WAVI Holding AG and Taurus4757 GmbH Warrants [Member] | ||||||||
Stock Issued During Period, Shares, Cashless Warrant Exercises (in shares) | 2,747,970 | |||||||
Class of Warrant or Right, Exercised During Period (in shares) | 3,871,405 | 79,100 | 3,871,405 | |||||
Warrants Exercised [Member] | ||||||||
Stock Issued During Period, Shares, Cashless Warrant Exercises (in shares) | 70,030 | |||||||
Class of Warrant or Right, Exercised During Period (in shares) | 79,100 |
Note 9 - Warrants - Summary of
Note 9 - Warrants - Summary of Warrant Activity (Details) - $ / shares | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Outstanding at beginning of year (in shares) | 79,100 | 3,959,005 | 4,080,005 |
Outstanding, weighted average exercise price (in dollars per share) | $ 4.75 | $ 4.33 | $ 4.35 |
Exercised, number of shares (in shares) | (79,100) | (3,879,905) | (121,000) |
Exercised, weighted average exercise price (in dollars per share) | $ 4.75 | $ 4.33 | $ 4.75 |
Outstanding, number of shares (in shares) | 0 | 79,100 | 3,959,005 |
Outstanding, weighted average exercise price (in dollars per share) | $ 0 | $ 4.75 | $ 4.33 |
Note 10 - Stock-based Compens_3
Note 10 - Stock-based Compensation (Details Textual) - USD ($) | May 03, 2021 | Feb. 08, 2021 | Mar. 25, 2020 | Apr. 01, 2019 | Feb. 25, 2019 | Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 | Dec. 31, 2017 | Sep. 30, 2021 | Jul. 31, 2021 | Jul. 31, 2020 | May 31, 2017 | Dec. 31, 2013 |
Share-based Payment Arrangement, Expense | $ 13,956,000 | $ 5,981,000 | $ 3,043,000 | ||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term (Year) | 3 years 2 months 26 days | ||||||||||||||
Share-based Payment Arrangement, Option [Member] | |||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance (in shares) | 624,531 | 844,455 | 1,570,455 | ||||||||||||
Share-based Payment Arrangement, Expense | $ 25,000 | $ 119,000 | $ 370,000 | ||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value | 21,900,000 | ||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value | 21,900,000 | ||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value | $ 6,900,000 | $ 13,100,000 | $ 7,100,000 | ||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares) | 0 | 0 | 0 | ||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term (Year) | 3 years 2 months 12 days | ||||||||||||||
Performance Shares [Member] | |||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance (in shares) | 0 | 686,001 | 737,497 | ||||||||||||
Restricted Stock [Member] | |||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number, Ending Balance (in shares) | 1,212,783 | 930,854 | 429,399 | ||||||||||||
Share-based Payment Arrangement, Expense | $ 12,700,000 | $ 3,000,000 | $ 1,200,000 | ||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares) | 801,484 | 717,267 | |||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Fair Value | $ 37,800,000 | $ 15,300,000 | 5,300,000 | ||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value | $ 15,900,000 | $ 4,500,000 | $ 1,900,000 | ||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share) | $ 47.20 | $ 20.88 | |||||||||||||
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total | $ 38,900,000 | ||||||||||||||
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year) | 3 years | ||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period (in shares) | 378,502 | 208,858 | |||||||||||||
Restricted Stock [Member] | Executive Officer [Member] | |||||||||||||||
Share-based Payment Arrangement, Expense | $ 666,000 | ||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares) | 34,154 | ||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share) | $ 9.18 | ||||||||||||||
Performance-based Restricted Stock [Member] | |||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number, Ending Balance (in shares) | 0 | 0 | 0 | ||||||||||||
Share-based Payment Arrangement, Expense | $ 0 | $ 760,000 | $ 0 | ||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares) | 82,805 | 0 | 82,805 | ||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share) | $ 9.18 | $ 0 | $ 9.18 | ||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Aggregate Fair Value | $ 0 | $ 760,000 | 0 | ||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested | $ 0 | $ 2,300,000 | $ 0 | ||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period (in shares) | 0 | 82,805 | |||||||||||||
Market-based Restricted Stock [Member] | |||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number, Ending Balance (in shares) | 139,756 | 224,774 | 123,851 | ||||||||||||
Share-based Payment Arrangement, Expense | $ 2,100,000 | $ 1,500,000 | |||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares) | 6,415 | 115,634 | 109,140 | 29,604 | 94,247 | 152,665 | 109,140 | ||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share) | $ 32.50 | $ 10.95 | |||||||||||||
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total | $ 1,300,000 | $ 834,000 | $ 1,400,000 | ||||||||||||
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year) | 1 year | ||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Aggregate Fair Value | $ 1,800,000 | $ 1,200,000 | 3,300,000 | ||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested | $ 10,200,000 | $ 0 | 0 | ||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period (in shares) | 231,268 | 231,268 | 0 | ||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number, Ending Balance | 68.00% | 68.00% | 78.00% | 69.00% | |||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate | 0.00% | 0.00% | 0.00% | 0.00% | |||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant | 0.20% | 0.10% | 0.30% | 2.50% | |||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year) | 2 years | 2 years | 2 years | 2 years | |||||||||||
Market-based Restricted Stock [Member] | Maximum [Member] | |||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Awards | 200.00% | 200.00% | 200.00% | 200.00% | |||||||||||
Market-based Restricted Stock [Member] | Minimum [Member] | |||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Awards | 0.00% | 0.00% | 0.00% | ||||||||||||
Market-based Restricted Stock [Member] | Executive Officer [Member] | |||||||||||||||
Share-based Payment Arrangement, Expense | $ 0 | ||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares) | 30,616 | ||||||||||||||
Market-based Restricted Stock First Issuance [Member] | |||||||||||||||
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total | $ 3,100,000 | ||||||||||||||
Market-based Restricted Stock Second Issuance [Member] | |||||||||||||||
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total | $ 1,200,000 | ||||||||||||||
The 2013 Performance Incentive Plan [Member] | |||||||||||||||
Common Stock, Capital Shares Reserved for Future Issuance (in shares) | 6,500,000 | 5,000,000 | 4,100,000 | 3,100,000 | |||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance (in shares) | 589,000 | ||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number, Ending Balance (in shares) | 1,400,000 | ||||||||||||||
All Other Unapproved Compensation Plans [Member] | |||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance (in shares) | 36,000 | ||||||||||||||
Management Performance Bonus Plan 2017 [Member] | Performance Shares [Member] | |||||||||||||||
Share-based Payment Arrangement, Expense | $ 0 | 0 | 0 | ||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value | $ 27,400,000 | $ 1,300,000 | $ 3,700,000 | ||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares) | 0 | 0 | 0 | ||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares) | 1,000,000 | ||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price (in dollars per share) | $ 1.64 | ||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares (in shares) | 999,997 | 999,997 |
Note 10 - Share-based Compensat
Note 10 - Share-based Compensation - Stock Option Activity (Details) - $ / shares | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Outstanding as of end of year (in dollars per share) | $ 2.13 | |
Share-based Payment Arrangement, Option [Member] | ||
Outstanding (in shares) | 844,455 | 1,570,455 |
Outstanding, weighted average exercise price (in dollars per share) | $ 2 | $ 1.96 |
Exercised (in shares) | (183,064) | 0 |
Exercised, weighted average exercise price (in dollars per share) | $ 1.61 | $ 0 |
Forfeited (in shares) | (1,146) | (726,000) |
Forfeited, weighted average exercise price (in dollars per share) | $ 5.69 | $ 1.91 |
Expired (in shares) | (35,714) | 0 |
Expired, weighted average exercise price (in dollars per share) | $ 1.73 | $ 0 |
Outstanding as of end of year (in shares) | 624,531 | 844,455 |
Outstanding as of end of year (in dollars per share) | $ 2.13 | $ 2 |
Stock options exercisable at year end (in shares) | 624,531 | 832,478 |
Options exercisable, weighted average exercise price (in dollars per share) | $ 2.13 | $ 1.98 |
Performance Shares [Member] | ||
Outstanding (in shares) | 686,001 | 737,497 |
Outstanding, weighted average exercise price (in dollars per share) | $ 1.64 | $ 1.64 |
Exercised (in shares) | (686,001) | (51,496) |
Exercised, weighted average exercise price (in dollars per share) | $ 1.64 | $ 1.64 |
Outstanding as of end of year (in shares) | 0 | 686,001 |
Outstanding as of end of year (in dollars per share) | $ 0 | $ 1.64 |
Stock options exercisable at year end (in shares) | 0 | 686,001 |
Options exercisable, weighted average exercise price (in dollars per share) | $ 0 | $ 1.64 |
Note 10 - Stock-based Compens_4
Note 10 - Stock-based Compensation - Shares Authorized Under Stock Option Plan (Details) | 12 Months Ended |
Dec. 31, 2021$ / sharesshares | |
Number of shares outstanding (in shares) | shares | 624,531 |
Weighted average remaining contractual life (Year) | 3 years 2 months 26 days |
Weighted average exercise price (in dollars per share) | $ 2.13 |
Price Range 1 [Member] | |
Exercise price, lower range (in dollars per share) | 1 |
Exercise price, upper range (in dollars per share) | $ 1.50 |
Number of shares outstanding (in shares) | shares | 26,428 |
Weighted average remaining contractual life (Year) | 1 year 18 days |
Weighted average exercise price (in dollars per share) | $ 1.38 |
Price Range 2 [Member] | |
Exercise price, lower range (in dollars per share) | 1.51 |
Exercise price, upper range (in dollars per share) | $ 2 |
Number of shares outstanding (in shares) | shares | 290,760 |
Weighted average remaining contractual life (Year) | 3 years 3 months 7 days |
Weighted average exercise price (in dollars per share) | $ 1.87 |
Price Range 3 [Member] | |
Exercise price, lower range (in dollars per share) | 2.01 |
Exercise price, upper range (in dollars per share) | $ 2.50 |
Number of shares outstanding (in shares) | shares | 265,775 |
Weighted average remaining contractual life (Year) | 3 years 4 months 6 days |
Weighted average exercise price (in dollars per share) | $ 2.06 |
Price Range 4 [Member] | |
Exercise price, lower range (in dollars per share) | 2.51 |
Exercise price, upper range (in dollars per share) | $ 8.60 |
Number of shares outstanding (in shares) | shares | 41,568 |
Weighted average remaining contractual life (Year) | 3 years 9 months |
Weighted average exercise price (in dollars per share) | $ 4.86 |
Note 10 - Share-based Compens_2
Note 10 - Share-based Compensation - Restricted Stock Activity (Details) - $ / shares | May 03, 2021 | Feb. 08, 2021 | Mar. 25, 2020 | Apr. 01, 2019 | Feb. 25, 2019 | Dec. 31, 2021 | Dec. 31, 2020 |
Restricted Stock [Member] | |||||||
Outstanding (in shares) | 930,854 | 429,399 | |||||
Outstanding at beginning of year, grant date fair value (in dollars per share) | $ 19.31 | $ 13.25 | |||||
Granted (in shares) | 801,484 | 717,267 | |||||
Granted, grant date fair value (in dollars per share) | $ 47.20 | $ 20.88 | |||||
Granted in lieu of cash (in shares) | 0 | 34,154 | |||||
Granted in lieu of cash, grant fair value (in dollars per share) | $ 0 | $ 9.18 | |||||
Vested (in shares) | (378,502) | (208,858) | |||||
Vested, grant date fair value (in dollars per share) | $ 19.31 | $ 11.32 | |||||
Forfeited (in shares) | (141,053) | (41,108) | |||||
Forfeited, grant date fair value (in dollars per share) | $ 36.95 | $ 15.47 | |||||
Outstanding (in shares) | 1,212,783 | 930,854 | |||||
Outstanding at end of year, grant date fair value (in dollars per share) | $ 37.48 | $ 19.31 | |||||
Performance-based Restricted Stock [Member] | |||||||
Outstanding (in shares) | 0 | 0 | |||||
Outstanding at beginning of year, grant date fair value (in dollars per share) | $ 0 | $ 0 | |||||
Granted, grant date fair value (in dollars per share) | $ 9.18 | $ 0 | $ 9.18 | ||||
Vested (in shares) | 0 | (82,805) | |||||
Vested, grant date fair value (in dollars per share) | $ 0 | $ 9.18 | |||||
Outstanding (in shares) | 0 | 0 | |||||
Outstanding at end of year, grant date fair value (in dollars per share) | $ 0 | $ 0 | |||||
Granted (in shares) | 82,805 | 0 | 82,805 | ||||
Market-based Restricted Stock [Member] | |||||||
Outstanding (in shares) | 224,774 | 123,851 | |||||
Outstanding at beginning of year, grant date fair value (in dollars per share) | $ 19.20 | $ 26.99 | |||||
Granted, grant date fair value (in dollars per share) | $ 32.50 | $ 10.95 | |||||
Vested (in shares) | (231,268) | (231,268) | 0 | ||||
Vested, grant date fair value (in dollars per share) | $ 26.98 | $ 0 | |||||
Forfeited (in shares) | (6,415) | (8,217) | |||||
Forfeited, grant date fair value (in dollars per share) | $ 40.65 | $ 27.02 | |||||
Outstanding (in shares) | 139,756 | 224,774 | |||||
Outstanding at end of year, grant date fair value (in dollars per share) | $ 19.86 | $ 19.20 | |||||
Granted (in shares) | 6,415 | 115,634 | 109,140 | 29,604 | 94,247 | 152,665 | 109,140 |
Note 10 - Share-based Compens_3
Note 10 - Share-based Compensation - Stock Compensation Expense (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Stock compensation expense | $ 13,956 | $ 5,981 | $ 3,043 |
Research and Development Expense [Member] | |||
Stock compensation expense | 1,906 | 1,012 | 571 |
Selling and Marketing Expense [Member] | |||
Stock compensation expense | 1,788 | 852 | 711 |
General and Administrative Expense [Member] | |||
Stock compensation expense | 8,061 | 3,518 | 1,584 |
Cost of Sales [Member] | |||
Stock compensation expense | $ 2,201 | $ 599 | $ 177 |
Note 12 - Acquisitions (Details
Note 12 - Acquisitions (Details Textual) - USD ($) | Sep. 01, 2021 | May 03, 2021 | Oct. 01, 2020 | Sep. 30, 2020 | Nov. 12, 2019 | Aug. 08, 2019 | Apr. 01, 2019 | Dec. 31, 2019 | Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2021 | Dec. 31, 2019 | Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | Nov. 11, 2019 | Aug. 07, 2019 |
Goodwill, Ending Balance | $ 33,637,000 | $ 224,741,000 | $ 58,449,000 | $ 33,637,000 | $ 224,741,000 | $ 33,637,000 | $ 224,741,000 | $ 58,449,000 | $ 33,637,000 | |||||||||
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable | 264,718,000 | 0 | 0 | |||||||||||||||
Payment for Contingent Consideration Liability, Financing Activities | 0 | 483,000 | 0 | |||||||||||||||
Sexton Acquisition [Member] | ||||||||||||||||||
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares (in shares) | 530,502 | |||||||||||||||||
Business Acquisition, Percentage of Equity Issuable Shares Held in Escrow Accounts for Post Closing Claims | 10.00% | |||||||||||||||||
Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Gain (Loss), Net, Total | $ 6,500,000 | |||||||||||||||||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Gross Receivables | 509,000 | |||||||||||||||||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Uncollectable Receivables | 17,000 | |||||||||||||||||
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustments Related to Previous Period | 198,000 | |||||||||||||||||
Goodwill, Ending Balance | 28,470,000 | |||||||||||||||||
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable | 32,095,000 | |||||||||||||||||
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net, Total | 39,928,000 | |||||||||||||||||
Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value | $ 7,951,000 | |||||||||||||||||
Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual | 1,800,000 | |||||||||||||||||
Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual | (1,000,000) | |||||||||||||||||
Sexton Acquisition [Member] | Common Stock Issued to Acquire Participating Holders [Member] | ||||||||||||||||||
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares (in shares) | 477,452 | |||||||||||||||||
Sexton Acquisition [Member] | Common Stock Deposited Into Escrow [Member] | ||||||||||||||||||
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares (in shares) | 53,050 | |||||||||||||||||
GCI Acquisition [Member] | ||||||||||||||||||
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares (in shares) | 6,636,470 | |||||||||||||||||
Business Acquisition, Percentage of Equity Issuable Shares Held in Escrow Accounts for Post Closing Claims | 9.00% | |||||||||||||||||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Gross Receivables | $ 7,100,000 | |||||||||||||||||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Uncollectable Receivables | 53,000 | |||||||||||||||||
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustments Related to Previous Period | $ 607,000 | |||||||||||||||||
Goodwill, Ending Balance | $ 137,822,000 | |||||||||||||||||
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares, Before Adjustments (in shares) | 6,646,870 | |||||||||||||||||
Business Combination, Stock Reduced During Period, Satisfy Note Receivable (in shares) | 10,400 | |||||||||||||||||
Business Combination, Escrow Shares, Period (Month) | 24 months | |||||||||||||||||
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable | $ 232,741,000 | |||||||||||||||||
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net, Total | $ 234,909,000 | |||||||||||||||||
Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual | 39,100,000 | |||||||||||||||||
Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual | $ (19,600,000) | |||||||||||||||||
GCI Acquisition [Member] | One GCI Stockholder [Member] | ||||||||||||||||||
Business Combination, Stock Reduced During Period, Satisfy Note Receivable (in shares) | 10,400 | |||||||||||||||||
Financing Receivable, after Allowance for Credit Loss, Total | $ 374,000 | |||||||||||||||||
SciSafe Holdings, Inc [Member] | ||||||||||||||||||
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares (in shares) | 611,683 | |||||||||||||||||
Goodwill, Ending Balance | $ 24,943,000 | |||||||||||||||||
Business Combination, Step Acquisition, Equity Interest in Acquiree, Percentage | 100.00% | |||||||||||||||||
Business Acquisition, Share Price (in dollars per share) | $ 29.29 | |||||||||||||||||
Payments to Acquire Businesses, Gross | $ 15,000,000 | |||||||||||||||||
Business Acquisition, Amount Held in Escrow | 1,500,000 | |||||||||||||||||
Payments to Acquire Notes Receivable | $ 500,000 | |||||||||||||||||
Business Combination, Indemnification Assets, Amount as of Acquisition Date | 130,000 | |||||||||||||||||
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable | 17,916,000 | |||||||||||||||||
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net, Total | 36,526,000 | |||||||||||||||||
Business Combination, Consideration Transferred, Liabilities Incurred | $ 3,663,000 | |||||||||||||||||
Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual | 1,800,000 | |||||||||||||||||
Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual | $ (416,000) | |||||||||||||||||
SciSafe Holdings, Inc [Member] | Maximum [Member] | ||||||||||||||||||
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares (in shares) | 626,000 | |||||||||||||||||
CBS Acquisition [Member] | ||||||||||||||||||
Goodwill, Ending Balance | $ 2,954,000 | |||||||||||||||||
Payments to Acquire Businesses, Gross | $ 11,000,000 | |||||||||||||||||
Business Combination, Consideration Transferred, Excluding Contingent Consideration | 15,000,000 | |||||||||||||||||
Business Combination, Acquisition Related Costs | 11,000,000 | |||||||||||||||||
Business Combination, Cash Holdback Escrow to Satisfy Indemnification Claims | 550,000 | |||||||||||||||||
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable | 4,000,000 | 0 | 0 | 4,000,000 | ||||||||||||||
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable, Escrow Holdback | 3,000,000 | |||||||||||||||||
Payment for Contingent Consideration Liability, Financing Activities | 0 | 0 | ||||||||||||||||
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net, Total | $ 15,856,000 | |||||||||||||||||
Business Combination, Consideration Transferred, Liabilities Incurred | 856,000 | |||||||||||||||||
Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual | 2,100,000 | |||||||||||||||||
Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual | $ 187,000 | |||||||||||||||||
CBS Acquisition [Member] | Earning Payments Payable in Each Calendar Year 2020, 2021, 2022, 2023, and 2024 [Member] | ||||||||||||||||||
Business Combination, Consideration Transferred, Liabilities Incurred | $ 15,000,000 | |||||||||||||||||
SAVSU [Member] | ||||||||||||||||||
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares (in shares) | 1,100,000 | |||||||||||||||||
Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Gain (Loss), Net, Total | $ 10,100,000 | 0 | 0 | 10,108,000 | ||||||||||||||
Goodwill, Ending Balance | $ 21,037,000 | |||||||||||||||||
Business Combination, Step Acquisition, Equity Interest in Acquiree, Percentage | 44.00% | |||||||||||||||||
Business Acquisition, Share Price (in dollars per share) | $ 18.12 | |||||||||||||||||
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable | $ 19,932,000 | $ 0 | $ 0 | $ 19,932,000 | ||||||||||||||
Business Combinations, Number of Shares Acquired (in shares) | 8,616 | |||||||||||||||||
Business Acquisition, Percentage of Voting Interests Acquired | 55.60% | |||||||||||||||||
Business Combination, Step Acquisition, Equity Interest in Acquiree, including Subsequent Acquisition, Percentage, Total | 100.00% | |||||||||||||||||
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net, Total | $ 35,800,000 | $ 35,850,000 | ||||||||||||||||
Equity Method Investments | 5,800,000 | |||||||||||||||||
Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value | 15,900,000 | |||||||||||||||||
Business Combination, Consideration Transferred, Including Equity Interest in Acquiree Held Prior to Combination, Total | $ 35,800,000 | |||||||||||||||||
Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual | 692,000 | |||||||||||||||||
Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual | $ (1,700,000) | |||||||||||||||||
Astero [Member] | ||||||||||||||||||
Goodwill, Ending Balance | $ 9,515,000 | |||||||||||||||||
Payments to Acquire Businesses, Gross | 12,521,000 | |||||||||||||||||
Business Combination, Acquisition Related Costs | 8,000,000 | |||||||||||||||||
Payment for Contingent Consideration Liability, Financing Activities | 483,000 | |||||||||||||||||
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net, Total | 13,941,000 | |||||||||||||||||
Payments to Acquire Businesses, Deferred Cash Payment | 4,500,000 | |||||||||||||||||
Business Combination, Consideration Transferred, Liabilities Incurred | 1,491,000 | |||||||||||||||||
Business Acquisition, Goodwill, Expected Tax Deductible Amount | 1,100,000 | |||||||||||||||||
Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual | 1,200,000 | |||||||||||||||||
Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual | $ (1,500,000) | |||||||||||||||||
Astero [Member] | Maximum Potential Earnout Payment for 2019, 2020, and 2021 [Member] | ||||||||||||||||||
Business Combination, Consideration Transferred, Liabilities Incurred | 3,500,000 | |||||||||||||||||
Astero [Member] | Earnout Payment for Calendar Year 2021 [Member] | ||||||||||||||||||
Business Combination, Consideration Transferred, Liabilities Incurred | $ 5,000,000 |
Note 12 - Acquisitions - Consid
Note 12 - Acquisitions - Consideration (Details) - USD ($) $ / shares in Units, $ in Thousands | Sep. 01, 2021 | May 03, 2021 | Oct. 01, 2020 | Nov. 12, 2019 | Aug. 08, 2019 | Apr. 01, 2019 | Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 |
BioLife stock price (in dollars per share) | $ 60.50 | $ 35.07 | |||||||
Value of issued shares | $ 264,718 | $ 0 | $ 0 | ||||||
BioLife shares outstanding (as of March 19, 2021) (in shares) | 33,401,359 | ||||||||
Sexton Acquisition [Member] | |||||||||
Merger consideration shares (in shares) | 530,502 | ||||||||
Value of issued shares | $ 32,095 | ||||||||
plus: Fair value of BioLife’s existing investment in Sexton | 7,951 | ||||||||
less: Net working capital adjustment | (118) | ||||||||
Merger Consideration | 39,928 | ||||||||
Working capital adjustment | $ 118 | ||||||||
SciSafe Holdings, Inc [Member] | |||||||||
Merger consideration shares (in shares) | 611,683 | ||||||||
Value of issued shares | $ 17,916 | ||||||||
less: Net working capital adjustment | 53 | ||||||||
Merger Consideration | 36,526 | ||||||||
Cash consideration | 15,000 | ||||||||
Contingent consideration | 3,663 | ||||||||
Working capital adjustment | $ (53) | ||||||||
CBS Acquisition [Member] | |||||||||
Value of issued shares | $ 4,000 | 0 | 0 | 4,000 | |||||
Merger Consideration | 15,856 | ||||||||
Cash consideration | 11,000 | ||||||||
Contingent consideration | $ 856 | ||||||||
SAVSU [Member] | |||||||||
Merger consideration shares (in shares) | 1,100,000 | ||||||||
Value of issued shares | $ 19,932 | $ 0 | $ 0 | $ 19,932 | |||||
plus: Fair value of BioLife’s existing investment in Sexton | $ 15,900 | ||||||||
Astero [Member] | |||||||||
less: Net working capital adjustment | $ 71 | ||||||||
Merger Consideration | 13,941 | ||||||||
Cash consideration | 12,521 | ||||||||
Contingent consideration | 1,491 | ||||||||
Working capital adjustment | $ (71) | ||||||||
GCI Acquisition [Member] | |||||||||
Merger consideration shares (in shares) | 6,636,470 | ||||||||
Value of issued shares | $ 232,741 | ||||||||
Merger Consideration | $ 234,909 | ||||||||
Merger consideration percentage | 19.90% | ||||||||
Merger consideration shares (in shares) | 6,646,870 | ||||||||
less: Merger consideration shares withheld to satisfy outstanding GCI stockholder obligations to GCI (in shares) | 10,400 | ||||||||
plus: Settlement of BioLife prepaid deposits | $ 2,152 | ||||||||
plus: Net settlement of BioLife accounts receivable | $ 16 |
Note 12 - Acquisitions - Cons_2
Note 12 - Acquisitions - Consideration (Details) (Parentheticals) | Aug. 08, 2019 |
SAVSU [Member] | |
Percentage equity interest purchased | 55.60% |
Note 12 - Acquisitions - Fair V
Note 12 - Acquisitions - Fair Value of Net Assets Acquired (Details) - USD ($) $ in Thousands | Dec. 31, 2021 | Sep. 01, 2021 | May 03, 2021 | Dec. 31, 2020 | Oct. 01, 2020 | Dec. 31, 2019 | Nov. 12, 2019 | Nov. 11, 2019 | Aug. 08, 2019 | Aug. 07, 2019 | Apr. 01, 2019 |
Goodwill | $ 224,741 | $ 58,449 | $ 33,637 | ||||||||
Sexton Acquisition [Member] | |||||||||||
Cash | $ 1,516 | ||||||||||
Accounts receivable, net | 492 | ||||||||||
Inventory | 1,310 | ||||||||||
Prepaid expenses and other current assets | 670 | ||||||||||
Property, plant and equipment, net | 737 | ||||||||||
Operating lease right-of-use assets, net | 470 | ||||||||||
Goodwill | 28,470 | ||||||||||
Accounts payable | (291) | ||||||||||
Lease liabilities, operating | (470) | ||||||||||
Deferred tax liability | (1,500) | (1,482) | |||||||||
Other liabilities | (316) | ||||||||||
Fair value of net assets acquired | 39,928 | ||||||||||
Sexton Acquisition [Member] | Customer Relationships [Member] | |||||||||||
Developed technology | 2,276 | ||||||||||
Sexton Acquisition [Member] | Trade Names [Member] | |||||||||||
Developed technology | 2,324 | ||||||||||
Sexton Acquisition [Member] | Developed Technology Rights [Member] | |||||||||||
Developed technology | 4,132 | ||||||||||
Sexton Acquisition [Member] | Noncompete Agreements [Member] | |||||||||||
Developed technology | $ 90 | ||||||||||
GCI Acquisition [Member] | |||||||||||
Cash | $ 43 | ||||||||||
Accounts receivable, net | 7,076 | ||||||||||
Inventory | 15,547 | ||||||||||
Prepaid expenses and other current assets | 639 | ||||||||||
Property, plant and equipment, net | 3,512 | ||||||||||
Operating lease right-of-use assets, net | 1,741 | ||||||||||
Goodwill | 137,822 | ||||||||||
Accounts payable | (9,837) | ||||||||||
Lease liabilities, operating | (1,880) | ||||||||||
Deferred tax liability | $ (24,100) | (24,133) | |||||||||
Other liabilities | (7,464) | ||||||||||
Fair value of net assets acquired | 234,909 | ||||||||||
Financing lease right-of-use assets, net | 114 | ||||||||||
Long-term deposits and other assets | 4 | ||||||||||
Line of credit | (4,231) | ||||||||||
Lease liabilities, financing | (114) | ||||||||||
Long-term debt | (4,410) | ||||||||||
GCI Acquisition [Member] | Indefinite In Process Research and Development [Member] | |||||||||||
In-process research and development | 67,440 | ||||||||||
GCI Acquisition [Member] | Customer Relationships [Member] | |||||||||||
Developed technology | 7,020 | ||||||||||
GCI Acquisition [Member] | Trade Names [Member] | |||||||||||
Developed technology | 26,640 | ||||||||||
GCI Acquisition [Member] | Developed Technology Rights [Member] | |||||||||||
Developed technology | 18,140 | ||||||||||
GCI Acquisition [Member] | Noncompete Agreements [Member] | |||||||||||
Developed technology | $ 1,240 | ||||||||||
SciSafe Holdings, Inc [Member] | |||||||||||
Cash | $ 500 | ||||||||||
Accounts receivable, net | 945 | ||||||||||
Prepaid expenses and other current assets | 31 | ||||||||||
Property, plant and equipment, net | 3,400 | ||||||||||
Developed technology | 12,100 | ||||||||||
Goodwill | 24,943 | ||||||||||
Accounts payable | (885) | ||||||||||
Deferred tax liability | (3,297) | ||||||||||
Other liabilities | (2,758) | ||||||||||
Fair value of net assets acquired | 36,526 | ||||||||||
Other assets | 1,547 | ||||||||||
SciSafe Holdings, Inc [Member] | Customer Relationships [Member] | |||||||||||
Developed technology | 7,420 | ||||||||||
SciSafe Holdings, Inc [Member] | Trade Names [Member] | |||||||||||
Developed technology | 4,020 | ||||||||||
SciSafe Holdings, Inc [Member] | Noncompete Agreements [Member] | |||||||||||
Developed technology | $ 660 | ||||||||||
CBS Acquisition [Member] | |||||||||||
Accounts receivable, net | $ 1,044 | ||||||||||
Inventory | 3,232 | ||||||||||
Prepaid expenses and other current assets | 29 | ||||||||||
Property, plant and equipment, net | 3,615 | ||||||||||
Developed technology | $ 6,790 | ||||||||||
Goodwill | 2,954 | ||||||||||
Accounts payable | (1,197) | ||||||||||
Other liabilities | (611) | ||||||||||
Fair value of net assets acquired | 15,856 | ||||||||||
CBS Acquisition [Member] | Customer Relationships [Member] | |||||||||||
Developed technology | 560 | 560 | |||||||||
CBS Acquisition [Member] | Trade Names [Member] | |||||||||||
Developed technology | 800 | 800 | |||||||||
CBS Acquisition [Member] | Developed Technology Rights [Member] | |||||||||||
Developed technology | $ 5,430 | $ 5,430 | |||||||||
SAVSU [Member] | |||||||||||
Cash | $ 1,251 | ||||||||||
Accounts receivable, net | 753 | ||||||||||
Prepaid expenses and other current assets | 19 | ||||||||||
Property, plant and equipment, net | 546 | ||||||||||
Developed technology | $ 12,150 | ||||||||||
Goodwill | 21,037 | ||||||||||
Accounts payable | (807) | ||||||||||
Deferred tax liability | (1,541) | ||||||||||
Other liabilities | (232) | ||||||||||
Fair value of net assets acquired | 35,800 | 35,850 | |||||||||
Operating right-of-use asset | 233 | ||||||||||
Assets held for lease | 2,441 | ||||||||||
SAVSU [Member] | Customer Relationships [Member] | |||||||||||
Developed technology | 80 | 80 | |||||||||
SAVSU [Member] | Trade Names [Member] | |||||||||||
Developed technology | $ 1,320 | 1,320 | |||||||||
SAVSU [Member] | Developed Technology Rights [Member] | |||||||||||
Developed technology | $ 10,750 | ||||||||||
Astero [Member] | |||||||||||
Cash | $ 11 | ||||||||||
Accounts receivable, net | 154 | ||||||||||
Inventory | 456 | ||||||||||
Developed technology | 4,120 | ||||||||||
Goodwill | 9,515 | ||||||||||
Accounts payable | (250) | ||||||||||
Other liabilities | (164) | ||||||||||
Fair value of net assets acquired | 13,941 | ||||||||||
Other assets | 99 | ||||||||||
Astero [Member] | Customer Relationships [Member] | |||||||||||
Developed technology | 160 | ||||||||||
Astero [Member] | Trade Names [Member] | |||||||||||
Developed technology | 470 | ||||||||||
Astero [Member] | Developed Technology Rights [Member] | |||||||||||
Developed technology | 2,840 | ||||||||||
Astero [Member] | In Process Research and Development [Member] | |||||||||||
Developed technology | $ 650 |
Note 12 - Acquisitions - Acquir
Note 12 - Acquisitions - Acquired Intangible Assets (Details) - USD ($) $ in Thousands | Sep. 01, 2021 | May 03, 2021 | Oct. 01, 2020 | Nov. 12, 2019 | Aug. 08, 2019 | Apr. 01, 2019 | Nov. 11, 2019 | Aug. 07, 2019 |
Total identifiable intangible assets | $ 8,822 | |||||||
Sexton Acquisition [Member] | Developed Technology Rights [Member] | ||||||||
Developed technology | $ 4,132 | |||||||
Sexton Acquisition [Member] | Developed Technology Rights [Member] | Minimum [Member] | ||||||||
Intangible assets, estimated useful life (Year) | 5 years | |||||||
Sexton Acquisition [Member] | Developed Technology Rights [Member] | Maximum [Member] | ||||||||
Intangible assets, estimated useful life (Year) | 9 years | |||||||
Sexton Acquisition [Member] | Customer Relationships [Member] | ||||||||
Developed technology | $ 2,276 | |||||||
Intangible assets, estimated useful life (Year) | 2 years | |||||||
Sexton Acquisition [Member] | Trade Names [Member] | ||||||||
Developed technology | $ 2,324 | |||||||
Intangible assets, estimated useful life (Year) | 11 years | |||||||
Sexton Acquisition [Member] | Noncompete Agreements [Member] | ||||||||
Developed technology | $ 90 | |||||||
Intangible assets, estimated useful life (Year) | 1 year | |||||||
GCI Acquisition [Member] | ||||||||
Total identifiable intangible assets | $ 120,480 | |||||||
GCI Acquisition [Member] | Indefinite In Process Research and Development [Member] | ||||||||
In-process research and development | 67,440 | |||||||
GCI Acquisition [Member] | Developed Technology Rights [Member] | ||||||||
Developed technology | $ 18,140 | |||||||
Intangible assets, estimated useful life (Year) | 6 years | |||||||
GCI Acquisition [Member] | Customer Relationships [Member] | ||||||||
Developed technology | $ 7,020 | |||||||
Intangible assets, estimated useful life (Year) | 12 years | |||||||
GCI Acquisition [Member] | Trade Names [Member] | ||||||||
Developed technology | $ 26,640 | |||||||
Intangible assets, estimated useful life (Year) | 15 years | |||||||
GCI Acquisition [Member] | Noncompete Agreements [Member] | ||||||||
Developed technology | $ 1,240 | |||||||
Intangible assets, estimated useful life (Year) | 4 years | |||||||
SciSafe Holdings, Inc [Member] | ||||||||
Developed technology | $ 12,100 | |||||||
SciSafe Holdings, Inc [Member] | Customer Relationships [Member] | ||||||||
Developed technology | $ 7,420 | |||||||
Intangible assets, estimated useful life (Year) | 14 years | |||||||
SciSafe Holdings, Inc [Member] | Trade Names [Member] | ||||||||
Developed technology | $ 4,020 | |||||||
Intangible assets, estimated useful life (Year) | 19 years | |||||||
SciSafe Holdings, Inc [Member] | Noncompete Agreements [Member] | ||||||||
Developed technology | $ 660 | |||||||
Intangible assets, estimated useful life (Year) | 4 years | |||||||
CBS Acquisition [Member] | ||||||||
Developed technology | $ 6,790 | |||||||
CBS Acquisition [Member] | Developed Technology Rights [Member] | ||||||||
Developed technology | $ 5,430 | $ 5,430 | ||||||
Intangible assets, estimated useful life (Year) | 9 years | |||||||
CBS Acquisition [Member] | Customer Relationships [Member] | ||||||||
Developed technology | $ 560 | 560 | ||||||
Intangible assets, estimated useful life (Year) | 6 years | |||||||
CBS Acquisition [Member] | Trade Names [Member] | ||||||||
Developed technology | $ 800 | $ 800 | ||||||
Intangible assets, estimated useful life (Year) | 6 years | |||||||
SAVSU [Member] | ||||||||
Developed technology | $ 12,150 | |||||||
SAVSU [Member] | Developed Technology Rights [Member] | ||||||||
Developed technology | $ 10,750 | |||||||
SAVSU [Member] | Customer Relationships [Member] | ||||||||
Developed technology | $ 80 | 80 | ||||||
Intangible assets, estimated useful life (Year) | 6 years | |||||||
SAVSU [Member] | Trade Names [Member] | ||||||||
Developed technology | $ 1,320 | $ 1,320 | ||||||
Intangible assets, estimated useful life (Year) | 9 years | |||||||
SAVSU [Member] | Technology-Based Intangible Assets [Member] | ||||||||
Developed technology | $ 10,750 | |||||||
SAVSU [Member] | Technology-Based Intangible Assets [Member] | Minimum [Member] | ||||||||
Intangible assets, estimated useful life (Year) | 7 years | |||||||
SAVSU [Member] | Technology-Based Intangible Assets [Member] | Maximum [Member] | ||||||||
Intangible assets, estimated useful life (Year) | 8 years | |||||||
Astero [Member] | ||||||||
Developed technology | $ 4,120 | |||||||
Astero [Member] | Developed Technology Rights [Member] | ||||||||
Developed technology | $ 2,840 | |||||||
Astero [Member] | Developed Technology Rights [Member] | Minimum [Member] | ||||||||
Intangible assets, estimated useful life (Year) | 5 years | |||||||
Astero [Member] | Developed Technology Rights [Member] | Maximum [Member] | ||||||||
Intangible assets, estimated useful life (Year) | 9 years | |||||||
Astero [Member] | Customer Relationships [Member] | ||||||||
Developed technology | $ 160 | |||||||
Intangible assets, estimated useful life (Year) | 4 years | |||||||
Astero [Member] | Trade Names [Member] | ||||||||
Developed technology | $ 470 | |||||||
Intangible assets, estimated useful life (Year) | 9 years | |||||||
Astero [Member] | In Process Research and Development [Member] | ||||||||
Developed technology | $ 650 |
Note 12 - Acquisitions - Pro Fo
Note 12 - Acquisitions - Pro Forma Information (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Sexton Acquisition [Member] | |||
Total revenue | $ 122,494 | $ 50,856 | |
Net income (loss) | (9,860) | (1,028) | |
GCI Acquisition [Member] | |||
Total revenue | 143,732 | 87,370 | |
Net income (loss) | $ (16,375) | 501 | |
SciSafe Holdings, Inc [Member] | |||
Total revenue | 52,613 | $ 43,221 | |
Net income (loss) | $ 1,798 | (4,528) | |
CBS Acquisition [Member] | |||
Total revenue | 37,001 | ||
Net income (loss) | (493) | ||
SAVSU [Member] | |||
Total revenue | 28,824 | ||
Net income (loss) | (1,518) | ||
Astero [Member] | |||
Total revenue | 28,745 | ||
Net income (loss) | $ (183) |
Note 13 - Consolidated Balanc_3
Note 13 - Consolidated Balance Sheet Detail (Details Textual) - USD ($) | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Depreciation, Total | $ 2,900,000 | $ 1,400,000 | $ 544,000 |
Note 13 - Consolidated Balanc_4
Note 13 - Consolidated Balance Sheet Detail - Property and Equipment (Details) - USD ($) $ in Thousands | Dec. 31, 2021 | Dec. 31, 2020 |
Property and equipment | $ 24,398 | $ 13,962 |
Less: Accumulated depreciation | (6,741) | (3,842) |
Net property and equipment | 17,657 | 10,120 |
Leasehold Improvements [Member] | ||
Property and equipment | 3,840 | 2,393 |
Furniture and Computer Equipment [Member] | ||
Property and equipment | 1,861 | 902 |
Manufacturing Facility [Member] | ||
Property and equipment | 16,675 | 10,076 |
Construction in Progress [Member] | ||
Property and equipment | $ 2,022 | $ 591 |
Note 13 - Consolidated Balanc_5
Note 13 - Consolidated Balance Sheet Detail - Accrued Liabilities and Other Current Liabilities (Details) - USD ($) $ in Thousands | Dec. 31, 2021 | Dec. 31, 2020 |
Accrued expenses | $ 1,656 | $ 472 |
Accrued taxes | 27 | 112 |
Accrued compensation | 4,351 | 2,898 |
Deferred revenue, current | 814 | 931 |
Other | 294 | 130 |
Total accrued expenses and other current liabilities | $ 7,142 | $ 4,543 |
Note 13 - Consolidated Balanc_6
Note 13 - Consolidated Balance Sheet Detail - Warranty Reserve Liability (Details) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Beginning balance | $ 212 | $ 191 |
Warranty reserve acquired in the acquisition of Global Cooling | 3,353 | 0 |
Provision for warranties | 9,845 | 137 |
Settlements of warranty claims | (4,012) | (116) |
Ending Balance | $ 9,398 | $ 212 |
Note 14 - Employee Benefit Pl_2
Note 14 - Employee Benefit Plan (Details Textual) - Defined Contribution Plan, 401 K [Member] - Pension Plan [Member] - USD ($) | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay | 100.00% | ||
Defined Contribution Plan, Employer Discretionary Contribution Amount | $ 822,000 | $ 347,000 | $ 158,000 |